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Senescence is classically defined as an irreversible cell cycle arrest. There is now 
convincing evidence that senescent cells accumulate during human ageing, potentially 
driving age-related dysfunction through depletion of mitotically active cells and 
stimulation of chronic inflammation. Recently, a landmark paper demonstrated that 
removal of p16INK4A (p16)-positive senescent cells in mice prolonged healthy lifespan, 
suggesting a direct link between senescence and age-related dysfunction. As such, 
restraining the senescent pool or slowing their rate of accumulation presents an 
attractive therapeutic strategy for extending healthspan. Previously, our laboratory has 
demonstrated that siRNA transfection can reverse deep senescence in p16-positive 
primary adult human mammary epithelial cells using a panel of senescence markers. 
Subsequent siRNA screening revealed 28 hits which strongly induced reversal in the 
deeply senescent HMECs. In this project, siRNA knockdown of p16 combined with 
p21WAF1/CIP1 (p21) was found to reverse deep replicative senescence in primary adult 
human mammary fibroblasts, as defined by a panel of senescence markers. This 
discovery provided the opportunity to screen for novel siRNAs which induce reversal in 
both cell types. Screening in the deeply senescent HMFs of the 28 shortlisted candidates 
and 33 protein interactors identified using bioinformatics revealed 45 siRNAs which 
significantly increased cell number compared to the negative siRNA control. Subsequent 
immunofluorescence staining and high content analysis of the top 14 candidates 
identified 10 hit siRNAs which induced senescence reversal as defined by a panel of 
markers. Interestingly, these 10 hits were enriched for cytoskeletal and cell adhesion 
processes, suggesting an interplay between external forces and senescence induction. 
The top siRNA hit, early growth response 2 or EGR2, a transcription factor, was validated 
and selected for further exploration as a novel driver of senescence. Bioinformatics 
analysis revealed an enrichment for EGR2 binding sites within genes dynamically 
expressed in HMEC senescence, including p16, p21, and nine hits identified to reverse 
senescence in HMFs and HMECs. Furthermore, deeply senescent HMFs and HMECs were 
found to have a significantly increased nuclear EGR2 foci number compared to 
proliferating cells, and this was significantly decreased in reversed HMFs. In conclusion, 
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1.1 The cell cycle 
1.1.1 Cell cycle regulation 
The eukaryotic cell cycle consists of four phases: G1, a growth phase during which cell 
components are synthesised; S phase, where DNA synthesis occurs; G2, a second growth 
phase; and mitosis (M phase) where cell division takes place. Progression through these 
cell cycle phases requires passage through sequential checkpoints, namely G1-S, G2-M, 
and the Spindle checkpoint which controls entry into anaphase. The G1-S and G2-M 
checkpoints are controlled by cyclin-dependent kinases (CDKs) and their regulatory 
cyclin subunits (reviewed in Lim & Kaldis 2013), that form cyclin-CDK complexes which 
act to regulate cell cycle progression by modulating expression of transcription factors 
and crucial cell cycle components.  
 
In most adult tissues, the majority of cells are maintained in a quiescent non-
proliferating state called G0. Recent evidence has shown that cell cycle gene expression 
is repressed during quiescence by a multi-subunit protein complex called DREAM, 
containing p130 or p107, dimerisation partner (DP), RB-like, E2F and MuvB (Figure 1.1) 
(Sadasivam and DeCaprio, 2013). In order to stimulate re-entry into the cell cycle for 
tissue homeostasis and repair, mitogenic signals, including the RAS subfamily, mitogen-
activated protein kinase (MAPK) (Ladha et al., 1998), and mechanistic target of 
rapamycin (mTOR) (Rodgers et al., 2014), regulate CDK4 and CDK6 complex activity 
(reviewed in Asghar et al. 2015). Together with the D-type cyclins, CDK4 and CDK6 
control the transition to S phase via phosphorylation of the retinoblastoma tumour 
suppressor protein (pRB) and the related family proteins p107 and p130 (Kato et al., 
1993; Matsushime et al., 1994). Subsequently, activated cyclin E-CDK2 complexes 
function to hyperphosphorylate pRB, disrupting its association with the E2F family of 
transcription factors. Different E2F complexes either activate or repress transcription, 
and pRB family members inhibit E2F-mediated activation and augment E2F-mediated 
repression, thus disruption of pRB-E2F binding enables expression of E2F-responsive 
genes critical for cell cycle progression, including cyclins E and A which then reinforce 
progression through to S phase (reviewed in Dyson 1998; Lim & Kaldis 2013). Cyclin E-
CDK2 maintains the hyperphosphorylated state of pRB throughout the remainder of the 
cell cycle, ensuring progression. Cyclin A-CDK2 is then responsible for the continuation 
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of S phase (Krude et al., 1997), and, together with cyclin A- and cyclin B-CDK1, for 
transition through the G2/M checkpoint and entry into mitosis (Chen et al., 2009; Marais 
et al., 2010) (Figure 1.1).  
 
Cell cycle exit can be triggered at the G1/S checkpoint by senescence or differentiation 
signals via two families of cyclin-dependent kinase inhibitors (CDKIs), INK4 and Cip/Kip, 
which function to inactivate cyclin-CDK complexes (reviewed in Buttitta and Edgar 
2007). Members of the INK4 group include p16INK4A (chromosome 9p21), p15INK4B (9p21), 
p18INK4C (1p32) and p19INK4D (19p13) which function to inhibit CDK4 and CDK6 in G1 by 
inhibiting the CDK catalytic domains and weakening affinity of the cyclins for the CDKs 
(Figure 1.1). The Cip/Kip group comprises p21WAF1/CIP1 (p21), p27KIP1 (p27) and p57KIP2 
(p57) which function more broadly to inhibit cyclin D-, E-, A- and B- dependent CDKs 
throughout G1, S and G2 (Sherr & Roberts 1999; reviewed in Lim & Kaldis 2013). INK4 
and Cip/Kip inhibition of cyclin D-CDK4 and -CDK6 and cyclin E-CDK2 at G1 results in 
hypophosphorylated pRB sequestration of E2F transcription factors and subsequent cell 
cycle arrest.  
 
Recent evidence has suggested that G2 cell cycle progression is controlled by cyclin A-
CDK2 and cyclin B-CDK1 phosphorylation of FOXM1, a member of the forkhead box (Fox) 
superfamily of transcription factors, thus activating transcriptional activity and 
promoting the expression of genes responsible for driving mitotic entry (Chen et al. 
2009; Marais et al. 2010; reviewed in Lim & Kaldis 2013). Up-regulation of Cip/Kip 
proteins in response to DNA damage or incomplete replication leads to inhibition of 
cyclin A- and cyclin B-CDK1 activity, FOXM1 hypophosphorylation and subsequent loss 
of transcriptional activity, thus inducing G2 cell cycle arrest (Figure 1.1). Progression 
through the G2/M checkpoint into mitosis stimulates degradation of the A- and B-type 
cyclins by the anaphase-promoting complex, also known as APC/C, leading to mitotic 





Figure 1.1 Schematic summarising the stages of the cell cycle.  In most adult tissues, the 
majority of cells are maintained in a quiescent state (G0). The DREAM complex (DP, p107/p130, 
E2F, and MuvB) represses cell cycle gene expression during quiescence. The cell cycle is 
regulated by complexes of cyclins (yellow) and cyclin-dependent kinases (CDKs, orange). In 
addition, there are various important inhibitors of these cyclin-CDK complexes (INK4 and Cip/Kip 
families, blue). To progress through the cell cycle, cells have to pass through the G1/S transition 
checkpoint (red bar) that is controlled by cyclin D-CDK4/6 and cyclin E-CDK2 pRB and p107/p130 
family members (pRBs)/E2F signalling pathways. The G2/M transition checkpoint is controlled 




1.1.2 The INK4/ARF locus  
 
 
Figure 1.2 The INK4/ARF locus.  Genes of the INK4/ARF locus are shown with coloured boxes 
representing the coding exons of INK4b (green), ARF (purple/blue) and INK4a (blue). 
The INK4/ARF locus on human chromosome 9p21 comprises three tumour suppressors: 
p16; p15INK4B (p15); and p14ARF (ARF) (the equivalent in mice is p19Arf) genes (Figure 
1.2). p15 and p16 bind directly to CDK4 and -6 preventing association with cyclin-D1, 
thus inhibiting kinase activity and halting cell cycle progression (Sherr & Roberts 1999), 
as explored in more detail in Section 1.1.1. ARF functions to stabilise tumour suppressor 
p53 by inhibiting MDM2, leading to up-regulation of p21, inhibition of several CDK 
kinase complexes and subsequent cell cycle arrest (Stott et al. 1998) (Figure 1.3). 
 
Overexpression of oncogenes (e.g. HRas proto-oncogene, GTPase (HRAS); B-Raf proto-
oncogene, serine/threonine kinase (BRAF); CRAF; v-myc avian myelocytomatosis viral 
oncogene homolog (MYC)), or loss of tumour suppressors, such as phosphatase and 
tensin homolog (PTEN), are known to be activators of the INK4/ARF locus (Serrano et 
al., 1997; Zhu et al., 1998; Chen et al., 2005). For example, RAS signalling through the 
RAF-MEK-ERK kinase cascade is thought to stimulate ETS1 and 2 transcription factors to 
induce p16 expression (Ohtani et al., 2001) as well as increasing levels of intracellular 
reactive oxygen species (ROS), thus enabling activation of p16 via the p38 family of 
stress-activated kinases (Deng et al., 2004) (Figure 1.3). Additional regulators of the 
locus present a complex picture of INK4/ARF activation (reviewed in Gil & Peters 2006; 
Martin et al. 2014). Immediate early genes which are up-regulated in response to 
mitogenic signals are known to regulate the INK4/ARF locus, including members of the 
activator protein 1 (AP-1) family (JUNB, c-JUN, and JUND) and early growth response 1 
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(EGR1). In mouse embryonic fibroblasts (MEFs), overexpression of JUNB induces p16 
expression, c-JUN modestly represses p16 but activates the ARF promoter (Passegué 
and Wagner, 2000), and JUND represses ARF in MEFs (Weitzman et al. 2000). EGR1, a 
transcription factor, is also known to repress ARF in MEFs (Krones-Herzig, Adamson and 
Mercola, 2003), as discussed in more detail in Section 1.8.5. Additionally, the WNT/β-
catenin signalling pathway has been proposed to regulate p16 in a cell type-dependent 
manner (reviewed in Martin et al. 2014). A β-catenin binding site has been identified in 
the INK4a promoter (Wassermann et al., 2009), and β-catenin induced ARF 
accumulation in MEFs (Damalas et al., 2001) and stimulated expression of p16 in human 
colorectal cancer cell lines (Wassermann et al., 2009). However, β-catenin repressed p16 
in murine melanocytes (Damalas et al., 2001) and was identified as a repressor of p16 in 
human mammary epithelial cells (HMECs) in a genome-wide RNA interference (RNAi) 
screen (Bishop et al., 2010). SUFU, a negative regulator of hedgehog signalling, is known 
to interact with β-catenin and decrease β-catenin nuclear levels, and was revealed as a 
p16 activator in HMECs (Bishop et al., 2010). There is also evidence to suggest that 
aberrantly high levels of E2F transcription factors stimulate up-regulation of ARF; 
however, there is no direct evidence that p16 is regulated by the E2Fs (Komori et al., 
2005). 
 
As p16 plays a crucial role in ageing, cancer, and other diseases, it is essential for a 
normal cell to maintain reliable repression of the INK4/ARF locus. Thus, epigenetic 
regulation of the INK4/ARF locus is performed by the polycomb repressive complexes 1 
and 2 (PRC1 and PRC2), which function to repress transcription through histone 
methylation and ubiquitination (Jacobs et al. 1999; Gil et al. 2004; reviewed in Martin et 
al. 2014). PRC2, comprised of embryonic ectoderm development (EED); SUZ12 
polycomb repressive complex 2 subunit (SUZ12); and the histone methyltransferase, 
enhancer of zeste 1 polycomb repressive complex 2 subunit (EZH1) functions as an 
initiator of transcription repression by catalysing histone H3 lysine 27 trimethylation, an 
epigenetic mark recognised by PRC1. Subsequently, PRC1, comprised of BMI1 proto-
oncogene polycomb ring finger (BMI1), polyhomeotic homolog 1 or 2 (Ph1 or 2), 
chromobox homolog 7 (CBX7), and the ubiquitin E3 ligases, ring finger protein 1A or B 
(RING1A or B), catalyses the monoubiquitination of lysine 119 of histone H2A and 
implements gene silencing (reviewed in Martin et al. 2014). Importantly, PRC1 and PRC2 
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have been found to bind directly to the INK4/ARF locus (Bracken et al., 2007). 
Furthermore, reduced expression of these complexes results in increased p16 levels and 
activation of senescence (Gil et al., 2004), and overexpression of individual PRC 
components extends replicative lifespan via repression of INK4/ARF (Jacobs et al., 1999; 
Gil et al., 2004; Bruggeman et al., 2011). Although it is well-established that BMI1 and 
CBX7 levels decline during senescence in fibroblasts (Jacobs et al., 1999; Gil et al., 2004) 
the molecular pathways that regulate expression of these complexes during senescence 
is unclear. However, recent work has identified senescence-associated microRNAs (SA-
miRNAs) which directly repress transcription of polycomb group complex members 
(Overhoff et al., 2014).  
1.1.3 p21 
p21, cyclin-dependent kinase inhibitor 1A (CDKN1A), is a well-characterised member of 
the Cip/Kip family of CDKIs which functions mainly to inhibit cyclin/CDK2 complexes, as 
described in Section 1.1.1 in more detail. p21, a transcriptional target of the tumour 
suppressor p53, plays an important role in mediating DNA-damage induced cell-cycle 
arrest in G1 and G2. DNA damage sensors, including ataxia-telangiectasia mutated 
(ATM) (Lavin and Shiloh, 1997) and ataxia-telengiectasia mutated and Rad3-related ATR 
(ATR) (Cliby et al., 1998), phosphorylate the checkpoint kinases CHK1 and CHK2 
(Matsuoka, Huang and Elledge, 1998; Liu et al., 2000), which in turn phosphorylate p53 
on serine 20, preventing MDM2 binding, ubiquitination and targeting for degradation 
(Dumaz et al., 2001). Following this, p53 then acts as a transcription factor inducing the 
expression of p21 which in turn inhibits several cyclin-CDK complexes and halts the cell 
cycle (Figure 1.1) (Turenne et al., 2001). In order to maintain low levels of p53 under 
normal conditions, MDM2 ubiquitinates p53 to facilitate degradation (Oren, 1999). This 
process can be modulated by the products of the INK4/ARF locus, as ARF is known to 
bind to MDM2 preventing MDM2-mediated p53 degradation (Zhang, Xiong and 





Figure 1.3 Pathways to p16 and p21 activation and senescence induction. Senescence triggers 
(grey boxes) stimulate downstream genes (blue) ultimately leading to up-regulation and 
activation of tumour suppressors p16 and p21 (dark blue), arresting the cell by inhibition of pRB 
phosphorylation, subsequent sequestration of E2F transcription factors and inhibition of 
transcription of downstream E2F-regulated genes critical for cell cycle progression. 
Other mechanisms of p21 activation include PTEN loss or AKT serine/threonine kinase 
(AKT) activation which subsequently activates mechanistic target of rapamycin complex 
1 (mTORC1), inducing p53 activity and p21 up-regulation (Astle et al., 2012). Similar to 
the INK4/ARF locus (see Section 1.1.2), the RAS-RAF-MEK-ERK cascade induces high 
levels of ROS, activating p38 MAPK which leads to increased p53 transcriptional activity 
and up-regulation of p21 (Sun et al., 2007). In addition, the senescence-associated 
secretory phenotype (SASP) (see Section 1.4.2) component TGF-β can induce p15 and 
p21 up-regulation in a paracrine manner via a mechanism that generates ROS and DNA 
damage (Acosta et al., 2013) (Figure 1.3). It has been suggested that DNA damage 
signalling through p53-p21-p38-TGF-β during senescence stimulates mitochondrial 
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dysfunction and increases ROS levels, thus inducing further DNA damage and generating 
a stable self-sustaining feedback loop reinforcing senescence (Passos et al., 2010). 
 
Furthermore, p21 is a multi-functional protein which plays key roles in processes not 
limited to CDK inhibition. Independently of CDKs, p21 regulates cell cycle progression 
via inhibition of proliferating cell nuclear antigen (PCNA), subsequently blocking DNA 
synthesis (Luo, Hurwitz and Massagué, 1995; Warbrick et al., 1995), and is also known 
to interact directly with and inhibit a range of transcription factors, including E2F1, c-
Myc, and STAT3 (Delavaine and La Thangue, 1999; Coqueret and Gascan, 2000; Kitaura 
et al., 2000). Paradoxically, studies have also reported that p21 participates in the 
assembly of cyclin D-CDK4/6 complexes, promoting CDK catalytic activity and 
sequestration of p21 into cyclin D-CDK4/6 complexes, thus allowing downstream 
activation of cyclin E-CDK2 and cell cycle progression (Figure 1.1) (Labaer et al., 1997; 
Perez-Roger et al., 1999). In addition, the p53/p21 pathway is also known to be 
important for triggering apoptosis. The mechanisms by which a cell decides whether to 
induce apoptosis or senescence in response to sustained p53/p21 signalling are 
currently unknown; however, it is thought that high levels of p53 and lysine 117 
acetylation lead to transcription of apoptotic genes whereas low levels of p53 with 
transient kinetics and lysine 161/162 acetylation promotes senescence (reviewed in 
Childs et al. 2014). In addition, the apoptotic function of p53 is enhanced by binding of 
two members of the apoptosis stimulating protein of p53 (ASPP) family, ASPP1 and 2, to 
the p53 DNA binding domains, specifically stimulating the transactivation function of 
p53 at promoters of pro-apoptotic genes (Samuels-Lev et al., 2001). Alterations to the 
p53/p21 signalling pathway during senescence, such as decreased ability to stabilise p53 
to the levels required for apoptosis (Seluanov et al. 2001) and senescence-specific p53 
post-translational modifications (Webley et al. 2000), together with senescence-
associated up-regulation of pro-survival, anti-apoptotic genes, such as B-cell lymphoma 
2 (BCL-2) (Wang, 1995), are thought to lead to resistance to p53-dependent apoptosis 
(Webley et al. 2000; Seluanov et al. 2001; Zhu et al. 2015; reviewed in Childs et al. 2014).  
1.2 Fibroblast replicative senescence 
Hayflick & Moorhead (1961) first discovered the limited replicative capacity of primary 
human foetal fibroblasts in culture. They found that early passage cells (hereafter known 
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as ‘early proliferating’ (EP)) proliferated in vitro for approximately 55 population 
doublings before succumbing to stable, G1 cell cycle arrest. This replicative barrier, or 
‘Hayflick limit’, is now known as replicative senescence (RS) (Figure 1.4). Recent 
evidence has suggested that replicative senescence is a multi-step, dynamic process 
throughout which senescent cells evolve and progress (Kim et al., 2013). Deep 
senescence (DS), a stable, actively maintained senescent phenotype, takes over 7-10 
days to develop post-senescence induction (Coppé et al. 2008; Rodier et al. 2009; Passos 
et al. 2010), and is characterised by additional markers of senescence such as a loss of 
lamin B1 and nuclear envelope integrity (Freund et al. 2012; reviewed in Baker & Sedivy 
2013), as well as large scale chromatin changes (Narita et al., 2003; Freund et al., 2012; 
Shah et al., 2013; Swanson et al., 2013). 
 
Figure 1.4 The Hayflick limit.  (A) Early proliferating (EP, red) normal human fibroblasts undergo 
replicative senescence (RS, green) after a finite number of cell divisions in culture, as observed 
by Hayflick & Moorhead (1961). Deeply senescent (DS, blue) cells undergo no further expansion 
upon at least two serial passages. (B) Images depicting early proliferating (EP, top panel) and 
replicatively senescent (RS, bottom panel) normal adult human mammary fibroblasts (HMFs), 




Telomere dysfunction is well-established as the main trigger of replicative senescence 
(Bodnar et al., 1998). Telomeres are regions of repetitive nucleotide sequences 
(TTAGGG in vertebrates) that cap the ends of linear chromosomes and protect them 
from chromosomal fusion. Telomeres progressively shorten during each cell division due 
to a phenomenon known as the 'end replication problem'. In brief, the bi-directional 
DNA helix can be replicated in only one direction (5’ to 3’), meaning that the 'lagging 
strand' (3’ to 5’) must be replicated in small fragments as the replication fork unwinds 
the DNA helix. DNA polymerase requires a primer for each fragment to initiate synthesis, 
thus the end sequence of the lagging strand  serves as a primer and is not replicated. 
When the telomeres reach a critically short length, a DNA damage response (DDR) is 
rapidly triggered as described in Section 1.1.3 (Figure 1.3) leading to activation of p53, 
increased transcription of p21 and cell cycle arrest (Turenne et al., 2001). This process is 
associated with the appearance of DDR foci which stain positive for phosphorylated 
histone variant H2AX (γ-H2AX) and the DNA damage checkpoint factor 53BP1, two 
widely accepted markers of replicative senescence (di Fagagna et al., 2003).  
 
The p16/pRB pathway is also activated by dysfunctional telomeres, albeit with slower 
kinetics than the p53/p21 pathway (Jacobs and De Lange, 2004). It is thought that rapid 
DDR-induction of p21 expression inhibits cyclin D1-CDK4, -CDK6, and cyclin E-CDK2 
providing a primary halt to cell proliferation (Stein et al., 1999). Subsequent activation 
of p16 then acts as an important secondary barrier to proliferation and contributes to 
maintenance of the senescent phenotype (Stein et al., 1999). Consistent with this idea, 
p21 protein expression reaches a peak during the final two to three passages as the 
culture nears senescence (Alcorta et al., 1996). p16 protein levels gradually rise in 
senescent fibroblasts, reaching a maximum after p21 levels have started to decline 
(Alcorta et al. 1996, Figure 1.5). Consequently, senescent fibroblast cultures can be 




Figure 1.5 p16 and p21 kinetics and roles in replicative senescence.  An early proliferating (EP) 
fibroblast population expresses a low level of p21 but not p16. Increased expression of p21 and 
p16 in senescence occurs with different kinetics in a fibroblast population. During the final two 
to three passages prior to senescence, p21 expression increases in the population due to 
telomere shortening triggering a DNA damage response. Telomere shortening then also triggers 
p16 activation with slower kinetics in the population. As senescence deepens, p21 expression 
declines in the population whereas p16 expression continues to gradually rise. 
1.3 Other types of senescence 
1.3.1 Epithelial cellular senescence 
Unlike fibroblasts, epithelial cells exhibit a two-step pattern of senescence, where cells 
first undergo p16-dependent senescence in the absence of telomere erosion and p53 
expression, referred to in this report as cellular senescence (Brenner, Stampfer and 
Aldaz, 1998). As mentioned previously, the exact mechanisms of p16 activation are 
currently unclear and occur heterogeneously within an EP HMEC proliferation; however, 
there is evidence to suggest that, in epithelial cells, this is induced by exposure to stress 
and a decline in polycomb proteins repressing transcription of the INK4/ARF locus 
(Ramirez et al., 2001; Gil et al., 2004; Garbe et al., 2009). Evidence both in vitro and in 
vivo has shown that epithelial cells will typically bypass cellular senescence via p16 
promoter methylation (Huschtscha et al., 1998; Holst et al., 2003). After p16 promoter 
methylation, epithelial cells will then continue on to divide until telomere-dependent 
senescence is triggered (Garbe et al., 2009); thus, unlike fibroblasts, replicative 





Figure 1.6 Schematic illustrating epithelial cellular senescence and replicative senescence.  
Early proliferating (EP) epithelial cells undergo p16-dependent cellular senescence after serial 
passaging reaching deep senescence (DS) after being kept in culture for three weeks. Epithelial 
cells can bypass cellular senescence via p16 promoter methylation and continue to proliferate 
until critically short telomeres trigger p53/p21 pathway activation inducing senescence.  
1.3.2 Premature senescence 
In addition to replicative senescence and cellular senescence, fibroblasts, epithelial cells 
and other cell types may also undergo premature senescence in response to a variety of 
triggers. Oncogene-induced senescence (OIS) is caused by activated oncogenes (RAS, 
MEK, BRAF) or loss of tumour suppressors (PTEN), involves both the p53/p21 and 
p16/pRB pathways (see Sections 1.1.2 and 1.1.3), and is thought to suppress 
tumourigenesis in vivo (Serrano et al., 1997; Lin et al., 1998; Zhu et al., 1998; Dimri et 
al., 2000). Oxidative stress or suboptimal cell culture can initiate stress-induced 
premature senescence (SIPS), engaging the p38 pathway and inducing either or both the 
p16/pRB and p53/p21 pathways, although the nature of this mechanism is poorly 
understood (Takahashi et al. 2006; reviewed in Muñoz-Espín & Serrano 2014). In 
addition, recent evidence has suggested that dysfunctional mitochondria can induce 
senescence (Wiley et al., 2016). Little is known about the mechanisms which mediate 
this effect but studies implicate increased ROS, sustained activation of 5’ AMP-activated 
protein kinase (AMPK), or interplay between the DDR and mTOR signalling (Moiseeva et 
al., 2009; Correia-Melo et al., 2016; Wiley et al., 2016).  
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1.3.3 Senescence in other cell types 
In addition to fibroblasts and epithelial cells, other cell types have been detected to 
undergo senescence, including endothelial cells (Erusalimsky, 2009), vascular smooth 
muscle cells (VSMC) (Matthews et al., 2006), T lymphocytes (Brzezińska, Magalska and 
Sikora, 2003), glial cells (Chinta et al., 2013), melanocytes (Michaloglou et al., 2005), 
foam cells (fat-laden macrophages, VSMC-like, and endothelial-like cells present in 
atherosclerosis) (Childs et al., 2016) and islet cells (Krishnamurthy et al., 2006) (reviewed 
in Sikora 2013). Furthermore, recent studies reported that post-mitotic cells such as 
neurons (Geng et al., 2010; Panossian et al., 2011; Jurk et al., 2012), and adipocytes 
(Tchkonia et al., 2010) can also acquire features of senescence.  
 
T cell senescence has been particularly well-characterised in vitro. Following multiple 
rounds of stimulation by antigen-presenting cells (APCs) and subsequent proliferation, 
senescence is triggered in T cells by critically short telomeres via p53/p21, p16/pRB and 
p38 signalling pathways (Liu et al. 2009; Lanna et al. 2015). Similar to fibroblasts, 
senescent CD8 T cells have shortened telomeres, increased expression of p16 and p21, 
and a pro-inflammatory secretory phenotype, including interleukin 6 (IL-6) and tumour 
necrosis factor alpha (TNF-α) (reviewed in Chou & Effros 2013). However, unlike 
fibroblasts, a crucial phenotype in T cell senescence is the permanent loss of the CD28 
co-stimulatory molecule, an essential signalling receptor that activates T cells via the NF-
κB pathway. As CD28 surface expression is necessary to mount effective T cell immune 
responses, down-regulation of CD28 fundamentally alters normal T cell function, 
survival and proliferation. For example, proliferating CD8 T cells possess the ability to 
up-regulate telomerase but CD28 down-regulation stimulates the loss of telomerase 
activity (Parish, Wu and Effros, 2010). In addition, consistent with observations in 
fibroblasts (see Section 1.2), senescent CD8 T cells are resistant to apoptosis (Spaulding, 
Guo and Effros, 1999). In support of in vitro evidence for T cell senescence, studies in 
vivo have shown that older persons have higher proportions of CD28-CD8+ T cells with 
shortened telomeres compared to younger adults (Fagnoni et al. 1996; reviewed in Chou 
& Effros 2013).  
 
 The majority of research exploring T cell senescence focuses on CD8 effector T cells. 
However, CD4 T cells, which normally function to co-ordinate signalling between T cells, 
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B cells, and APCs, have also been identified to undergo senescence characterised 
according to the same criteria as CD8 T cell senescence (reviewed in Chou & Effros 2013). 
However, upon senescence, CD4 T cells develop cytotoxic abilities normally reserved for 
CD8 cells and have been shown to kill endothelial cells in vitro (Nakajima et al., 2002). 
Senescent CD4 T cells may play an important role in development of age-related 
autoimmune disorders as an increase in numbers of CD28-CD4+ T cells has been found 
in elderly patients with rheumatoid arthritis (Koetz et al., 2000). 
1.4 Markers of senescence  
1.4.1 Commonly used markers of senescence 
As described in Section 1.2 and Section 1.3, senescence can be induced by different 
triggers in multiple different cell types with subsequently varying senescent features, 
resulting in many markers of senescent phenotypes but no universal marker of the 
senescent state. Thus, multiple markers representing different characteristics of 
senescence should be used to clearly indicate the presence of senescence. A panel of 
markers should represent at least three of the following senescence-associated 
phenotypes: lack of proliferation; changes in nuclear and cellular morphology; 
expression of tumour suppressor genes; increased DNA damage; altered epigenetic 
landscape; expression of secretory factors; and senescence-associated β-galactosidase 
(SA-β-Gal) activity, as summarised in Appendix Table A.1. 
 
Replicatively senescent fibroblasts adopt a complex phenotype characterised by an 
enlarged, flattened, and often vacuolated cellular morphology in vitro (reviewed in 
Sikora et al. 2011). Senescent fibroblasts possess enlarged nuclei which are irregularly 
shaped due to down-regulation of lamin B1, a structural protein of the nuclear envelope 
(Freund et al., 2012). In addition, senescent fibroblasts up-regulate the p16/pRB and 
p53/p21 pathways; β-galactosidase activity detectable at pH 6.0 (SA-β-Gal) resulting 
from increased lysosomal biogenesis (Dimri et al., 1995; Lee et al., 2006); DDR foci 
characterised by γ-H2AX (di Fagagna et al., 2003); and levels of oxidative DNA damage, 
measured using 8-oxoguanine (8-oxoG); Chen et al. 1995). Furthermore, activation of 
the p16/pRB pathway in replicative senescence can lead to the formation of distinct 
DAPI-dense foci known as senescence-associated heterochromatin foci (SAHF). In 
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fibroblasts, SAHF formation is variable between cell strains and is not considered a 
universal feature of replicative senescence (Kosar et al., 2011). SAHFs play a role in 
sequestering and silencing E2F target genes essential for cell proliferation, and are 
associated with the presence of chromatin modifications (for example, methylation of 
histone 3 (H3) on lysine 9 (Lys9)), macroH2A, a histone variant known to contribute to 
gene silencing, and heterochromatin protein-1 (HP1), a common marker of 
heterochromatin (Narita et al., 2003). In addition, promyelocytic leukaemia (PML) is 
known to promote the localisation of pRB/E2F complexes to PML nuclear bodies, a 
macromolecular structure associated with the nuclear matrix, which sequesters E2F and 
further inhibits its transcriptional activity (Vernier et al., 2011). 
 
It is well-established that total genomic DNA methylation decreases during ageing and 
replicative senescence (reviewed in Sedivy et al. 2008). Furthermore, recent work in 
replicatively senescent fibroblasts (Cruickshanks et al., 2013; Hänzelmann et al., 2015), 
as well as senescent mesenchymal stromal cells (Bork et al., 2010), epithelial cells (Lowe 
et al. 2015) , and endothelial cells (Lowe, Horvath and Raj, 2016) has shown that 
senescent human cells possess a distinct DNA methylation signature from the 
proliferating culture, establishing this DNA modification as a novel marker of 
senescence. It has yet to be elucidated whether alterations in the global methylation 
state translates into specific gene expression changes, presenting an interesting topic 
for future research. 
1.4.2 Senescence-associated secretory phenotype (SASP) 
Senescent cells remain metabolically active and undergo widespread gene expression 
changes including increased expression of genes encoding secreted factors comprising 
the SASP. The SASP secretome is diverse and includes a range of 40-80 factors, such as 
inflammatory cytokines (IL-6, IL-8), growth factors, matrix metalloproteinases (MMPs) 
known to remodel the extracellular matrix, ROS which reinforce senescence in an 
autocrine fashion, and TGF-β family members which induce senescence in neighbouring 
cells (paracrine senescence) (Coppé et al., 2008; Passos et al., 2010; Nelson et al., 2012; 
Acosta et al., 2013). The SASP is a complex phenotype and develops slowly. From the 
point of triggering senescence, it can take seven to 10 days for the full pro-inflammatory 
SASP phenotype to appear in human fibroblasts (Coppé et al., 2008; Rodier et al., 2009; 
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Passos et al., 2010), although an early peak in platelet-derived growth factor AA (PDGF-
AA), a SASP factor which promotes myofibroblast differentiation, can be seen as early 
as two days post-senescence induction in wound-associated senescent cells (Demaria et 
al., 2014). Interestingly, neither the p16/pRB or p53/p21 pathway is required for 
induction of the SASP (Coppé et al. 2008; reviewed in Coppé et al. 2010). Consequently, 
the pathways which regulate the SASP are distinct from those involved in initiating or 
enforcing cell cycle arrest. It is currently not clear how senescence stimuli trigger the 
downstream gene expression changes necessary for the SASP. However, recent work 
has suggested that redistribution of high mobility group box 1 (HMGB1), a protein 
capable of modulating gene expression when localised in the nucleus and, in a secreted 
form, stimulating cytokine secretion, is a possible mechanism linking the p53/p21 
pathway and SASP induction. Prior to the development of the SASP, HMGB1 is 
relocalised from the nucleus to the extracellular milieu in a p53-dependent manner 
which is essential for senescence induction. Once secreted, HMGB1 can then stimulate 
cytokine secretion via toll like receptor 4 (TLR-4) and NF-κB signalling (Davalos et al., 
2013). Furthermore, HMGB2 has been found to potentially preferentially localise to 
SASP gene loci during senescence, thus excluding SASP loci from the surrounding 
repressive heterochromatin environment (Aird et al. 2016). Up-regulation of SASP 
factors is dependent on the increased activity of transcription factors NF-κB and C/EBPβ 
(Figure 1.7) (Coppé et al. 2008; reviewed in Freund et al. 2010). NF-κB, a downstream 
target of the DDR, is also thought to be gradually up-regulated by persistent low-level 
DDR signalling during senescence (Rodier et al., 2009). Recent work suggests that the 
DDR induces the SASP by inhibiting autophagy of GATA binding protein 4 (GATA4), a 
transcription factor and upstream regulator of NF-κB via TRAF3 interacting protein 1 
(TRAF3IP1) and IL-1α (Kang et al., 2015). In addition, there is evidence to suggest that 
p38 MAPK activation plays a role in SASP activation, as inhibition reduced IL-8 expression 
in OIS neonatal foreskin IMR-90 fibroblasts (Acosta et al., 2008), a range of SASP factors 
in SIPS neonatal foreskin HCA2 fibroblasts (Freund, Patil and Campisi, 2011), and IL-6 
expression in replicatively senescent human dermal fibroblasts (Alimbetov et al., 2016). 
IL-1α, a component of the SASP, has also been shown to participate in a positive 
feedback loop via NF-κB activation to stimulate IL-6 and IL-8 secretion (Orjalo et al., 
2009). Furthermore, two microRNAs, miR-146a and miR-146b, have been identified to 
negatively regulate the SASP via interleukin 1 receptor associated kinase 1 (IRAK1), a 
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positive regulator of NF-κB (Bhaumik et al., 2009). However, inhibition of IL-1 signalling 
prevents up-regulation of miR-146a and miR-146b, indicating the important role of NF-
κB in both positive and negative regulation of the SASP (Bhaumik et al., 2009). In a recent 
screen, an extra layer of regulation was discovered as mTOR was identified to regulate 
SASP induction via down-regulation of mitogen-activated protein kinase-activated 
protein kinase 2 (MAPKAPK2) and IL-1α translation (Herranz et al., 2015; Laberge et al., 
2015). MAPKAPK2 functions to phosphorylate and inhibit ZFP36 ring finger protein like 
1 (ZFP36LI), a messenger RNA (mRNA)-binding protein which targets SASP components 
for decay (Herranz et al., 2015). Further work has revealed that mitochondrial 
dysfunction-associated senescence (MiDAS) leads to a decreased nicotinamide adenine 
dinucleotide (NAD+)/reduced NAD (NADH) ratio, activation of protein kinase AMP-
activated catalytic subunit alpha 1 (AMPK) and the tumour suppressor p53, which 
modifies the SASP by preventing secretion of IL-1-dependent pro-inflammatory factors 
(Wiley et al., 2016). Importantly, a recent study identified NOTCH1 as a key regulator of 
SASP composition, allowing senescent cells to switch between a pro-inflammatory 






Figure 1.7 Pathways to SASP induction.  As neither the p16/pRB nor p53/p21 pathway is 
required for SASP induction, the pathways which regulate the SASP are distinct from those 
enforcing cell cycle arrest. Regulation of the SASP involves co-ordination between transcription 
factors NF-κB and C/EBPβ, which are regulated by signalling pathways, including p38, NOTCH1, 
mTOR, and mitochondrial dysfunction, as well as feedback loops, including IL-1α, and miR-146a 
and -146b. 
1.5 Senescence in vivo 
1.5.1 Senescence, tissue dysfunction, and ageing 
The world's population is rapidly ageing. In the UK, around one in six people is currently 
over 65, and this is predicted to rise to one in four within the next 30 years. Ageing is a 
major risk factor for developing most late-onset diseases (i.e. cardiovascular disease, 
neurodegenerative disease, and cancer). Furthermore, our ageing society presents 
considerable socio-economic challenges for individuals, families, and governments 
facing increased expenditure on health, social care, and pensions (reviewed in Tchkonia 




Several studies present convincing evidence of a correlation between ageing and 
senescence; for example, expression of p16 increases with age in human tissues 
(Krishnamurthy et al., 2006). Senescent cells are present in sites of age-related diseases 
such as osteoarthritis, atherosclerosis, and Alzheimer’s disease (Naylor, Baker and van 
Deursen, 2013). Furthermore, genome-wide associated studies (GWAS) repeatedly link 
the INK4/ARF locus with susceptibility to prevalent age-related disorders, such as 
coronary heart disease and type 2 diabetes (reviewed in Jeck et al. 2012). 
 
In 2011, the first in vivo evidence for a causal link between p16-positive senescent cells 
and the development of age-related pathologies was presented (Baker et al., 2011). In 
this study, a progeroid mouse model was used in combination with a transgene, INK-
ATTAC, to selectively induce apoptosis in p16-positive senescent cells upon 
administration of a synthetic drug (AP20817). Late-life clearance of p16-positive 
senescent cells attenuated the progression of already-established age-related disorders 
in skeletal muscle, fat, and eyes. However, clearance of p16-positive senescent cells did 
not attenuate deterioration in the cardiovascular system and brain, as these 
dysfunctions developed independently of elevated p16 expression. Consequently, 
elimination of p16-positive senescent cells did not prolong lifespan in the BubR1 
progeroid mice because of accelerated cardiovascular disease. Importantly, the authors 
recently demonstrated that use of the INK-ATTAC transgene in two genetic strains of 
wild-type (WT) mice significantly extended both the median health- and lifespan in male 
and female mice (Baker et al., 2016), presenting exciting implications for the treatment 
of age-related diseases and improving healthspan in humans.  
 
An important question that has yet to be addressed is how senescence in humans drives 
age-related dysfunction. The gradual accumulation of senescent cells in tissues with age 
is described as ‘chronic senescence’, and is thought to contribute to age-related 
disorders through a few key mechanisms (reviewed in van Deursen 2014). First, 
senescence can deplete the pools of cycling cells in an organism (including stem cells) 
subsequently disrupting tissue homeostasis and regeneration. For example, p16 
expression increases with age in the stem and progenitor cells of the mouse brain 
(Molofsky et al., 2006), bone marrow (Janzen et al., 2006), and pancreas (Krishnamurthy 
et al., 2006), where it suppresses stem cell proliferation and regeneration. Notably, the 
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age-related decline in stem/progenitor cell function and tissue regenerative capacity is 
substantially reduced in p16 knockout mice (Janzen et al., 2006; Molofsky et al., 2006). 
In addition, senescence is known to act as a barrier for efficient reprogramming of 
primary cells into pluripotent stem cells (Banito et al., 2009). Secondly, senescent cells 
are thought to impair the function of the surrounding tissue through secretion of 
biologically active molecules in the SASP. For example, the fibroblast SASP contains 
components, such as extracellular matrix (ECM) remodelling proteins (e.g. MMP-3 and -
10), which can disrupt tissue structure and organisation (Parrinello et al., 2005). In 
addition, the SASP contains pro-inflammatory proteins, including IL-6 and IL-8, which 
may act as a source of chronic inflammation in tissues where senescent cells have 
accumulated (Coppé et al., 2008). Low-level chronic tissue inflammation is a hallmark of 
ageing and plays an important role in the development and progression of several age-
related diseases (reviewed in Freund et al. 2010). Together with MMPs, these 
inflammatory factors are thought to create a cancer permissive microenvironment. In 
line with this theory, the fibroblast SASP has been observed to promote the proliferation 
of premalignant or malignant epithelial cells in culture (Krtolica et al., 2001) and in vivo 
(Liu and Hornsby, 2007). In addition, the fibroblast SASP may also intensify age-related 
dysfunction by spreading senescence to healthy neighbouring cells through secretion of 
TGF-β family members, chemokines and other factors (paracrine senescence) (Nelson et 





Figure 1.8 Mechanisms of senescence-induced tissue degeneration.  There are a number of 
potential mechanisms by which senescence could drive age-related pathologies. The first 
mechanism proposes that senescent cells deplete pools of cycling cells in organisms, disrupting 
tissue homeostasis and rejuvenation (Janzen et al., 2006; Krishnamurthy et al., 2006; Molofsky 
et al., 2006). Another mechanism suggests that senescent cells damage the tissue environment 
through chronic inflammation, extracellular matrix degradation, and tumour-inducing 
components of the SASP (Krtolica et al. 2001; Coppé et al. 2008; reviewed in Freund et al. 2010). 
Recently, the ability of senescent fibroblasts to spread senescence through their neighbouring 
environment (paracrine) was discovered (Acosta et al., 2013), which may exacerbate the tissue 
damage.  
Furthermore, why do these chronically senescent cells accumulate in tissues with age?  
There are currently two proposed mechanisms for senescent cell accumulation 
(reviewed in van Deursen 2014). The first is that senescent cell production increases 
with age in vivo. In line with this, several studies have demonstrated that stresses which 
induce senescence increase with age (reviewed in Garinis et al. 2008). Second, the ability 
of the body to efficiently clear senescent cells may decline with age. In support of this 
idea, senescent cells are known to attract immune cells through secretion of chemokines 
and activating cytokines present within the SASP (see Section 1.4.2) (Acosta et al., 2013). 
In addition, recent evidence has convincingly shown that senescent cells can be 
eliminated by immune cells including T cells (Kang et al., 2011), macrophages (Xue et al., 
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2007; Lujambio et al., 2013; Yun, Davaapil and Brockes, 2015), neutrophils (Xue et al., 
2007), and natural killer cells (Xue et al., 2007; Krizhanovsky et al., 2008; Iannello et al., 
2013; Sagiv et al., 2016). Immune clearance of senescent cells may be affected by an 
age-dependent decline in immunological effectiveness, referred to as 
‘immunosenescence’ (reviewed in Goronzy & Weyand 2013). Immunosenescence 
describes a complex and multi-faceted pattern of changes within the immune system 
with age. One of the most important changes is the loss of naïve T cells with age and 
subsequent loss of diversity in the T cell receptor (TCR) repertoire, thus impairing the 
ability of the immune system to respond to antigens (Yager et al., 2008). Other major 
changes include an increase in the number of senescent T cells (see Section 1.3.3). 
Further stimulating chronic inflammation, senescent T cells have a lower production of 
anti-viral cytokines, increased secretion of pro-inflammatory cytokines and also 
secretion of a cytokine which may promote accelerated senescence in other non-
senescent T cells (Lewis et al. 2004; reviewed in Chou & Effros 2013). Interestingly, 
senescent T cells have also been identified at sites of age-related disorders (Pietschmann 
et al. 2001; reviewed in Chou & Effros 2013). In addition, the efficiency and diversity of 
B cell antibody production is also reduced in immunosenescence (reviewed in Goronzy 
& Weyand 2013).  
 
The recent awareness that senescence can drive ageing and age-related disorders (Baker 
et al., 2011, 2016) has inspired efforts to further identify and understand the processes 
driving senescence in order to develop potential therapeutics. Thus, strategies that 
postpone senescence induction and delay senescent cell accumulation could exert a 
beneficial effect on healthspan by delaying or preventing multiple age-related diseases 
(reviewed in Tchkonia et al. 2013). 
1.5.2 Other roles of senescence in vivo  
Studies in vitro and in vivo present convincing evidence that senescence is a crucial 
tumour suppressor mechanism. For example, senescence induction depends on the 
tumour suppressor pathways (p16/pRB and p53/p21) (see Section 1.1.2 and Section 
1.1.3) and most, if not all, cancers harbour mutations in one or both of these pathways 
(reviewed in Rodier & Campisi 2011). Furthermore, senescence may be activated in 
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response to oncogenic events in vitro and in vivo (see Section 1.3.2) (Serrano et al., 
1997).  
Given that senescent cells are known to promote tumourigenesis, it seems paradoxical 
that senescence should also be an established anti-cancer mechanism. However, the 
evolutionary theory of antagonistic pleiotropy stipulates that a biological process 
selected as beneficial in young organisms can become deleterious in later life when 
selection is weak (Williams, 1957).  
Beyond tumour suppression, recent discoveries have expanded our understanding of 
the beneficial roles of senescence in vivo. In contrast to ‘chronic senescence’ (i.e. 
accumulation of deleterious senescent cells with ageing), cells can undergo ‘acute 
senescence’ as part of tightly spatially and temporally controlled biological processes, 
which limits their ability to accumulate with age.  
Senescence has been observed to occur during development in mouse, chicken, quail, 
and human embryos, suggesting conservation of the process across vertebrates (Nacher 
et al., 2006; Muñoz-Espín et al., 2013; Storer et al., 2013). Senescence was detected in 
multiple embryonic structures including the mesonephros (transitory embryonic 
kidney), endolymphatic sac (a filtering tube regulating pressure in the inner ear), and 
the apical ectodermal ridge (AER) (a transient structure marking a limb bud) (Muñoz-
Espín et al., 2013; Storer et al., 2013). Further analysis of the senescent cells in these 
structures revealed that p21 up-regulation and senescence induction is controlled by 
the TGF-β-SMAD and PI3K-FOXO developmental pathways. Interestingly, these 
pathways are already known to induce oncogene-induced and paracrine senescence 
(Figure 1.3) (see Section 1.1.3). As discussed in Section 1.5.1, there is now compelling 
evidence that senescent cells are removed via immune-mediated clearance (Xue et al., 
2007; Iannello et al., 2013; Sagiv et al., 2016). In line with this, senescent cells were 
found to be surrounded by macrophages in the mesonephros and AER during regression 
of these embryonic structures. Furthermore, there was a loss of macrophage 
recruitment to the mesonephros and AER in p21-null embryos resulting in delayed 
elimination of the structures, indicating a causal relationship between induction of 
senescence, macrophage recruitment and clearance of senescent cells (Muñoz-Espín et 
al., 2013; Storer et al., 2013). It is hypothesised that acute senescence during embryonic 
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development plays a compensatory role to apoptosis in morphogenesis (reviewed in 
Muñoz-Espín & Serrano 2014). To further support this idea, Yun et al. 2015 
demonstrated that senescence occurs in vivo at sites of limb regeneration in 
salamanders using SA-β-Gal staining. Senescent cells are found transiently during the 
intermediate stages of regeneration and, in line with the findings described above, are 
subsequently cleared from the limb via macrophage-dependent immune clearance (Yun, 
Davaapil and Brockes, 2015).  
In addition to embryonic development, acute senescence can also occur in adult 
organisms during tissue remodelling in response to damage. The matricellular protein, 
cysteine rich angiogenic inducer 61 (CCN1) expressed at cutaneous wound sites induces 
fibroblast senescence, leading to an accumulation of senescent fibroblasts promoting 
myofibroblast differentiation, anti-fibrosis, and wound healing through the SASP (Jun & 
Lau 2010; Demaria et al. 2014; reviewed in Muñoz-Espín & Serrano 2014). Recent work 
has also demonstrated that connective tissue growth factor (CCN2), a matricellular 
protein up-regulated during the inflammatory phase of wound healing, induces 
senescence in human foetal foreskin fibroblasts (BJ) in vitro and murine fibroblasts in 
vivo (Jun and Lau, 2016). In line with this literature, wound healing was shown to be 
delayed during drug treatment and senescent cell clearance in the INK-ATTAC WT mice, 
which was recovered following suspension of drug treatment (Baker et al., 2016). 
Similarly, the accumulation of senescent activated stellate cells restricts liver fibrosis by 
secretion of MMPs present within the SASP (Krizhanovsky et al., 2008). However, aged 
drug-treated INK-ATTAC WT mice did not show evidence of increased fibrosis in skin or 
other tissues (Baker et al., 2016). 
Importantly, given the role for acute senescence in embryonic and adult tissue 
remodelling, this thesis is focused on exploring the drivers of replicative senescence in 
normal adult human fibroblasts to further understanding of chronic senescence, ageing, 
and age-related diseases. 
1.6 Senescence as a therapeutic target 
As senescent cells are one of the causes of age-associated diseases and ageing, 
preventing or delaying the accumulation of senescent cells could be beneficial to health- 
and lifespan (see Section 1.5.1). Genetic elimination of senescent cells in a mouse model 
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of accelerated ageing delayed ageing and age-related diseases, indicating that targeting 
senescent cells is a promising strategy to improve healthspan (Baker et al., 2011, 2016). 
However, p16/pRB or p53/p21 pathway inactivation is not a feasible therapeutic 
approach in humans as it would eliminate crucial tumour-suppressive mechanisms, thus 
increasing susceptibility to cancer.  
 
A number of different anti-senescence strategies are currently being developed to 
address the deleterious effects of senescent cell accumulation with ageing. One option 
would be to target the pathways driving senescence (see Section 1.7). As mentioned 
previously, it is important not to interfere with tumour suppressor pathways that are 
likely to promote cancer. However, strategies that reduce the processes driving cells into 
chronic senescence, thus delaying age-related senescent cell accumulation could be 
beneficial. For example, short term dietary restriction in middle-aged mice, a treatment 
with known beneficial effects on health and lifespan, is associated with decreased 
abundance of senescent cells in the liver and intestine (Wang et al., 2010). The authors 
speculate that dietary restriction delays accumulation of senescent cells via mTOR 
inhibition, improved mitochondrial function and decreased ROS. Interestingly, 
rapamycin (Demidenko et al., 2009), a mTORC1 inhibitor, and AZD8055 (Walters, 
Deneka-Hannemann and Cox, 2016), a pan-mTOR inhibitor, have been identified to 
delay onset of replicative senescence in vitro (see Section 1.7). In addition, one recent 
study demonstrated that fast food diet (FFD) consumption in mice had a deleterious 
effect on health which was associated with an increase in senescent cells (Schafer et al., 
2016). Furthermore, exercise initiated in mice post-long-term FFD reduced senescent 
phenotype markers and attenuated physical deterioration, indicating that exercise could 
also play a role in delaying senescent cell accumulation in vivo. Thus, strategies designed 
to delay the onset of senescence and prevent senescent cell accumulation in vivo could 
potentially exert a beneficial effect on healthspan in humans. In order to achieve this, 
further understanding of the mechanisms driving senescence is required. 
 
Another option would be to target pathways which can interfere with the adverse 
effects of the SASP. As discussed in Section 1.5.1, the SASP of accumulated senescent 
cells may act as a source of chronic inflammation and play an important role in the 
development and progression of several age-related diseases. Two recent studies have 
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identified key regulators of SASP composition in senescent cells, in particular NOTCH1 
(Hoare et al., 2016), and NAD+/NADH ratios (Wiley et al., 2016) (see Section 1.4.2). 
Targeting these in vivo could manipulate senescent cells to either down-regulate the 
pro-inflammatory arm of the SASP to diminish chronic inflammation, or up-regulate the 
pro-inflammatory arm to facilitate elimination of senescent cells via immune clearance.  
 
In addition, there is a growing body of literature identifying ‘senolytics’, compounds 
which selectively kill senescent cells. As discussed previously in Section 1.1.3, senescent 
cells are known to up-regulate pro-survival pathways that contribute to their resistance 
to apoptosis. An initial study employed gene expression analysis of non-senescent and 
senescent preadipocytes to identify up-regulated negative regulators of apoptosis and 
subsequent siRNA screening to discover potential senolytic targets (Zhu et al., 2015). 
The senolytic targets included components of ephrin survival-regulating dependence 
receptor mechanisms, ephrin ligand (EFN) B1 and EFNB3, as well as the p21 
plasminogen-activated inhibitor 2 (PAI-2), the PI3K delta catalytic subunit (PI3KCD), and 
BCL-XL, which regulates mitochondrial-dependent apoptosis. Screening of drugs known 
to target these genes identified dacatinib (a kinase inhibitor known to interfere with 
ephrin ligand B (EFNB)-dependent apoptosis suppression) and quercetin (a natural 
flavonol inhibiting PI3K and other kinases) (Zhu et al., 2015; Roos et al., 2016), and 
navitoclax (an inhibitor of pro-survival gene Bcl-2) as promising senolytics in vitro and in 
vivo (Zhu et al., 2016). However, all three drugs were identified to eliminate senescent 
cells in a cell type-dependent manner and all are known to have side effects, including 
haematologic dysfunction such as transient thrombocytopenia and neutropenia 
(deficiency of platelets and neutrophils in the blood, respectively), fluid retention, skin 
rash, and QT prolongation. Therefore, further work needs to be performed to explore 
whether these drugs can be used to delay age-related diseases in humans.  
 
In line with previous studies, recent compound screening in non-senescent and 
senescent foetal WI-38 fibroblasts has identified a potent senolytic drug, ABT263, which 
potentially targets BCL-XL and pro-apoptotic BAK (Chang et al., 2016). Treatment of mice 
irradiated to stimulate senescence demonstrated that ABT263 is a potent and broad 
spectrum senolytic drug in vivo, eliminating both senescent bone marrow 
haematopoietic stem cells and senescent muscle stem cells. In addition, ABT-737 (a 
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small molecule inhibitor of BCL-2, BCL-XL, and BCL-W) has been identified to eliminate 
senescent foetal lung IMR-90 fibroblasts in vitro and senescent cells in lung and skin in 
vivo, leading to improved ageing-related phenotypes (Yosef et al., 2016). Although 
ABT263 appears an exciting candidate for future therapeutics, it has some common toxic 
side effects in patients; namely, transient thrombocytopenia and neutropenia, leading 
to increased susceptibility to injury, bruising, and infection. Thus, similar to dacatanib 
and quercetin, further work needs to determine whether ABT263 treatment can be used 
to delay age-related diseases in humans, as well as explore potential adverse side-
effects of ABT-737. Furthermore, there are a number of theoretical side effects caused 
by eliminating senescent cells which need to be tested in normally aged animal models, 
including impaired wound healing or fibrosis during liver regeneration (see Section 
1.5.2) (Krizhanovsky et al., 2008; Demaria et al., 2014). In addition, clearance of 
senescent cells would not restore depleted pools of cycling cells or repair damage to 
non-senescent cells in tissues where senescent cells have accumulated. Thus, true 
rejuvenation would require a combination of senescent cell clearance and extensive 
replacement of depleted and damaged non-senescent cells. In order to restore depleted 
tissues, targeted reversal of senescent progenitor cells could potentially be employed. 
However, senescence has long been considered an irreversible process.  
1.7 Reversal of senescence  
Senescence is classically defined as an irreversible proliferative arrest. Over the past 20 
years, only a few studies have challenged this dogma. An initial study retrovirally 
transduced mutant p53 into ‘near-senescent’ human neonatal foreskin fibroblasts 
(HCA2) and found that this stimulated bypass of senescence-induced growth arrest 
(Bond et al., 1995). Later work then demonstrated that p53 antibody micro-injection in 
senescent HCA2 fibroblasts reinitiated DNA synthesis but with limited proliferation (Gire 
and Wynford-Thomas, 1998). However, as the study did not determine whether residual 
cycling cells were present in the population, no conclusion could be made as to whether 
senescent or slowly cycling cells were re-entering the cell cycle. In addition, ablation of 
p53 function in pre-senescent human fibroblasts delayed but did not prevent replicative 
senescence, indicating that p53 inactivation alone was not sufficient to mediate stable 
reversion of senescence in primary human fibroblasts (Gire and Wynford-Thomas, 
1998). Further work identified that the senescent phenotype in MEFs can be rescued 
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using p53 or pRB inactivation (Dirac and Bernards, 2003; Sage et al., 2003). It should be 
noted here that MEF replicative senescence is distinct from senescence in human cells 
(reviewed in Kuilman et al. 2010). MEFs express telomerase, possess long, stable 
telomeres, and undergo senescence after a limited number of passages in culture, 
despite retaining long telomeres. Furthermore, MEF senescence is dependent on p53 
and p19ARF, not p16 expression. Subsequently, a study investigating the consequences 
of p53 or pRB inactivation in replicatively senescent human foetal fibroblasts concluded 
that in some human cells, p16 provides a dominant, irreversible second barrier to 
proliferation which cannot be completely overcome (Beauséjour et al., 2003).  
 
Recent work has explored mTOR inhibition as a route to senescence reversal. AZD8055 
delayed onset of replicative senescence in ‘near-senescent’ human neonatal fibroblasts 
(Walters, Deneka-Hannemann and Cox, 2016), and senescence induced by progerin, the 
truncated form of lamin A found in patients with Hutchinson-Gilford progeria (Cao et al., 
2011). However, a study investigating rapamycin treatment of human and rodent cell 
lines induced to senesce via exogenous p16 or p21 expression found that rapamycin 
prevents permanent loss of proliferative potential in arrested cells, but does not 
stimulate arrested cells to proliferate (Demidenko et al., 2009). Importantly, epithelial 
cellular senescence has been shown to be reversible using p16 siRNA knockdown in 
normal adult DS HMECs (Lowe et al., 2015); however, unlike fibroblast replicative 
senescence, epithelial cellular senescence occurs solely dependent on p16 expression 
(discussed further in Section 1.3.1). Thus, fibroblast replicative senescence is currently 
still viewed as an irreversible cell cycle arrest in the literature. Given that cells undergo 
acute senescence in development via a different mechanism (Muñoz-Espín et al., 2013; 
Storer et al., 2013) (see Section 1.5.2), it is important to note that none of the previous 
work on senescence reversal was performed in normal adult human fibroblasts. In this 
project, reversal of senescence is defined as the return of DS cells to a state similar to 
that of proliferating cells and distinct from cells which have overcome or bypassed 
senescence. 
 
The ability to reverse replicative senescence in normal adult human fibroblasts would 
contribute to further understanding of the processes driving chronic senescence, 
potentially benefitting all of the anti-senescence strategies outlined in Section 1.6. 
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Therapeutically, it is important to recognise that senescence is known to occur as a 
tumour suppressor mechanism in vivo. As currently it is not possible to distinguish 
senescent cells in vivo by their senescence trigger, a method to identify and specifically 
target non-tumourigenic senescent cells would need to be developed prior to 
therapeutic use of senescence reversal. 
1.8 Early growth response 2 (EGR2) 
In this project, early growth response 2 (EGR2) was identified as the top hit for reversal 
of replicative senescence in HMFs. As such, a brief introduction to the gene is included 
below. 
1.8.1 EGR2 gene locus, isoforms, and family 
The early growth response 2 (EGR2) gene maps to human chromosome 10 at bands q21-
22, with multiple transcript variants encoding isoform A and the slightly shorter isoform 
B (Figure 1.9) (O’Leary et al., 2016). The protein encoded by this gene is a transcription 
factor with three tandem Cys2His2-type zinc fingers (Beckmann and Wilce, 1997). It is 
part of the immediate early gene EGR family encoding Cys2His2 zinc-finger transcription 
factors, comprising EGR1 (5q31), EGR2 (10q21), EGR3 (8p21), and EGR4 (2p13) (Figure 
1.9) (Beckmann and Wilce 1997; reviewed in Poirier et al. 2008). The four EGR family 
members share three highly homologous DNA binding zinc finger domains that can bind 
to the same GC-rich consensus DNA binding motif. The zinc fingers each contain a 
nuclear localisation signal (Matheny, Day and Milbrandt, 1994), which might be involved 
in nuclear localisation of the EGR proteins (Beckmann and Wilce, 1997), as EGR2 is 
known to exist in both the cytoplasm and nucleus (Herdegen et al., 1993). A few other 
conserved domains have also been identified including the R1 domain which is the site 
of interaction for NGFI-A binding (NAB) 1 and 2 proteins that can repress or activate 
transcriptional activity of EGR proteins (Russo, Sevetson and Milbrandt, 1995; Svaren et 
al., 1996). In addition, the transactivity of EGR family members can be regulated by other 
co-modulators such as host cell factor C1 (Luciano and Wilson, 2003), and Ddx20 (Gillian 
and Svaren, 2004). Members of the EGR family have been implicated in a diverse array 






Figure 1.9 Schematic representation of the four members of the human EGR family, including 
the two EGR2 isoforms.  There are several conserved regions between the EGR family members: 
the DNA binding zinc finger domains (blue); regions flanking the zinc finger domains (dark grey); 
NAB interaction domain (green); and transcriptional activation domains (light grey). Outside of 
these regions, the sequences of the EGR family members have less homology suggesting that 
they are differentially regulated by different pathways and may serve different functions. 
Adapted from (Poirier et al., 2008). 
Although these transcription factors show a high degree of homology within the DNA 
binding domains, it is clear that each individual member is regulated by distinct signalling 
pathways in a cell-type dependent manner, and this is highlighted by studies 
demonstrating that EGR1 homozygote knockout mice present a normal phenotype 
whereas EGR2 homozygote knockout results in post-natal lethality (Schneider-
Maunoury et al., 1993; Lee et al., 1996). 
1.8.2 EGR2 and development  
Early work noted that homozygous EGR2 mouse knockouts were lethal in the early 
postnatal period (Schneider-Maunoury et al., 1993). Initial analysis of EGR2 knockout 
embryos demonstrated a tightly controlled role for EGR2 in a number of sites, including 
hindbrain segmentation and development (Schneider-Maunoury et al., 1993; Swiatek 
and Gridley, 1993), endochondral ossification (bone formation) (Levi et al., 1996), and 
myelination of peripheral nerves (Zorick et al., 1996). Fibroblast growth factor (FGF) 
signalling activates EGR2 expression specifically in rhombomere 3 and 5 in the hindbrain 
which is essential for the establishment of these developmental compartments. Within 
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these rhombomeres, cells undergo neuronal differentiation, nerve organisation, and 
neural crest differentiation into a range of cells including Schwann cells which play an 
important role in peripheral nerve myelination (Sham et al., 1993; Labalette et al., 2011). 
Despite early studies identifying the role of EGR2 in endochondral ossification, little is 
known about the role of EGR2 in bone formation. However, there is some evidence to 
suggest that EGR2 is responsible for regulating proliferation and terminal differentiation 
in chondrocytes and osteoclasts via PI3K-AKT and MEK-ERK signalling during 
embryogenesis and post-natal development (Levi et al., 1996; Gabet et al., 2010; Chen 
et al., 2015).  
1.8.3 EGR2 and the peripheral nervous system 
As mutations in EGR2 were identified to result in inherited peripheral neuropathies, 
including Charcot-Marie-Tooth type 1 (Šafka Brožková et al., 2012), Dejerine-Sottas 
syndrome (Gargaun et al., 2016), congenital hypomyelinating neuropathy (Warner et 
al., 1998), progressive scoliosis (Mikešová et al., 2005), and Guillain-Barré Syndrome 
(Doncel-Perez et al., 2015), the main focus of the literature to date has been on the role 
of EGR2 in the peripheral nervous system (PNS). Schwann cells, the principal glial cells 
of the vertebrate PNS, are essential for support and myelination of PNS axons. The 
development of Schwann cells into a final pro-myelinating form requires precise control 
of proliferation and cell cycle exit, with impaired control resulting in the inherited 
peripheral neuropathies as described above (Atanasoski et al., 2006). Accumulating 
evidence suggests that EGR2 is a master regulator of proliferation and final 
differentiation in Schwann cells thus controlling onset of myelination in the PNS (Topilko 
et al., 1994; Zorick et al., 1996; Decker, 2006). Further studies elucidating the 
mechanism of EGR2-regulated Schwann cell myelination have identified p38 as an up-
stream activator of EGR2 expression leading to strongly reduced proliferation, increased 
levels of the cell cycle inhibitor p27, inhibition of apoptosis via the JNK/c-Jun pathway, 
and altered expression of myelin-associated genes (Parkinson et al., 2004; LeBlanc et al., 
2006; Hossain et al., 2012). As both p21 and p16 are required for control of Schwann 
cell proliferation and differentiation (Atanasoski et al., 2006), it seems likely that EGR2, 
a master regulator of the process, modulates the expression of these proteins. Using 
microarray expression analysis, EGR2 has been discovered to coordinate a diverse range 
of genes, including p21, in myelinating Schwann cells (Nagarajan et al., 2001; Le et al., 
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2005). Furthermore, in order to identify genes directly activated by EGR2 binding, in vivo 
chromatin immunoprecipitation sequencing (ChIP-Seq) has been performed on 
myelinating rat sciatic nerve, revealing peaks of EGR2 binding in the cell cycle regulators 
p21 and p27 (Srinivasan et al., 2012).  
1.8.4 EGR2 and the immune system 
During T cell development, a population with a diverse range of TCRs is generated in the 
thymus through signals derived from the interaction of TCRs on thymocytes with their 
ligands, major histocompatibility complex (MHC) molecules bound with peptides. 
Thymocytes bearing a TCR able to interact with a self-MHC can receive signals that 
induce either differentiation into a mature T cell (positive selection) or apoptosis 
(negative selection). In mice with a conditional homozygote knockout of EGR2 in T cells, 
positively selected thymocytes fail to sustain expression of Bcl-2, a pro-survival gene, in 
the absence of EGR2 and are thus blocked from developing into mature T cells (Lauritsen 
et al., 2008). Using EGR2-overexpressing mice, the effect of EGR2 on T cell development 
was confirmed, and EGR2 was also observed to promote maturation in B cell 
development (Li et al., 2011). In addition, EGR2 was found to be expressed during the 
later stages of dendritic cell development in mouse bone marrow cells (Miah et al., 
2013).  
 
In addition to thymocyte development, EGR2 expression can also regulate naïve T cell 
differentiation. Naïve CD4+ T cells can commit to a diverse range of helper cell subsets 
characterised by distinct cytokine profiles which are important for activation of B cells 
and cytotoxic T cells. Recent work has shown that overexpression of EGR2 in murine 
CD4+ T cells induced differentiation into regulatory T cells, whereas EGR2 deficiency 
rendered naïve murine CD4+ T cells prone to differentiation into T helper 17 cells 
(Okamura et al., 2009; Miao et al., 2013).  
 
TCR engagement in the absence of proper co-stimulation, such as CD28/B7 signalling, 
leads to a hyporesponsive growth arrest state known as T cell anergy (reviewed in 
Schwartz 2003). Multiple studies have demonstrated that EGR2 expression is up-
regulated in T cells in response to TCR stimulation without co-stimulatory signals (Harris 
et al., 2004; Safford et al., 2005; Anderson et al., 2006). In normal mice under clean 
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conditions, conditional homozygote knockout of EGR2 in T cells led to the accumulation 
of effector T cells in response to self-antigens without proper co-stimulation. The EGR2 
knockout T cells were hyperproliferative with decreased p21 expression, indicating that 
EGR2 functions to control anergy induction and proliferation of T cells in vivo (Zhu et al., 
2008; Zheng et al., 2012). Furthermore, ChIP performed in EGR2 overexpressing T cells 
demonstrated that EGR2 directly binds to the p21 promoter (Zhu et al., 2008). To further 
investigate the EGR2-regulated transcriptome, microarray and ChIP-Seq analyses were 
performed revealing 49 directly EGR2-regulated genes in murine T cell anergy, including 
BCL2L11, a protein known to interact with pro-survival protein BCL-2 (Zheng et al., 
2013). Interestingly, after one year, conditional EGR2 knockout mice exhibited features 
of lupus-like autoimmune disease compared with age-matched WT mice (Zhu et al., 
2008). Together, these data suggest that EGR2 may play an important role in T cell 
proliferation and development of autoimmune disease. 
 
In support of this idea, dysregulation of EGR2 has been found in autoimmune conditions 
(reviewed in Zhang et al. 2015). The chromosome where EGR2 is located, 10q21, has 
been identified as a candidate locus for autoimmune diseases, such as Crohn’s disease, 
in two GWAS (Rioux et al., 2007; The Wellcome Trust Case Control Consortium, 2007). 
Furthermore, a single nucleotide polymorphism (SNP) in the 5’ flanking region of EGR2 
was associated with susceptibility to systemic lupus erythematosus, a systemic 
autoimmune disease, in a Japanese population (Myouzen et al., 2010). Systemic 
sclerosis (SSc) or scleroderma is an autoimmune disease of the connective tissue disease 
of unknown aetiology associated with progressive fibrosis in the skin and internal 
organs. Examination of skin and lung biopsy specimens from SSc patients and a SSc 
mouse model indicated that expression of EGR2 is elevated in SSc (Fang et al., 2011). 
Furthermore, TGF-β stimulated expression of EGR2 in explanted foreskin fibroblasts via 
SMAD3 signalling. Microarray analysis of EGR2-overexpressing human neonatal foreskin 
fibroblasts compared to the transduced control identified a greater than two-fold 
change in nearly 700 transcripts, indicating that EGR2 has a broad effect on human 
fibroblast gene expression. Interestingly, EGR1-overexpressing fibroblasts modulated 
751 transcripts of which only nine overlapped with the EGR2-overexpressing profile, 




1.8.5 EGR2, cancer, and senescence 
As senescence is an important tumour suppressor mechanism (see Section 1.5.2), most 
cancer cells harbour mutations inactivating the senescence pathways in order to bypass 
senescence and induce proliferation. For example, the tumour suppressor p16 is 
typically down-regulated in cancer (Romagosa et al., 2011). Studies in vitro and ex vivo 
present convincing evidence that EGR2 may function as a tumour suppressor. 
Microarray analysis has identified EGR2 as down-regulated in primary ovarian cancer, as 
well as up-regulated by exogeneous PTEN overexpression in endometrial cancer cells, 
indicating a potential role for EGR2 as a tumour suppressor downstream of PTEN (Ono 
et al., 2000; Unoki and Nakamura, 2001). Further quantitative real time polymerase 
chain reaction (qRTPCR) analysis of endogenous EGR2 expression in 39 cancer cell lines, 
including colon, endometrial, gastric, lung, ovarian, and prostate cancer as well as 
glioblastoma and hepatoma, identified that expression of EGR2 was lower than the 
average normal adult tissue expression for 34 of the cancer cell lines (Unoki and 
Nakamura, 2003). In addition, there is a growing body of evidence to suggest that 
miRNA-mediated EGR2 suppression promotes in vitro proliferation of various human 
cancer cells including miR-20 in osteosarcoma (Zhuo et al., 2015), miR-330-3p in non-
small-cell lung cancer (Liu et al., 2015), and miR-20 and -150 in gastric cancer (Wu et al., 
2010; Li et al., 2013) (Figure 1.10). Interestingly, given that EGR2 is known to play a role 
in endochondral ossification, a recent GWAS has also identified SNPs within EGR2 which 
are strongly associated with susceptibility to Ewing sarcoma, an aggressive paediatric 
sarcoma (Postel-Vinay et al., 2012). However, in contrast with the down-regulation of 
EGR2 observed in 34 other cancers (Unoki and Nakamura, 2003), EGR2 expression 
appeared to be up-regulated in Ewing sarcoma tissue, and EGR2 knockdown in Ewing 
sarcoma cell lines reduced proliferation and cell viability (Grunewald et al., 2015). 
However, it should be noted that the tumour suppressor p16 has also been observed to 
be overexpressed in a rare subset of p16-positive human cancers (Romagosa et al., 
2011). Examination of the EGR2 gene and promoter sequence identified the presence 
of a 5'-C-phosphate-G-3' (CpG) island in intron 1 which tended to be hypermethylated 
in cancer cell lines where endogenous EGR2 expression was aberrantly high, leading the 
authors to postulate that methylation of intron 1 may function as an enhancer of EGR2 
transcription during cancer (Unoki and Nakamura, 2003). 
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One study has identified EGR2 as a direct transcriptional target of the p53 family, as 
endogenous EGR2 mRNA and protein were up-regulated by ectopic p53 overexpression 
and in response to DNA damage in a p53-dependent manner in human oral, colorectal, 
osteosarcoma, and lung cancer cells (Yokota et al., 2010) (Figure 1.10). Furthermore, a 
conserved p53-response element was identified in the EGR2 gene which was found to 
be transactivated by p53 in a luciferase reporter assay (Yokota et al., 2010). In line with 
previous studies indicating that miRNA-mediated suppression of EGR2 induced 
proliferation (Wu et al., 2010; Li et al., 2013; Liu et al., 2015; Zhuo et al., 2015), 
overexpression of EGR2 in the human oral and cervical cancer cell lines was found to 
inhibit proliferation (Yokota et al., 2010). In further support of a role for EGR2 in the p53 
pathway, a number of studies have identified a role for EGR2 directly up-regulating 
expression of p21, a known target of p53 (Le et al., 2005; Zhu et al., 2008; Pospisil et al., 
2011; Srinivasan et al., 2012) (Figure 1.10).  
Interestingly, the EGR family member, EGR1, has been identified to be required for 
replicative senescence in MEFs (Krones-Herzig, Adamson and Mercola, 2003). EGR1-null 
MEFs bypass senescence and have decreased expression of p53, p21, and other known 
p53 target genes. Re-expression of EGR1 restores senescence in EGR1-null MEFs but not 
p53-null MEFs, indicating that EGR1 induces replicative senescence via the p53/p21 
pathway (Krones-Herzig, Adamson and Mercola, 2003) (Figure 1.10). In line with this 
theory, EGR1 has been identified to transactivate the p53 promoter in MEFs (Das et al., 
2001). However, there are a number of significant differences between MEF and human 
fibroblast replicative senescence (see Section 1.7) including that senescence induction 
occurs independent of telomere length and p16 expression (reviewed in Kuilman et al. 
2010). Given that the EGR family members share a transcription factor binding sequence 
but are known to possess distinct roles in a cell-type-dependent manner, it is plausible 
that the EGR family member important in human replicative senescence could be EGR2. 
In support of this, a recent whole-blood gene expression meta-analysis looking at over 
7,000 human samples showed that EGR2 increases with age but EGR1 does not (Peters 




Figure 1.10 Schematic summarising potential relationship between EGR2, p53 and p21 in the 
literature.  As EGR1, a close family member, up-regulates p53 expression in MEF senescence 
(Krones-Herzig, Adamson and Mercola, 2003), EGR2 (orange) potentially up-regulates p53 (blue) 
in human cell senescence as well as directly up-regulating expression of p21 (blue) (Le et al., 
2005; Zhu et al., 2008; Pospisil et al., 2011; Srinivasan et al., 2012). Furthermore, EGR2 has been 
identified as a direct transcriptional target of p53, and multiple miRNAs (light green) have been 
found to suppress EGR2 expression in various human cancers (Wu et al., 2010; Li et al., 2013; 
Liu et al., 2015; Zhuo et al., 2015). 
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1.9 Small interfering RNA (siRNA) technology 
Fire and Mello were awarded the Nobel Prize for their discovery that injection of double 
stranded RNA (dsRNA) triggers RNAi in Caernohabditis elegans (Fire et al., 1998). RNAi 
is an endogenous pathway found in eukaryotic cells which silences specific mRNAs using 
targeted RNA sequences, either by suppressing transcription or by activating sequence-
specific RNA degradation. The RNAi mechanism can be induced endogenously by dsRNA 
cleaved by the enzyme Dicer into fragments of 21-23 nucleotides known as small 
interfering RNAs (siRNAs), or by synthetic siRNAs artificially transfected into the cell 
using lipid reagents. The RNA-induced silencing complex (RISC) then incorporates the 
siRNA, and Argonaute 2, a protein within RISC, unwinds the siRNA and cleaves the sense 
(passenger) strand. The antisense (guide) strand remains bound to the now activated 
RISC complex which probes for and degrades mRNA complementary to the antisense 
strand (Whitehead, Langer and Anderson, 2009).  
 
Figure 1.11 Schematic of the RNAi pathway.  Endogenous dsRNA is cleaved by DICER into short 
sequences of RNA known as siRNA. Endogenous siRNA or synthetic siRNA transfected into the 
cell are incorporated into the RISC complex where Argonaute 2 (Ago2) cleaves the sense strand 
(passenger, black) from the antisense strand (guide, red). The activated siRNA-RISC complex 
then targets the complementary mRNA sequence for translational suppression or to induce 
cleavage and degradation. 
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The availability of genome-wide siRNA libraries has made it possible to carry out high-
throughput, high-content large-scale RNAi screening experiments, leading to siRNA 
screening becoming a powerful tool for dissecting gene function in human cells in vitro 
(reviewed in Boutros & Ahringer 2008).  
High-throughput, high-content siRNA screening allows the use of large sample sizes 
which generate statistically significant data with relative experimental ease. In addition, 
automated microscopy images provide morphological and immunofluorescence data 
that can be mined using independent, un-biased, multi-parameter analysis. 
Furthermore, the technology is cheaper than alternative techniques for studying gene 
knockdown (i.e. creation of transgenic models) and possesses the potential possibility 
of translation into human siRNA therapies.  
However, siRNA screens have a number of limitations, namely the potential for false 
negatives, false positives and off-target effects (OTEs). False negatives can arise from 
incomplete knockdown of gene expression caused by inefficient siRNAs, insufficient 
siRNA dose, or too short an incubation period. Thus, false negatives can be minimised 
by pooling three to four independent non-overlapping siRNAs thus increasing 
knockdown efficiency, and by optimising the screen (i.e. seeding density, transfection 
reagent dose, siRNA concentration, and experimental protocol) to ensure maximum 
transfection efficiency and optimal detection of altered phenotypes (reviewed in 
Falschlehner et al. 2010).  
False positives can occur as an indirect phenotypic response due to cell stress from the 
transfection protocol. In order to control for this, a negative siRNA control, such as 
siGLO, a siRNA targeting Cyclophilin B, a non-essential housekeeping gene, labelled with 
Dylight 547 (DY547) should be used. In addition, a poorly defined phenotypic read-out 
can allow one phenotype to appear similar to another, which if studied in more detail 
would emerge to be two different results (e.g. quiescence and senescence). Multi-
parameter assessment can increase the selectivity of the phenotype and reduce false 
positives (reviewed in Echeverri et al. 2006).  
OTEs can be caused by non-specific siRNA knockdown of an unknown gene (not the 
candidate gene) resulting in non-specific gene expression changes and phenotypes. To 
control for this, siRNA pools should be deconvoluted and each siRNA tested individually. 
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If at least two siRNAs from a given pool induce similar phenotypic changes characterised 
by multi-parameter analysis, it is unlikely that the phenotype is a result of OTEs. 
Additional replicates of the screen will also help to control for OTEs and reduce false 
positives. Lastly, effective siRNA knockdown at the message or protein level should be 
carefully validated for each hit using qRTPCR, immunofluorescence, or western blotting 
(reviewed in Echeverri et al. 2006).  
1.10 Project aims  
The overall aim of this project is to determine whether reversal of senescence in normal 
adult human mammary fibroblasts (HMFs) is achievable using siRNA transfection in 
order to subsequently employ siRNA screening as a tool to discover novel drivers of 
senescence. 
 
Previously, our laboratory (lab.) has shown that cellular senescence in DS HMECs is 
reversible using siRNA transfection (Lowe et al., 2015). Gene expression arrays 
subsequently identified genes with increased expression in DS HMECs compared to EP 
and reversed HMECs, and a siRNA screen of the top 200 hits in DS HMECs was 
performed. This revealed 28 siRNAs that strongly induced the reversal phenotype, as 
defined by a loss of a panel of senescence markers, including a significant increase in cell 
number, together with reduced cellular and nuclear area.  
 
To determine whether senescence reversal is achievable in other cell types, this project 
will first aim to determine if siRNA reversal of deep senescence can be performed in 
fibroblasts. Secondly, the most potent rejuvenators in HMECs will be screened in the DS 
fibroblasts, in addition to potential candidates identified as known interactors in 
literature and database searches. Successful development of a novel technique to 
reverse senescence in fibroblasts will provide the opportunity to investigate the genes 
enforcing senescence (‘drivers’) in both HMECs and fibroblasts. Once validated, the top 
hit will be investigated to provide further insight into the mechanisms driving 
senescence, as well as potentially identifying a novel marker of senescence and future 
















2.1 Mammalian cell culture  
All reagents and chemicals used were purchased from Sigma (UK) unless otherwise 
stated. Cells were cultured as monolayers in T75 centimetre squared (cm2) vented flasks 
(Corning, UK) at 37°C in the presence of 5% carbon dioxide (CO2) and 95% humidity. Cells 
were passaged every seven days by aspirating the culture medium, washing the cells 
with 15 millilitres (mL) phosphate-buffered saline (PBS), and detaching them with 3 mL 
1X trypsin-ethylenediaminetetraacetic acid (EDTA) (Life Technologies, UK) for 5-15 
minutes at 37°C. Trypsin-EDTA was neutralised by adding 15 mL medium with 
supplements and cells were then centrifuged for five minutes at 1,200 revolutions per 
minute (rpm) (600 x g) (IEC CL10 centrifuge, Thermo Scientific, UK). Medium was 
aspirated and the cells were gently re-suspended in an appropriate volume of medium 
with supplements and cells were counted using a haemocytometer before re-seeding. 
Medium was changed every two to three days. 
2.1.1 Culture of normal human mammary fibroblasts 
Normal finite lifespan HMFs were kindly donated by Martha Stampfer (Lawrence 
Berkeley National Laboratory, Berkeley). These were obtained from reduction 
mammoplasty tissue of a 16-year-old individual, donor 48 (Stampfer et al., 1981). The 
cells were seeded at 10,000 cells/cm2 and maintained in Dulbecco’s Modified Eagles 
Medium (DMEM) (Life Technologies, UK) supplemented with 10% foetal bovine serum 
(FBS) (Labtech.com, UK), L-glutamine (2 millimolar (mM) final concentration) (Life 
Technologies, UK) and insulin from bovine pancreas (10 microgram (μg)/mL final 
concentration). HMFs were serially passaged from passage (P) four (P4) until the 
population reached replicative senescence at P29 or 35 cumulative population 
doublings. The natural log of the cell numbers was plotted as a function of time and the 
number of population doublings determined from the slope of the line. Senescent HMFs 
were defined as being in deep senescence (DS) when no population expansion was 
observed after being kept in culture for three weeks beyond replicative senescence 
(P29+3). 
Stocks of senescent HMFs were frozen down at P29 and thawed three weeks prior to 
each experiment involving DS cells. 
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2.1.2 Culture of wild-type and p21 double knockout human fibroblasts  
Loxo26 wild-type (WT Loxo26) and Loxo26 p21 double knockout (Loxo26 p21-/-) human 
fibroblasts were a kind gift from Prof. Ken Parkinson (Munro et al., 2004). Loxo26 
fibroblasts were cultured in T75 cm2 vented flasks (Corning, UK) at 37°C in a 10% CO2 
atmosphere. The cells were maintained in DMEM (Life Technologies, UK) supplemented 
with 10% FBS (Labtech.com, UK), L-glutamine (2 mM final concentration) (Life 
Technologies, UK), and penicillin-streptomycin (50 units (U)/mL and 50 μg/mL final 
concentration, respectively) (Life Technologies, UK). The fibroblasts were passaged as 
outlined previously in Section 2.1.  
2.1.3 Culture of normal human mammary epithelial cells 
Normal HMECs were isolated from reduction mammoplasty tissue and kindly provided 
by Dr Martha Stampfer (Lawrence Berkeley National Laboratory, Berkeley, CA, USA) and 
kindly cultured by Dr Cleo Bishop. The cells were seeded at 5,000 cells/cm2 and 
maintained in ‘M87A’ medium composed of 50% (v/v) Mammary Epithelial Basal 
Medium (MEBM, Lonza, UK) supplemented with MEGM SingleQuot Kit Supplements 
(excluding gentamycin) (Lonza, UK), 5 µg/mL transferrin, 5 µM isoproterenol, and 2 mM 
L-glutamine, together with 50% (v/v) DMEM nutrient mixture F-12 (DMEM/F-12) (Life 
Technologies, UK) supplemented with 10 µg/mL insulin, 5% (v/v) FBS (Labtech.com, UK), 
100 nanograms (ng)/mL hydrocortisone, 10 nanomolar (nM) 3,3’,5-triiodo-L-thyronine, 
10 nM β-estradiol, 5 ng/mL epidermal growth factor (Life Technologies, UK), 0.1% (v/v) 
AlbuMAXTM (Life Technologies, UK), and 0.1 nM oxytocin (Bachem, Switzerland). 
HMECs were serially passaged as outlined previously from P4 until the population 
reached senescence at P11. Senescent HMECs were defined as being DS when no 
population expansion was observed after being kept in culture for three weeks beyond 
replicative senescence (P11+3). 
2.2 Ultraviolet irradiation-induced senescence 
In order to generate a p21 positive cell lysate to use alongside the Loxo26 p21-/- cell 
lysate in p21 antibody validation western blots, WT Loxo26 fibroblasts were irradiated 
by exposure to ultraviolet light (UV). 
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WT Loxo26 cells were seeded in 6-well plate format and sub-confluent cells were 
exposed to 10 millijoule (mJ)/cm2 UV irradiation (Chen et al., 2008). Cell lysates were 
collected 18-24 hours after UV irradiation according to Section 2.4.1.  
2.3 Paracrine senescence 
Conditioned medium was collected from proliferating (P15 and P16) HMFs and DS HMFs 
seeded in T25 flasks at 10,000 cells/cm2 at two incubation time points: 48 hours, and 72 
hours. The four conditioned medium samples were centrifuged in 50 mL falcon tubes at 
5,000 x g for 10 minutes at room temperature (RT) to remove dead cells and 
subsequently filtered through a 0.2 µm2 filter to remove cell debris. In order to 
supplement the nutrient-depleted conditioned medium, a solution of DMEM 40% FBS 
plus supplements (8 mM L-glutamine, 40 µg/mL insulin final concentrations) was 
prepared. To assess the effects of the conditioned medium, EP HMFs were seeded onto 
96-well plates (Thermo Scientific, UK) at a density of 10,000 cells/cm2 (3,200 cells/well) 
in two independent experiments, each performed in at least triplicate. The following 
day, a ratio of 3:1 conditioned medium to DMEM 40% was added to each well in order 
to generate 10% FBS conditioned medium. To achieve this, 90 µL of conditioned medium 
and 30 µL DMEM 40% FBS were added to each well. Control EP HMFs received 120 µL 
control medium as described in Section 2.1.1 (DMEM 10% FBS). Conditioned medium 
and control medium were replaced after 72 hours. Cells were fixed, stained, imaged and 
analysed after a further 48 hours according to Section 2.7 and Section 2.8. 
2.4 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western Blotting 
2.4.1 Protein lysate preparation 
Cells were washed with PBS and lysed by the addition of radio-immunoprecipitation 
assay (RIPA) buffer with 2X protease cocktail inhibitor (Roche, UK) at RT for five minutes. 
10X PhosSTOP, phosphatase inhibitor, was added to the RIPA and 2X protease cocktail 
inhibitor solution for lysates collected to assess dephosphorylation events on band 
resolution using western blotting. Protein lysate concentration was determined using 
the Bio-Rad Protein Assay kit (Bio-Rad, UK) according to manufacturer’s instructions. 
This assay is based on the Bradford dye-binding method and relies on the shift in 
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absorbance of Coomassie brilliant blue G-250 dye when binding to protein (absorption 
maximum equals 595 nm). Once the protein concentration of the lysate was determined 
from its absorbance compared to a standard curve, an appropriate volume of 2X 
Laemmli Sample Buffer (0.1 molar (M) Tris pH 6.8, 20% (v/v) glycerol, 1% (v/v) β-
mercaptoethanol, 1% (w/v) sodium dodecyl sulphate (SDS), 0.01% (v/v) Bromophenol 
blue) was added and the samples were heated to 95°C for five minutes. Samples were 
then centrifuged using a bench top centrifuge (Accuspin micro, Fisher Scientific, UK) at 
13,000 rpm for five minutes. The protein samples were either used for SDS-PAGE and 
Western Blotting immediately or stored at -20°C until required. MDA-MB-468 cell lysate 
(p16-positive breast cancer cell line) was a kind gift from Dr Maddi Moore (Bishop 
Group). 
2.4.2 SDS-PAGE 
SDS-PAGE is a technique which separates proteins according to their electrophoretic 
mobility. SDS denatures and binds to the polypeptides imparting a negative charge. 
When the uniformly negatively charged polypeptides are loaded onto a polyacrylamide 
gel with an electric field, the proteins will migrate towards the positive electrode 
(anode) and separate by size due to the sieving nature of the gel matrix. 
Gels were constructed and run using the Bio-Rad Mini-PROTEAN III system (Bio-Rad, UK). 
A sample volume of 20 microlitre (μL) was loaded in the wells of 5% stacking – 12% 
resolving gels (see Table 2.1) in a tank of running buffer (25 mM Tris (Fisher Scientific, 
UK), 192 mM Glycine, 0.1% SDS), and separated at 100 V for one to two hours. Proteins 
of known molecular weights (Precision Plus Protein All Blue Standards, Bio-Rad, UK) 
were loaded and used as reference. 
2.4.3 Immunoblot analysis 
Proteins were transferred onto a nitrocellulose membrane (Amersham Hybond ECL, GE, 
UK) using the Western transfer Mini-PROTEAN III system (Bio-Rad, UK) in transfer buffer 
(25 mM Tris, 192 mM Glycine, 20% (v/v) methanol (Fisher Chemical, UK)) for two hours 
at 350 milliamps (mA). The membrane was then washed in high-purity water and the 
protein temporarily visualised using Ponceau S stain (0.2% (w/v) Ponceau S in 1% acetic 
acid), which was removed by washing in PBS. 
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Non-specific binding sites on the membrane were then covered by blocking for one hour 
in 0.05% (v/v) Tween-20, 5% (w/v) Marvel skimmed milk in PBS (PBS-T-milk) at RT. The 
primary antibody was diluted in PBS-T-milk and incubated with the membrane under 
the appropriate conditions (see Table 2.2). The membrane was then washed in PBS-T-
milk for 30 minutes with three changes to remove any unbound primary antibody. The 
appropriate secondary antibody was then diluted in PBS-T-milk and incubated with the 
membrane (see Table 2.2). The unbound secondary antibody was then removed by 
washing the membrane in PBS-T-milk for 30 minutes with three changes before washing 
for 20 minutes with two changes in 0.05% PBS-T.  
Secondary antibodies are conjugated to horseradish peroxidase which converts a 
chemiluminescent substrate into a luminescent product. Enhanced-Chemiluminescence 
(ECL) (GE Healthcare, UK) was applied according to the manufacturer’s protocol and the 
membrane exposed to a photographic film (Hyperfilm, GE Healthcare, UK) for 
visualisation of the protein of interest. 
 5% Stacking gel 12% Resolving gel 
Acrylamide (30%) / Bis Acrylamide (0.8%) 
solution 
(National Diagnostics, UK) 
1.67 mL 4.15 mL 
Tris pH 8.8 (1 M) - 3.7 mL 
Tris pH 6.8 (1 M) 1.25 mL - 
20% (w/v) SDS 50 μL 50 μL 
20% (w/v) ammonium persulfate 50 μL 60 μL 
Temed (Severn Biotech Ltd, UK) 10 μL 10 μL 
Distilled water (dH2O) 7.03 mL 2.05 mL 











Anti-p16 JC8 Mouse 
Prof. James Koh, Duke 
Cancer Institute (UK) 
1:1,000 2 hours at RT 
Anti-p21 (12D1) Rabbit Cell Signalling (UK) 1:1,000 
Overnight at 
4°C 








1:200 2 hours at RT 
Anti-lamin B1 
(ab16048) 





Mouse Origene (USA) 1:500 

















Goat Dako (UK) 1:2,000 1 hour at RT 
HRP-conjugated 
anti-rabbit 
Goat Dako (UK) 1:5,000 1 hour at RT 
HRP-conjugated 
anti-rat 
Mouse Abcam (UK) 1:10,000 1 hour at RT 
Table 2.2 Antibodies used for immunoblotting, their working dilutions and conditions. All 
antibodies were diluted in PBS-T-milk with the exception of anti-human EGR2 (H220) which was 
diluted in 0.1% Tween in PBS supplemented with 5% (w/v) bovine serum albumin (BSA). 
2.4.4 Densitometry 
Protein quantification was performed using ImageJ software. Density levels were 
obtained and normalised against an appropriate loading control in order to calculate 
total protein levels. Protein levels were then normalised to the siGLO control and 
presented as a bar chart + standard deviation (SD) of two independent experiments. 
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2.4.5 Membrane stripping 
Membranes were stripped for 30 minutes at RT in 25 mL stripping buffer (25 mM glycine 
with 1% (w/v) SDS) and washed twice for 10 minutes with 0.05% PBS-T at RT before 
being blocked for one hour at RT in PBS-T-milk and re-probed with additional antibodies. 
2.5 siRNA forward-transfection optimisation 
Before conducting the siRNA screens, a transfection reagent was identified, and the cell 
seeding density and volume of transfection reagent used to transfect the HMFs was 
optimised in order to produce a high level of transfection efficiency.  
2.5.1 Identification of optimal transfection reagent 
The uptake efficiency of two transfection reagents (Dharmafect 2 (Dh2) and 4 (Dh4)) (GE 
Healthcare, UK) previously identified to transfect DS HMECs (Bishop, unpublished) was 
tested in the HMFs in order to identify the optimal transfection reagent. HMFs were 
seeded at a range of densities in 384-well plate format and incubated at 37°C overnight. 
After incubating the siRNA/Dharmafect complexes at RT for 20 minutes, the cells were 
forward transfected with a range of Dh2 and Dh4 concentrations combined with 30 nM 
siGLO (Thermo Scientific, UK). Plates were incubated at 37°C and medium changed after 
24 hours. Cells were fixed and stained five days later with 4',6-diamidino-2-phenylindole 
(DAPI), and then imaged and quantified according to Section 2.7 and Section 2.8. 
Visualisation of HMF siGLO uptake was used as a measure of transfection efficiency and 
subsequently the transfection reagent generating the highest siGLO uptake efficiency, 
Dh2, was chosen for use in further experiments.  
2.5.2 Optimisation of cell seeding density in 384-well plate format 
HMFs were seeded at 10,000-15,000 cells/cm2 in 384-well plate format (Thermo 
Scientific Nunc, UK) and were incubated at 37°C. Cells were fixed and stained five days 
later with DAPI according to Section 2.7. Cells were then imaged and quantified 
according to Section 2.8.  
2.5.3 Optimisation of transfection reagent dose 
In order to identify a transfection reagent dose producing a high level of transfection 
efficiency with minimal toxicity, the volume of the chosen transfection reagent (Dh2) 
was optimised for the DS fibroblasts. DS HMFs were seeded at the optimised density of 
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15,000 cells/cm2 in 384-well plates and incubated at 37°C overnight. Approximately 16 
hours later, 10 μL siRNA/Dh2 complexes were incubated at RT for 20 minutes before 
cells were forward transfected with a range of Dh2 concentrations (0-0.6 μL/well) 
combined with 30 nM siGLO (in a total volume of 70 μL/well). Target sequences for the 
siRNAs are shown in Table 2.3. Plates were incubated at 37°C and medium changed after 
24 hours and 48 hours. Cells were fixed and stained after a further 72 hours (i.e. five 
days post transfection) with DAPI and Cell Mask and then imaged and quantified 
according to Section 2.7 and Section 2.8. 
siRNA 
name siRNA target 
Accession 
number Supplier siRNA target sequence 
































Table 2.3 siRNA target sequences. 
2.6 siRNA forward transfections 
2.6.1 siRNA reversal of DS HMFs in 384-well plate format 
DS HMFs were seeded at 15,000 cells/cm2 and forward transfected with previously 
validated siRNAs targeting siGLO (Bishop et al., 2010), Cyclin-dependent kinase inhibitor 
2A (CDKN2A) (p16) (Bishop et al., 2010), Cyclin-dependent kinase inhibitor 1A (CDKN1A) 
(p21) (Borgdorff et al., 2010) and siRNA targeting p16 combined with siRNA targeting 
p21 siRNA (p16+p21) in 384-well plate format using 0.15 μL/well Dh2. Target sequences 
for the siRNAs are shown in Table 2.3. Plates were incubated at 37°C and medium 
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changed after 24 hours and 48 hours. Cells were fixed and stained after a further 72 
hours (i.e. five days post transfection) with DAPI according to Section 2.7. Cells were 
then imaged and quantified according to Section 2.8. 
2.6.2 siRNA screening in DS HMFs in 384-well plate format 
Pools of three siRNAs (Ambion, UK) were used to target each specified gene in the screen 
alongside control siRNAs targeting siGLO, p16, p21, and p16+p21. DS HMFs were seeded 
at 15,000 cells/cm2 and forward transfected with either 30 nM siRNA targeting the 
specified gene alone (Group 1), or 15 nM siRNA targeting the gene of interest in 
combination with 15 nM p16 siRNA (Group 2) or in combination with 15 nM p21 siRNA 
(Group 3) in 384-well plate format using 0.15 μL/well Dh2. Plates were incubated at 37°C 
and medium changed after 24 hours. Cells were fixed and stained five days later with 
DAPI according to Section 2.7. Cells were then imaged and quantified according to 
Section 2.8. After identifying the top hits from the initial screens, further screens were 
performed at both the five and seven day time point.  
2.6.3 Validation of EGR2 top hit in DS HMFs 
The EGR2 siRNA pool used in the siRNA screens was deconvoluted into three individual 
siRNAs. DS HMFs were subsequently forward transfected with the three EGR2 siRNAs 
(Ambion, UK) individually and pooled according to Section 2.6.2. siRNA target sequences 






























Table 2.4 Individual EGR2 siRNAs deconvoluted from the EGR2 siRNA pool used in the siRNA 
screens. All siRNAs were purchased from Ambion, UK. 
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2.6.4 siRNA forward transfection of DS HMFs in 6-well plate format 
DS HMFs were seeded at 15,000 cells/cm2 in 6-well plate format (Corning, UK) and 
forward transfected with 30 nM siRNA using 6.9 μL/well Dh2. siRNA/Dh2 complexes 
were incubated at RT for 20 minutes before cells were forward transfected. Cells were 
harvested for western blotting according to Section 2.4.1.  
2.7 Immunofluorescence staining 
Cells cultured on 384-well plates were washed with PBS and fixed using 3.7% 
paraformaldehyde (PFA) with 5% sucrose in PBS for 15 minutes at RT. After fixation, cells 
were washed with PBS and permeabilised with 0.1% Triton X-100 for 15 minutes at RT. 
Cells were washed with PBS and blocked with PBS supplemented with 0.25% (w/v) BSA 
(PBS/BSA) for 30 minutes before incubation with primary antibody diluted in PBS/BSA 
for two hours at RT. Cells were then washed with PBS/BSA for 30 minutes at RT and 
incubated with secondary antibody, DAPI (1:1,000), and Cell Mask Deep Red (1:10,000) 
(Life Technologies, UK) diluted in PBS/BSA for 2 hours at RT. Cells were washed with 
PBS/BSA for 30 minutes at RT before three final washes with PBS. Cells were then 
imaged and quantified according to Section 2.8. Details of the antibodies used for 
immunofluorescence staining and their dilutions are shown in Table 2.5.  
2.7.1 Bromodeoxyuridine (BrdU) immunofluorescence staining 
BrdU is a synthetic analogue for thymidine which is incorporated into DNA during the S 
phase of the cell cycle and is commonly used for detection of proliferating cells in vitro. 
For BrdU staining, cells were incubated with an optimised dose of 5 μM BrdU for an 
optimised incubation period of 16 hours. Cells were then washed with medium, PBS, 
and fixed with 3.7% PFA with 5% sucrose for 15 minutes at RT. After fixation, cells were 
washed with PBS and permeabilised with 0.1% Triton X-100 for 15 minutes at RT. Cells 
were washed with PBS and the DNA was denatured with 4 M hydrochloric acid (HCl) for 
10 minutes. Cells were then washed with PBS (pH 8.5) for 10 minutes with two changes, 
and PBS (pH 7.4) for 20 minutes with four changes, before washing briefly with analytical 
grade dH2O. After washing, the cells were incubated with the conjugated anti-BrdU 
mouse monoclonal antibody (clone MoBU-1) Alexa Fluor 488 conjugate (Life 
Technologies, UK) in 0.5% PBS-T supplemented with 1% BSA. Cells were washed with 
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PBS for 15 minutes with three changes. Cells were then imaged and quantified according 
to Section 2.8.  




Anti-p16 JC8 Mouse 
Prof. James Koh, 
Duke Cancer Institute 
(UK) 
1:200 2 hours at RT 
Anti-p21 (12D1) Rabbit Cell Signalling (UK) 1:1,000 Overnight at 4°C 






1:250 Overnight at 4°C 






1:500 2 hours at RT 






1:500 2 hours at RT 






1:500 2 hours at RT 






1:100 2 hours at RT 
Table 2.5 Working concentrations and incubation conditions of antibodies used for 
immunofluorescence staining. All antibodies were diluted in 0.25% (w/v) PBS/BSA. 
2.8 High content image analysis 
2.8.1 High content microscopy 
Cells were seeded in 384-well plate format and were fixed and stained according to 
Section 2.7. Cells were then imaged using the IN Cell 1000 automated microscope (GE, 
UK) at 10X magnification (nine fields/well) using a polyChroic mirror (89100 bs*) 
(Chroma, US), unless otherwise stated. Nine fields of view at 10X magnification covers 
an area of 0.054 cm2 out of the total area of a well of a 384-well plate (0.087 cm2). Thus, 
for a 384-well plate seeded with 1,305 senescent cells per well, approximately 800 cells 
will be imaged and analysed for each well. All excitation and emission filters were from 
Chroma, US. The different staining and secondary antibodies used were visualised using 
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the excitation and emission filter sets outlined in Table 2.6. Image quantitation was then 
performed using the Developer software version 1.9.1 (GE, UK).  
Immunofluorescence 
source Excitation filter Emission filter 
DAPI (blue) AT350_50X ET455_50M 
Alexa Fluor 488 (green) ET490_20X ET525_36M 
Alexa Fluor 546 (red) ET555_25X ET605_52M 
Cell Mask (far red) ET645_30X ET705_72M 
Table 2.6 Excitation and emission filter sets for visualising different stains and antibodies. 
2.8.2 Multi-parameter analysis and Z score generation  
Multi-parameter analysis was performed using the Developer software version 1.9.1 
(Figure 2.1) and a list of the measures used are displayed in Table 2.7. A full tabulation 






Figure 2.1 Representative images of DS fibroblasts and the Developer software image analysis 
and quantitation of nuclear and cellular phenotypes.  DS HMFs were seeded at 15,000 cells/cm2 
in 384-well plate format, fixed after five days, stained with (A) DAPI (blue) to detect nuclei, with 
Developer software subsequently used to generate a nuclear mask (magenta); and (B) Cell Mask 
(red) to detect cell morphology, with Developer analysis software subsequently used to 
generate a cellular mask (cyan). Scale bar denotes 100 µm. (C) Schematic for quantitation of 





Name of parameter 
(used within 
heatmaps) 




Number Count Total number of targets per well 
Area Area Target area (µm
2
) 
Roundness Form Factor 
Target circularity (expressed as a value 




Major axis length (the longest of two 
perpendicular axes of symmetry)/Minor 
axis length (the shortest of two 
perpendicular axes of symmetry) 
Protein intensity Dens Levels 
Mean grey level of the pixels contained 
within a target (expressed as a value 
from 0-4,095 where 0 equals black and 
4,095 equals white) 
Protein density Mass/Area 




Table 2.7 A description of each of the parameters used within the multi-parameter analysis.  
Measures were obtained using the Developer software version 1.9.1. Thresholding for protein 
intensity or density was performed using overlap of frequency distributions. 
Unless otherwise stated, Z scores were generated according to the formula below: 
Z score = (mean value of two independent experiments for experimental siRNA - mean 
value of two independent experiments for siGLO)/SD for siGLO of two independent 
experiments. 
For each of the parameters analysed, significance was defined as more than one Z score 
away from the siGLO mean in order to increase the window for hit detection and allow 
as many hits to be identified as possible. Z scores are given as a heatmap. 
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2.9 Scanning ion conductance microscopy (SICM) 
In collaboration with Dr Pavel Novak's lab., SICM was used to perform high resolution 
mapping of proliferating, DS, and p16+p21 siRNA transfected DS HMF cell surface 
topographies. 
SICM is a form of scanning probe microscopy which uses a capillary glass nanopipette in 
a conducting solution to image cell surface topography (Klenerman et al., 2013). 
Application of voltage between an electrode in the pipette and an electrode in the bath 
creates a flow of sodium and chloride ions. This ion flow is limited by the small aperture 
in the pipette tip and is further reduced as the pipette tip approaches the ion-
impermeable surface of the cell. The height of the nanopipette tip is adjusted to keep 
the ion flow constant as it scans the surface of the cell, which allows the topography of 
the cell surface to be recorded.  
Proliferating HMFs (P11 to P15) were seeded in 35 mm x 10 mm dishes (Corning, UK) at 
an optimised seeding density of 7,000 cells/cm2 in order to image individual HMF 
membranes in a sub-confluent population. Dishes were incubated at 37°C and medium 
changed after 48 hours and 96 hours. Cells were imaged live at 48 hours and 96 hours 
using SICM. 
DS HMFs were seeded at the optimised density of 7,000 cells/cm2 in 35 mm x 10 mm 
dishes and incubated at 37°C overnight. Approximately 16 hours later, siRNA/Dh2 
complexes were incubated at RT for 20 minutes before cells were forward transfected 
with 3.45 μL Dh2 combined with either 30 nM siGLO or 15 nM p16 siRNA in combination 
with 15 nM p21 siRNA. Dishes were incubated at 37°C and medium changed after 24 
hours and 48 hours. Cells were imaged live 72 hours later using SICM. 
2.10 Database searches 
Protein interaction datasets for each hit were generated using the BioGRID 
bioinformatics database (http://www.thebiogrid.org). These interactions were then 
overlaid to generate a network requiring that each interactor generated a chain with at 
least two other drivers, revealing a total of 33 protein interactions. Using this method, 
only one protein interaction network was generated.  
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To further explore the relationships between drivers and interactors, GeneMANIA 
(http://www.genemania.org) was used to generate an interaction network using data 
from a variety of sources, including physical interactions, co-expression, genetic 
interactions, co-localisation, predicted interactions, pathways, and shared protein 
domains.  
KEGG PATHWAY (http://www.genome.jp/kegg/pathway.html) and PANTHER 
(http://www.pantherdb.org) databases were searched to assign functional annotations 
to the 28 hits that strongly induced the reversal phenotype (‘drivers’) in the previous DS 
HMEC siRNA screen as well as the 33 interactors identified using bioinformatics.  
2.11 Bioinformatics analysis of binding site enrichment 
The genomic location for each gene measured on the array was extracted using biomart 
(Durinck et al., 2009) in R with Ensembl version 75. The promoter for each of these genes 
was calculated as ranging from 2 kilobase pairs (kbp) upstream of the transcription start 
site and 50 base pairs (bp) downstream and the genomic sequence was then obtained 
from the hg19 reference sequence. Transcription factor motifs for EGR2 were obtained 
from TRANSFAC (Matys et al., 2006). CountPWM function was used from the Biostrings 
package (Pagès et al., 2016) with default parameters to calculate the number of 
potential binding targets for the motifs. To calculate the enrichment of the potential 
binding targets for the differential gene expression lists generated by the HMEC gene 
expression array, a background set of genes of the same number as the original 
differential expression list was created by randomly sampling from the remaining genes. 
This was performed 1,000 times to create 1,000 random gene lists and subsequently 
compared with the potential binding targets of these lists to our original differential 
expression list. This analysis was performed by Dr Rob Lowe.  
2.12 Statistical analysis 
An un-paired, two-tailed t-test was performed to compare the means of two groups 
using the Microsoft Office Excel Analysis ToolPak (Microsoft, USA). A one-way analysis 
of variance (ANOVA) was used to analyse the differences between the means of three 
or more independent groups using Prism 7 (GraphPad Software Inc., USA). A two-way 
ANOVA was used to analyse the differences between multiple subgroups within multiple 
independent groups using Prism 7. Post-hoc statistical analysis was performed using 
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either a Dunnett’s or Tukey’s multiple comparison test. The Dunnett’s test was used to 
compare every mean to a control mean, whereas the Tukey test was used to compare 
every mean with every other mean. Unless otherwise stated, at least two independent 












Chapter 3  Reversal of deep 





The limited replicative capacity of primary human fibroblasts in culture was first 
discovered by Hayflick & Moorhead (1961). This replicative barrier, or ‘Hayflick limit’ is 
now known as replicative senescence; a state of stable cell cycle arrest in response to 
telomere erosion which is frequently referred to in the literature as an irreversible 
process (see Section 1.2). There is now compelling evidence that senescent cells 
accumulate in human tissues with age (Dimri et al., 1995; Krishnamurthy et al., 2004). 
Furthermore, senescent cells can be found at the sites of age-related diseases such as 
osteoarthritis, atherosclerosis, and Alzheimer's disease (Naylor, Baker and van Deursen, 
2012). In addition, GWAS have repeatedly linked the INK4/ARF locus (encoding p16, see 
Section 1.1.2) with numerous age-related diseases (Jeck, Siebold and Sharpless, 2012). 
Importantly, clearance of senescent cells using a transgenic approach (Baker et al. 2011) 
or senolytic pharmacological agents (Chang et al., 2015; Zhu et al., 2016) has been 
shown in mice to extend healthspan and recently, lifespan (Baker et al., 2016), 
demonstrating a direct relationship between senescence, age-related diseases, and 
ageing (see Section 1.5.1). 
In order to explore the mechanism of replicative senescence, a model will be established 
in this Chapter using normal adult HMFs serially passaged to senescence. Recent 
evidence has suggested that senescence is a multi-step, dynamic process, with a fully 
senescent phenotype taking over 10 days to develop post-senescence induction (see 
Section 1.2). Given this, HMFs will be kept in culture for three weeks post-senescence 
induction to ensure a stable, long-term, fully senescent phenotype defined as deep 
senescence (DS). Subsequently, DS HMFs will be validated and characterised using 
immunofluorescence staining, high-content imaging, and multi-parameter analysis.  
Previous work in our lab. has shown that cellular senescence in adult DS HMECs is 
reversible using siRNA transfection (Lowe et al., 2015). To investigate whether reversal 
of senescence is achievable in other cell types, this Chapter also aims to develop a 
protocol for the introduction of siRNA into adult DS HMFs in order to determine whether 




Figure 3.1 Schematic of senescence reversal strategy.  Early proliferating (EP) fibroblasts (red) 
will be serially passaged until reaching replicative senescence (RS, green) after a finite number 
of cell divisions, as observed by Hayflick & Moorhead (1961). RS fibroblasts will be kept in culture 
for three further weeks to ensure a stable, long-term, fully senescent phenotype defined as deep 
senescence (DS, blue), which will be validated and characterised using multi-parameter analysis 
and immunofluorescence staining for well-established markers of senescence. Subsequently, a 
siRNA transfection protocol will be developed for DS HMFs in order to investigate whether deep 
senescence can be reversed (R, purple) in adult human fibroblasts. 
3.1.1 Chapter aims 
1. To culture adult HMFs to deep senescence using serial passaging. 
2. To conduct multi-parameter analysis of EP and DS fibroblasts in order to validate 
and characterise the DS phenotype. 
3. To further validate and define the DS phenotype using staining for markers of 
senescence including BrdU, p16, p21, SAHF, and 8-oxoG. 
4. To optimise siRNA transfection of DS HMFs. 
5. To investigate whether reversal of deep senescence can be achieved in HMFs. 
3.2 Replicative senescence in adult human mammary fibroblasts 
3.2.1 Culturing adult human mammary fibroblasts to replicative senescence 
Normal, finite lifespan HMFs will be used to model replicative senescence throughout 
this thesis. These cells were obtained from reduction mammoplasty tissue of a healthy 
16-year old female donor (048R) (Stampfer et al., 1981). 
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To establish a model for replicative senescence in the lab., adult HMFs were serially 
passaged from P4 until proliferation ceased at P29 after 35 population doublings, which 
is equivalent to 175 days in culture (Figure 3.2). This is in line with previous work which 
showed that these fibroblasts reached replicative senescence after approximately 40 
population doublings when cultured from P1 (Romanov et al., 2001; Garbe et al., 2009).  
Fibroblasts at P11 were defined as EP. Recent evidence has suggested that senescence 
is a dynamic, multi-step process throughout which senescent cells evolve and progress 
into deep senescence (Freund et al., 2012; De Cecco et al., 2013; Shah et al., 2013; 
Swanson et al., 2013) (see Section 1.2). Thus, senescent fibroblasts were defined as DS 
(P29+3) when no further expansion was observed after being kept three weeks in 
culture beyond replicative senescence (P29). To examine the long-term stability of DS 
fibroblasts in culture, cells were kept up to 130 days after reaching deep senescence 
with standard medium changes. No further expansion was observed during this period, 





Figure 3.2 Cumulative population doublings of normal adult human mammary fibroblasts.  (A) 
Early proliferating (EP) fibroblasts at P11 were serially passaged until they reached replicative 
senescence at P29. Deeply senescent (DS) fibroblasts were defined as a population which did 
not expand when kept in culture for three weeks post-replicative senescence (P29+3). No 
expansion was observed in DS fibroblasts kept in culture for a further 130 days. N=1 between 
P4 and P6; N=2 or more between P7 and P29+3; N=1 P29+3 + 130 days. Error bars=SD of at least 
two independent experiments. (B) Representative brightfield images of EP and DS fibroblasts 




3.2.2 A panel of morphological markers to validate and characterise the DS phenotype  
It is important to note that senescence can be induced by multiple different triggers, 
causing subsequent heterogeneity in senescent cell morphology. As such, there are 
many markers of senescent phenotypes but no universal marker of the senescent state 
(Sharpless and Sherr, 2015) (see Section 1.4). Thus, a panel of markers is commonly used 
to validate the presence of senescence. Well-established markers of replicative 
senescence in vitro include a stable growth arrest (Hayflick and Moorhead, 1961), 
enlarged, and flattened cell morphology, an enlarged nucleus with an irregular nuclear 
envelope (Mehta et al., 2007; Freund et al., 2012), increased staining for p16 and p21 
(Alcorta et al., 1996), and increased staining for oxidative DNA damage (Chen et al., 
1995) (see Section 1.4.1).  
In order to validate the DS phenotype and identify a panel of senescence-associated 
markers in adult HMFs, morphological changes between EP and DS fibroblasts were 
quantified using multi-parameter analysis (see Section 2.8.2). Fibroblasts were seeded 
at 15,000 cells/cm2 (1,305 cells/well) and after five days, the cells were fixed, stained, 
and imaged according to Sections 2.7 and 2.8. Using this approach, a significant 
difference in cell number was observed between the EP and DS fibroblast phenotypes 
(2,739 ± 189 cells/well compared to 1,182 ± 156 cells/well, respectively; p=0.0004) 
(Figure 3.3), as measured by the cell number per well after five days. No increase in cell 
number compared to the original seeded cell number was observed in the DS fibroblasts 
over the five days (1,182 ± 156 cells/well versus 1,305 cells/well), indicating stable cell 
cycle arrest in the DS fibroblasts. A slight decrease in cell number was consistently 
observed when seeding senescent HMFs due to a small proportion of the population 
which did not re-attach. Furthermore, the DS fibroblast phenotype displayed significant 
changes in multiple nuclear measures compared to EP fibroblasts, including increased 
nuclear area (280 ± 5 µm2 versus 215 ± 5 µm2, respectively; p=0.0001), increased nuclear 
elongation (1.42 ± 0.03 arbitrary unit (AU) versus 1.37 ± 0.01 AU, respectively; p=0.049), 
and decreased nuclear roundness (0.91 ± 0.009 AU versus 0.94 ± 0.003 AU, respectively; 
p=0.004) (Figure 3.3).  
In some cell types, regions of highly condensed chromatin called SAHF are a marker of 
senescence (Narita et al., 2003) (see Section 1.4). However, SAHF formation in fibroblast 
strains is variable and is not considered a universal feature of replicative senescence 
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(Kosar et al., 2011). In line with this finding, DS nuclei examined three weeks post-
replicative senescence did not display SAHF (Figure 3.3E). Furthermore, DS nuclei kept 
in culture for 130 days further did not display SAHF (data not shown). Thus, the DS HMFs 
were determined to be SAHF negative.  
In addition, cellular morphological changes were quantified for EP and DS fibroblast 
phenotypes using multi-parameter analysis. The DS fibroblast phenotype displayed 
significant changes in cell morphology compared to the EP fibroblasts, including 
increased cell area (5,832 ± 424 µm2 versus 2,110 ± 280 µm2, respectively; p=0.0002) 
and decreased cell elongation (1.77 ± 0.013 AU versus 1.82 ± 0.003 AU, respectively; 




Figure 3.3 Multi-parameter analysis of nuclear morphological measures in EP and DS 
fibroblasts.  EP and DS cells were seeded at 15,000 cells/cm2 in 384-well plate format, fixed after 
five days, stained with DAPI, and nuclear phenotypes quantitated according to Section 2.7 and 
Section 2.8. (A) Mean cell number per well. (B) Mean nuclear area (μm2). (C) Mean nuclear 
elongation (AU). (D) Mean nuclear roundness (AU). Un-paired two-tailed t-test * p<0.05, ** 
p<0.01, *** p<0.001. N=3 throughout. Error bars=SD of three independent experiments, each 
performed with six replicates. (E) Representative images of EP and DS fibroblast nuclei. DAPI 





Figure 3.4 Multi-parameter analysis of cell morphological measures in EP and DS fibroblasts.  
EP and DS cells were seeded at 15,000 cells/cm2 in 384-well plate format, fixed after five days, 
stained with Cell Mask, and cell phenotypes quantitated according to Section 2.7 and Section 
2.8. (A) Mean cell area (μm2). (B) Mean cell elongation (AU). Un-paired two-tailed t-test * 
p<0.05, *** p<0.001. N=3 throughout. Error bars=SD of three independent experiments, each 
performed with six replicates. (C) Representative images of EP and DS fibroblasts. Cell Mask 




In summary, multi-parameter analysis identified a panel of six well-established 
morphological senescence markers which both validate and define the DS fibroblast 
phenotype. In subsequent work, this panel will be used to identify siRNA-induced 
morphological changes in the DS fibroblasts. 
3.2.3 Immunofluorescence staining further validates and characterises the DS 
fibroblast phenotype 
To further investigate the proliferative status of EP and DS cells, progression through S 
phase of the cell cycle was examined using immunofluorescence staining for BrdU 
incorporation. Following optimisation (data not shown), EP and DS fibroblasts were 
pulsed with BrdU for 16 hours then immediately fixed and stained with DAPI and mouse 
anti-BrdU Alexa Fluor 488 according to Sections 2.7.1. Cells were then imaged and BrdU 
positive nuclei quantified according to Section 2.8. Supporting the previous analysis 
which showed that DS HMFs did not increase in cell number (see Section 3.2.2), DS nuclei 
did not incorporate BrdU and therefore presented a significantly reduced percentage of 
BrdU positive nuclei (0% ± 0%) in comparison to EP nuclei (15% ± 1%; p=0.003) (Figure 
3.7). It is important to note that as fixation occurred immediately after the 16 hour BrdU 
pulse, the data generated here is representative only of the BrdU-incorporating cells, 
not the resulting daughter progeny. Thus, given the 16 hour BrdU incubation, 15% ± 1% 
BrdU incorporation in EP nuclei is in line with the data presented previously within this 
Chapter, as EP fibroblasts seeded at 15,000 cells/cm2 in 384-well plate format have a 
doubling time of approximately 100 hours, meaning that approximately 16% of cells 




Figure 3.5 Percentage of nuclei positive for BrdU incorporation in EP and DS fibroblasts. EP and 
DS cells were seeded at 15,000 cells/cm2 in 384-well plate format, fixed after five days, and 
stained with DAPI and mouse anti-BrdU Alexa Fluor 488 according to Section 2.7.1. Using the 
secondary only control, a nuclear intensity threshold was established to define BrdU positive or 
negative nuclei. (A) Bars denote mean percentage of BrdU positive nuclei. Un-paired two-tailed 
t-test ** p<0.01. N=2 throughout. Error bars=SD of two independent experiments, each 
performed with three replicates. (B) Representative immunofluorescence images and (C) 
digitally zoomed images of EP and DS fibroblasts. DAPI (blue), BrdU (green). Scale bar denotes 




Up-regulation of p16 and p21 expression is a hallmark of replicative senescence in 
fibroblasts. However, the increase of p16 and p21 expression levels during senescence 
occurs with different kinetics (Alcorta et al., 1996; Stein et al., 1999). Proliferating 
fibroblasts possess a basal endogenous level of p21 expression which increases sharply 
as the culture nears replicative senescence before declining (reviewed in Sherr & 
Roberts 1999). By contrast, p16 levels gradually accumulate, reaching a maximum in 
deep senescence after p21 levels have started to decline (Alcorta et al., 1996) (see 
Section 1.2). Consequently, a deeply senescent fibroblast culture may contain cells 
positive for p16, p21, or both.  
In order to further validate and explore the DS phenotype, p16 and p21 levels were 
investigated in EP and DS fibroblasts. To achieve this, multiple rabbit anti-p21 antibodies 
were validated via western blotting for the presence of a single band at the expected 
molecular weight. Subsequently, rabbit anti-p21 (12D1) and mouse anti-p16 (JC8) were 
identified as suitable antibodies and optimised for immunofluorescence staining 
(Appendix Figure A.1). Following this, p16 and p21 expression levels were quantified in 
the EP and DS fibroblasts using western blot (Appendix Figure A.2A-C) and 
immunofluorescence staining according to Section 2.4 and Section 2.8, respectively 
(Figure 3.6). Using the secondary only control, p16 and p21 nuclear intensity thresholds 
were established to define negative and positive nuclei, and analysis was performed to 
categorise the population into four subgroups: double negative; double positive; and 
positive for either p16 or p21. In line with the literature, a significantly increased 
percentage of DS nuclei were double positive (62% ± 18%) in comparison to EP nuclei 
(5% ± 1%; p=0.02), indicating up-regulation of both p16 and p21 expression. 
Correspondingly, a significantly decreased percentage of DS nuclei were identified as 
double negative (5% ± 6%) in comparison to EP nuclei (53% ± 9%; p=0.03). 
Unsurprisingly, given the heterogeneity of p16 and p21 expression in the senescent 
fibroblast population, 11% ± 8% of DS nuclei were positive for only p16 expression and 
23% ± 4% were positive for only p21 expression. Furthermore, in line with the literature 
demonstrating that proliferating fibroblasts possess a basal level of p21 expression, 37% 
± 8% of EP nuclei were positive for only p21 expression only. However, 6% ± 1% of EP 
nuclei were also positive for p16 expression only, perhaps indicating an early onset in 
the gradual accumulation of p16 levels. Further investigation revealed that EP HMFs 
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defined as positive for p16 or p21 possess lower average nuclear p16 or p21 intensity 
levels relative to positive DS HMFs (Figure 3.6C-D). This indicated that positive EP HMFs 
express each of these senescence markers at a lower level than positive DS HMFs, 
potentially at a level below the threshold level which is necessary for senescence 
induction.  
In summary, increased expression of p16 and p21 expression in the DS population 
further validated the senescent phenotype of the HMFs. Thresholding of p16 and p21 
nuclear intensities allowed subsequent categorisation into four subgroups, which 
further characterised the EP and DS populations, and demonstrated the variation in p16 





Figure 3.6 p16 and p21 expression in EP and DS fibroblasts.  EP and DS cells were seeded at 
15,000 cells/cm2 in 384-well plate format, fixed after five days, stained with DAPI, mouse anti-
p16 (JC8), rabbit anti-p21 (12D1), donkey anti-mouse Alexa Fluor 488, goat anti-rabbit Alexa 
Fluor 546, and nuclear intensities were quantitated according to Section 2.7 and Section 2.8. 
Nuclear intensity thresholds were established for p16 and p21 to define positive or negative 
nuclei. Nuclei were classified into four subgroups: p16 and p21 negative (p16- p21-); p16 
negative and p21 positive (p16- p21+); p16 positive and p21 negative (p16+ p21-); and p16 and 
p21 positive (p16+ p21+). (A) Bars denote mean percentage of nuclei per subgroup. Two-way 
ANOVA and Tukey’s test * p<0.05. Significance colours match nuclei subgroup. N=2 throughout. 
Error bars=SD of two independent experiments, each performed with three replicates. (B) 
Representative immunofluorescence images of EP and DS fibroblasts. DAPI (blue), p16 (green), 
p21 (red). Scale bar denotes 100 μm. (C) Representative frequency distribution of nuclear p16 
intensities in EP and DS p16 positive (p16+) HMFs. (D) Representative frequency distribution of 
nuclear p21 intensities in EP and DS p21 positive (p21+) HMFs.   
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Fibroblasts which have undergone replicative senescence have also been shown to have 
elevated levels of oxidative DNA damage in response to ROS. Oxidative DNA damage can 
be visualised by increased staining for 8-oxoG, an oxidatively damaged nucleotide 
excised from DNA and present within the cytoplasm (Chen et al., 1995) (see Section 
1.4.1). Using a previously validated mouse anti-8-oxoG antibody (Lowe et al., 2015) (data 
not shown), the levels of oxidative damage in EP and DS fibroblasts were examined 
(Figure 3.7). Following thresholding of 8-oxoG levels, a significant percentage of DS cells 
were defined as positive for 8-oxoG staining (71% ± 3%) versus EP cells (16% ± 4%; 
p=0.005). In addition, further investigation of the 8-oxoG positive (8-oxo+) subgroup in 
EP and DS HMFs revealed that 8-oxo+ DS HMFs possessed increased levels of 8-oxoG in 
comparison to EP HMFs (Figure 3.7C). Interestingly, there was a similar proportion of 
double positive (p16+ p21+) DS HMFs (62% ± 18%) in the population (Figure 3.6) as 8-
oxoG positive DS HMFs, potentially indicating a relationship between the kinetics of p16 
and p21 up-regulation and accumulation of 8-oxoG levels during the deepening of the 
senescence phenotype. Together, these data indicate the presence of elevated levels of 





Figure 3.7 Percentage of EP and DS nuclei positive for 8-oxoG.  EP and DS cells were seeded at 
15,000 cells/cm2 in 384-well plate format, fixed after five days, stained with DAPI, mouse anti-
8-oxoG, donkey anti-mouse Alexa Fluor 488, and 8-oxoG cellular density was quantitated 
according to Section 2.7 and Section 2.8. A cellular density threshold was established to define 
8-oxoG positive or negative cells. (A) Bars denote mean percentage of 8-oxoG positive cells. Un-
paired two-tailed t-test ** p<0.01. N=2 throughout. Error bars=SD of two independent 
experiments, each performed with three replicates. (B) Representative immunofluorescence 
images of EP and DS fibroblasts. DAPI (blue), 8-oxoG (green). Scale bar denotes 100 μm. (C) 
Representative frequency distribution of cellular 8-oxoG densities in EP and DS 8-oxoG positive 




3.2.4 Further markers of senescence to characterise the DS phenotype 
Acosta et al. (2013) recently demonstrated that OIS fibroblasts induce paracrine 
senescence in neighbouring proliferating fibroblasts via the SASP (see Section 1.4.2). In 
order to explore whether DS HMFs transmit senescence in a paracrine manner, EP HMFs 
were seeded at an optimised density of 10,000 cells/cm2 (data not shown) and exposed 
to conditioned medium which was incubated for 48 or 72 hours on DS HMFs seeded at 
10,000 cells/cm2 or on EP HMFs as a negative control, according to Section 2.3. After five 
days, EP fibroblasts were fixed and stained with DAPI and Cell Mask according to Section 
2.7. Cell number was quantitated according to Section 2.8.2. This work was performed 
by Arturo Robles Tenorio (an MSc student in the Bishop lab., May 2015-September 
2015). 
Using this approach, no difference in cell number was detected for EP HMFs exposed to 
conditioned medium which was incubated on EP HMFs (EP48, 5,379 ± 1,011 cells/well; 
EP72, 4,553 ± 239 cells/well), or conditioned medium incubated on DS HMFs for 48 
hours (DS48, 4,725 ± 794 cells/well) in comparison to the un-conditioned medium 
control (CTRL, 4,969 ± 241 cells/well). However, EP HMFs treated with conditioned 
medium which was incubated on DS HMFs for 72 hours (DS72) showed a significant 
decrease in mean cell number (3,518 ± 380 cells/well; p=0.0001) (Figure 3.8). Further 
preliminary data investigating nuclear and cellular morphology indicated a trend 
towards increased nuclear and cellular area in the DS72-treated EP HMFs as well as 
increased cellular 8-oxoG intensity compared to CTRL-treated EP HMFs (data not 
shown). These data demonstrate that conditioned medium incubated on DS HMFs can 
decrease cell number, nuclear and cellular area, and increase cellular 8-oxoG intensity 
of EP HMFs, which may indicate transmission of senescence to EP HMFs in a paracrine 




Figure 3.8 Analysis of cell number for EP HMFs exposed to DS HMF conditioned medium. EP 
cells were seeded at 10,000 cells/cm2 in a 96-well plate format, fixed, and stained with DAPI and 
Cell Mask after five days of exposure to either unconditioned control medium (CTRL) or 
conditioned medium collected under four conditions: 48 hour incubation on EP fibroblasts 
(EP48); 72 hour incubation on EP fibroblasts (EP72); 48 hour incubation on DS fibroblasts (DS48); 
or 72 hour incubation on DS fibroblasts (DS72); according to Section 2.3, 2.7, and 2.8. Cell 
number was quantitated according to Section 2.8.2. (A) Mean cell number of EP fibroblasts 
exposed to medium from five conditions. One-way ANOVA and Dunnett’s test **** p<0.0001. 
N=2 throughout. Error bars=SD of two independent experiments, each performed with six 
replicates. (B-C) Representative images of the five different conditions: (B) CTRL; (C) EP48; EP72; 
DS48; and DS72. DAPI (blue), Cell Mask (red). Scale bar denotes 100 µm. The data displayed 
within this figure were generated by Arturo Robles Tenorio, MSc student within the Bishop lab. 




As the progression from early to deep senescence is mediated by the down-regulation 
of lamin B1 (see Section 1.2), it was hypothesised that lamin B1 levels would be 
decreased in DS fibroblasts in comparison to EP HMFs. To explore this, lamin B1 levels 
were investigated in EP and DS HMFs using western blotting. Using this approach, DS 
HMFs displayed decreased lamin B1 levels in comparison to EP HMFs (N=1, 
representative experiment, Appendix Figure A.2A, D), indicating progression of the 
senescent HMFs into a deeply senescent phenotype. 
3.3 Reversal of deep senescence in fibroblasts 
3.3.1 Transfection optimisation of DS HMFs in 384-well plate format 
Senescent primary cells are notoriously difficult to transfect. Therefore, before reversal 
of deep senescence in fibroblasts could be tested, a transfection reagent with a high 
transfection efficiency and low cytotoxicity was sought to efficiently deliver siRNA to DS 
HMFs. 
In order to identify the optimal transfection reagent, the uptake efficiency of two 
different transfection reagents (Dh2 and Dh4), which had previously been shown to 
transfect DS epithelial cells (Lowe et al., 2015), were tested in the DS fibroblasts. Dh2 
demonstrated greater uptake efficiency than Dh4 and was accordingly selected as the 
optimal transfection reagent (data not shown). Subsequently, the cell seeding density 
and Dh2 dose were optimised in order to produce a high level of transfection efficiency 
with minimal toxicity. As senescent cells do not proliferate, an optimal seeding density 
to detect senescence reversal is one with enough cells to maximise the exponential 
increase in cell number, without reaching confluency by the experimental endpoint. 
Accordingly, an optimised seeding density of 15,000 cells/cm2 was chosen for the DS 
fibroblasts (data not shown).  
To identify a Dh2 dose with maximum transfection efficiency and minimal toxicity, 
siGLO, a fluorescently labelled control siRNA targeting a non-essential housekeeping 
gene, was used as a negative control for transfections. siGLO transfection enables 
quantification of the uptake of this DY547-labelled transfection reagent/siRNA mix (see 
Section 2.5). Using the optimised seeding density of 15,000 cells/cm2, DS fibroblasts 
were forward transfected with 30 nM siGLO using 0-0.6 µL/well Dh2 according to Section 
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2.5.3 (N=1, representative experiment, performed multiple times in different contexts). 
In order to identify the optimal Dh2 dose to be used in future experiments, two 
measures were investigated: average cell number per well to ensure minimal toxicity, 
as well as average siGLO uptake per cell to identify maximum transfection efficiency. No 
noticeable decrease in mean cell number/well was observed in Dh2 doses from 0 
µL/well (1,230 ± 66 cells/well) to 0.6 µL/well (1,206 ± 39 cells/well), indicating minimal 
toxicity even at 0.6 µL (N=1, Figure 3.9A). Further, 0.15 µL/well was identified as the 
lowest dose inducing effective siGLO uptake (32 ± 3 foci/cell) relative to the 0.15 µL Dh2 
only control (2 ± 0 foci/cell), and Dh2 doses higher than 0.15 µL/well did not produce a 
further increase in siGLO foci, indicating that 0.15 µL is the minimum effective dose. 
Accordingly, 0.15 µL/well was selected as the optimal Dh2 dose to be used in future 
experiments (Figure 3.9B-D). In addition, it was confirmed that siGLO was an appropriate 
negative control as there were no changes in proliferation, morphology, BrdU 
incorporation, or protein expression compared to untransfected (UTC) cells and cells 
treated with Dh2 alone (Appendix Figure A.3). Subsequently, siGLO was used throughout 
this thesis as a negative control for the siRNA reversal transfections.  
Polo-like kinase 1 (PLK1), a serine-threonine kinase that is essential for mitosis, is often 
used as a positive ‘killer’ control in siRNA transfections, as cells transfected with PLK1 
siRNA undergo apoptosis during cell division. PLK1 siRNA transfection in DS HMFs 
provided further confirmation that the culture was fully arrested as no significant 




Figure 3.9 Optimisation of Dh2 dose in DS fibroblasts. DS fibroblasts were seeded at 15,000 
cells/cm2 and forward transfected with either 0-0.6 µL/well Dh2 alone, or with 30 nM siRNA 
targeting cyclophilin B labelled with DY547 (siGLO) according to Section 2.5.3. After five days, 
cells were fixed, stained with DAPI and Cell Mask, imaged, and quantified according to Sections 
2.7 and 2.8. (A) Mean cell number/well of cells transfected with either 0-0.6 µL/well Dh2 alone 
or with 30 nM siGLO. (B) Mean cellular siGLO foci number of cells transfected with either 0-0.6 
µL/well Dh2 alone or with 30 nM siGLO. N=1 throughout. Single representative experiment 
which has been performed multiple times in different contexts. Error bars=SD of a single 
experiment containing three replicates. (C) Representative immunofluorescence images of DS 
HMFs transfected with 0.15 µL Dh2 alone or with 30 nM siGLO using 0.15 µL Dh2. DAPI (blue), 




3.3.2 Reversal of deep senescence in HMFs 
Previously, Lowe et al. (2015) demonstrated that p16 siRNA knockdown in DS HMECs 
transiently reverses epithelial cellular senescence creating a 'reversed' phenotype, as 
characterised by the loss of multiple senescence-associated features (see Section 1.7). 
Unlike replicative senescence in fibroblasts, which activates both the p53/p21 and 
p16/pRB pathways, HMECs exhibit a two-step pattern of senescence, where cells first 
undergo p16-dependent epithelial cellular senescence in the absence of telomere 
erosion and p53 or p21 expression (Brenner, Stampfer and Aldaz, 1998). With this in 
mind, it was hypothesised that transient knockdown using previously validated p16 
(Bishop et al., 2010) and p21 (Borgdorff et al., 2010) siRNAs together in DS fibroblasts 
would induce a ‘reversed phenotype’, as characterised by the previously defined panel 
of senescence-associated markers (see Section 3.2.3). Accordingly, DS fibroblasts were 
seeded at a previously optimised seeding density of 15,000 cells/cm2 and forward 
transfected with 30 nM p16 siRNA, 30 nM p21 siRNA, or 15 nM p16 siRNA combined 
with 15 nM p21 siRNA (p16+p21 siRNA) using the optimised dose of 0.15 µL Dh2 (see 
Section 2.6.1). After five days, cells were stained with DAPI and Cell Mask and 
senescence-associated markers quantified according to Section 2.7 and 2.8. 
DS fibroblasts transfected with p16 siRNA had no change in proliferation, nuclear or 
cellular morphology compared with cells transfected with siGLO (Figure 3.10A). DS 
fibroblasts transfected with p21 siRNA consistently increased cell number (1,476 ± 238 
cells/well) compared to siGLO transfected cells (1,017 ± 106 cells/well), and consistently 
altered multiple senescent morphologies, including reduced nuclear area (203 ± 8 µm2 
versus 281 ± 9 µm2), and reduced cell area (3,407 ± 661 µm2 versus 6,341 ± 800 µm2). 
There was also a trend towards altered nuclear elongation (1.36 ± 0.04 AU), nuclear 
roundness (0.92 ± 0.01 AU), or cell elongation (1.98 ± 0.09 AU) in the p21 siRNA 
transfected DS fibroblasts compared to the siGLO control (1.42 ± 0.03 AU; 0.90 ± 0.01 
AU; 1.80 ± 0.03 AU, respectively). Strikingly, siRNA knockdown of both p16 and p21 in 
DS fibroblasts consistently induced an increase in cell number (1,657 ± 214 cells/well) 
compared to the siGLO transfected cells. It is also interesting to note that in all four 
experiments presented in Figure 3.10, the combined knockdown of p16 and p21 
generated a greater cell number than the corresponding p21 siRNA transfected cells. 
Moreover, in all experiments, the p16+p21 transfected DS fibroblasts displayed altered 
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nuclear and cellular morphology in comparison to both the siGLO transfected and p21 
siRNA transfected cells, with reduced nuclear area (187 ± 9 µm2), reduced nuclear 
elongation (1.35 ± 0.03 AU), increased nuclear roundness (0.92 ± 0.007 AU), and 
decreased cell area (2,908 ± 676 µm2). There was also a trend towards increased cell 
elongation in p16+p21 siRNA knockdown HMFs in comparison to the siGLO transfected 
DS HMFs (2.02 ± 0.13 AU), although this was not as consistent as other measures, 
potentially due to the limitations of the IN Cell developer software segmentation of 
fibroblast cellular shape.  
In conclusion, p16 siRNA knockdown in DS HMFs did not increase cell number or alter 
DS HMF morphology. However, p21 siRNA knockdown in DS HMFs increased the cell 
number and altered senescent morphologies. In all experiments, knockdown of both 
p16 and p21 consistently induced an increase in cell number in comparison to both 
siGLO and p21 siRNA knockdown alone, as well as consistently inducing further changes 
towards a reversal phenotype in multiple senescent morphologies, including nuclear 
area, cell area, nuclear elongation, and roundness, indicating that knockdown of both 
p16 and p21 is necessary and sufficient to induce DS fibroblasts to a reversed phenotype. 
In order to determine the re-entry into the cell cycle of the reversed fibroblasts, 
immunostaining for BrdU incorporation was performed according to Section 2.7.1 and 
2.8. In line with cell number data previously presented in this Section (Figure 3.10 ), DS 
fibroblasts transfected with p16 siRNA did not increase the proportion of cycling cells 
(4% ± 2%) compared to cells transfected with siGLO (1% ± 1%). Importantly, in line with 
previous cell number data (Figure 3.10), p21 siRNA (17% ± 6%; p=0.03) and p16+p21 
siRNA (32% ± 10%; p=0.001) transfected DS HMFs had a significantly increased 
proportion of BrdU positive cells in comparison to the siGLO transfected DS HMF control. 
Furthermore, p16+p21 siRNA knockdown in DS HMFs induced an increase in BrdU 
incorporation greater than that observed in EP cells (15% ± 1%) (Figure 3.5). Together 
with the cell number data generated previously (Figure 3.10), this data further indicates 
that p16+p21 siRNA knockdown induced the DS HMF population to re-enter the cell 





Figure 3.10 Transfection of DS fibroblasts with p16 siRNA, p21 siRNA, or p16 siRNA together 
with p21 siRNA.  DS cells were seeded at 15,000 cells/cm2 in 384-well plate format and forward 
transfected with 30 nM siGLO (siGLO), 30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21), and 15 
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nM p16 together with 15 nM p21 siRNA (p16+p21) using 0.15 µL Dh2 according to Section 2.6.1. 
After five days, cells were fixed, stained with DAPI and Cell Mask, imaged, and quantified 
according to Sections 2.7 and 2.8. Data points denote four independent experiments (Exp 1 
(blue), Exp 2 (orange), Exp 3 (grey), Exp 4 (yellow)), each performed with at least three replicates, 
for the following measures: (A) mean cell number/well, (B) mean nuclear area (µm2), (C) mean 
nuclear elongation (AU), (D) mean nuclear roundness (AU), (E) mean cell area (µm2), (F) mean 
cell elongation (AU). (G) Representative immunofluorescence images of siGLO, p16, p21, and 
p16+p21 transfected DS HMFs. DAPI (blue), Cell Mask (red). Scale bar denotes 100 μm. Right 





Figure 3.11 Percentage of nuclei positive for BrdU incorporation in siRNA transfected DS 
fibroblasts.  DS cells were seeded at 15,000 cells/cm2 in 384-well plate format and forward 
transfected with 30 nM siGLO (siGLO), 30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21), and 15 
nM p16 together with 15 nM p21 siRNA (p16+p21) using 0.15 µL Dh2 according to Section 2.6.1. 
After five days, cells were fixed, stained with DAPI, mouse anti-BrdU Alexa Fluor 488, and nuclear 
intensity was quantitated according to Section 2.7.1 and 2.8. Using the secondary only control, 
a nuclear intensity threshold was established to define BrdU positive or negative nuclei. (A) Bars 
denote mean percentage of BrdU positive nuclei. One-way ANOVA and Dunnett’s test * p<0.05, 
*** p<0.001. N=3 throughout. Error bars=SD of three independent experiments, each 
performed with three replicates. (B) Representative immunofluorescence images and (C) 
digitally zoomed images of siGLO, p16, p21, and p16+p21 siRNA transfected DS HMFs. DAPI 
(blue), BrdU (green). Scale bar denotes 100 µm and 50 µm on zoomed images.  
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To further characterise the reversed phenotype, additional markers of senescence, such 
as p16 and p21 expression, were examined in the siRNA transfected DS population. First, 
p16 and p21 protein knockdown following p16 or p21 siRNA transfection in DS HMFs 
was assessed via western blotting. For both antibodies, western blot analysis revealed 
one clean band at the appropriate molecular weight (approximately 16 kilodalton (KDa) 
and 21 KDa) within the siGLO knockdown DS HMFs (Figure 3.12A). Importantly, 
quantification revealed a statistically significant reduction in p16 levels following p16 
siRNA knockdown (91% ± 7%; p=0.03) and p21 levels following p21 siRNA knockdown 
(48% ± 5%; p=0.03) relative to the siGLO knockdown control (Figure 3.12B). Interestingly, 
although not statistically significant, there was a trend towards increased p16 levels 
following p21 siRNA knockdown and increased p21 levels following p16 siRNA 






Figure 3.12 Western blot analysis of p21 and p16 levels in siGLO, p16, p21, and p16+p21 
transfected DS HMFs loaded by total protein concentration.  (A) Representative western blots 
depicting p16 and (B) p21 levels in 30 nM siGLO, 30 nM p16 siRNA, or 30 nM p21 siRNA 
transfected DS HMFs. Cell lysates were harvested for western blotting according to Section 
2.4.1. Lysates were probed for rabbit anti-p21 (12D1), mouse anti-p16 (JC8), and the rabbit anti-
GAPDH antibody was used as a loading control. Antibody dilutions and conditions may be found 
in Section 2.4.3. (C) Densitometry analysis of p16 and (D) p21 levels in transfected DS HMFs. 
Analysis was performed using ImageJ software. Bars denote mean density levels. One-way 
ANOVA and Dunnett’s test * p<0.05. N=2 throughout. Error bars=SD normalised to GAPDH siRNA 




Subsequently, p16 and p21 levels were investigated in the siGLO, p16, p21, and p16+p21 
transfected DS HMFs using immunofluorescence staining according to Section 2.7 and 
Section 2.8. In line with the western blotting data presented previously (Figure 3.12), 
immunofluorescence staining showed a reduction in p16 and p21 protein levels 
following p16 or p21 siRNA knockdown, respectively (Figure 3.13A-B). In addition, p16 
levels were increased following p21 siRNA knockdown and, to a lesser extent, p21 levels 
were increased following p16 siRNA knockdown in comparison to the siGLO transfected 
control, further suggesting the presence of a compensatory feedback loop upregulating 
p16 or p21, respectively, by the five day time point (Figure 3.13A-B).  
Using the immunofluorescence secondary only control, thresholds for positivity were 
determined for p16 and p21 nuclear intensities, and the population was fractioned into 
four subgroups: double negative; double positive; and positive for either p16 or p21 
expression. The proportion of each subgroup in the siGLO transfected DS HMFs is 
comparable to previous DS HMFs (Figure 3.6) and to the UTC and Dh2 only transfected 
DS HMF controls in this experiment (Appendix Figure A.3). In line with the finding that 
p16 levels decreased following p16 knockdown in DS HMFs (Figure 3.13A-B), this 
analysis revealed a significant increase in the p21 positive only population (59% ± 14%; 
p=0.0007) and significant decrease in the double positive population (35% ± 12%; 
p=0.0005) in the p16 siRNA transfected DS HMFs compared to the siGLO transfected 
cells (31% ± 10% and 64% ± 9%, respectively). In the p21 siRNA knockdown DS HMFs, 
the proportion of cells in the p16 positive only subgroup significantly increased (57% ± 
6%; p<0.0001), the double positive subgroup significantly decreased (23% ± 2%; 
p<0.0001), and the p21 positive only subgroup significantly decreased (4% ± 2%; 
p=0.001) compared to the siGLO transfected cells (2% ± 1%, 64% ± 9%, and 31% ± 10% 
respectively). Interestingly, there was a trend towards an increase in the double 
negative subgroup of p21 siRNA transfected DS HMFs (16% ± 2%; p=0.0958) compared 
to the siGLO transfected DS HMFs (3% ± 0%), potentially indicating a proportion of the 
population which have reversed senescence upon p21 siRNA knockdown. Importantly, 
following knockdown of both p16 and p21 in DS HMFs, there was a significant increase 
in the double negative subgroup (22% ± 0%; p=0.01) in comparison to the siGLO 
transfected cells (3% ± 0%), indicating a significant proportion of cells in which 
knockdown was successful. Interestingly, the increase in the double negative subgroup 
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was proportional to the increase in BrdU positive cells (32% ± 10%; p=0.001) (Figure 
3.11) following p16+p21 siRNA knockdown, potentially indicating that the double 
negative knockdown HMFs are progressing through the cell cycle at this 5 day post-
knockdown time-point. Furthermore, p16+p21 siRNA knockdown in DS HMFs 
significantly decreased the p21 positive only subgroup (6% ± 0%; p=0.002) and 
significantly decreased the double positive subgroup (30% ± 1%; p=0.0001), leading to a 
shift towards a significantly increased p16 positive only subgroup (42% ± 2%; p=0.0001) 
compared to the siGLO transfected cells.  
In summary, p16 siRNA knockdown alone did not increase the proportion of the double 
negative subgroup in DS HMFs, but p21 siRNA alone induced a trend towards an 
increased double negative subgroup, and p16+p21 siRNA significantly increased the 
proportion of the double negative subgroup. This suggests that p16 or p21 siRNA alone 
was not sufficient to significantly increase the proportion of reversed, double negative 
cells in the population, but that knockdown of both p16 and p21 together functions co-
ordinately to significantly increase the proportion of the double negative knockdown  
cells. Therefore, the data generated here indicates that p16+p21 siRNA double 
knockdown is required for significant knockdown of p16 and p21 in the population. 
Levels of oxidative damage were also investigated for the siRNA transfected DS HMFs 
according to Sections 2.7 and 2.8. Using this approach, the proportion of cells positive 
for 8-oxoG did not significantly change following p16 siRNA knockdown (84% ± 2%) 
compared to the siGLO transfected cells (89% ± 1%) (Figure 3.14). However, the 
percentage of 8-oxoG positive cells in the p21 siRNA transfected DS HMFs and p16+p21 
siRNA transfected DS HMFs (62% ± 7% and 55% ± 10%, respectively) decreased 
significantly compared to siGLO transfected DS HMFs (p=0.02 and p=0.01, respectively). 
In addition, further investigation of the 8-oxoG positive subpopulation revealed a 
decrease in 8-oxoG cellular density in the p21 and p16+p21 siRNA transfected cells 
compared to the siGLO transfected DS HMFs (Figure 3.14B). Together, these data 





Figure 3.13 p16 and p21 expression in siRNA transfected DS fibroblasts.  DS cells were seeded 
at 15,000 cells/cm2 in 384-well plate format and forward transfected with 30 nM siGLO (siGLO), 
30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21), or 15 nM p16 together with 15 nM p21 siRNA 
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(p16+p21) using 0.15 µL Dh2 according to Section 2.6.1. Cells were fixed at day five, stained with 
DAPI, mouse anti-p16 (JC8), rabbit anti-p21 (12D1), donkey anti-mouse Alexa Fluor 488, and 
goat anti-rabbit Alexa Fluor 546, and nuclear intensities were quantitated according to Section 
2.7 and 2.8. (A) Representative frequency distribution of nuclear p16 intensities after 
background removal in siGLO, p16, p21, and p16+p21 siRNA transfected HMFs. (B) 
Representative frequency distribution of nuclear p21 intensities after background removal in 
siGLO, p16, p21, and p16+p21 siRNA transfected HMFs. (C) Nuclear intensity thresholds were 
established for p16 and p21 to define positive or negative nuclei. Nuclei were classified into four 
subgroups: p16 and p21 positive (p16+ p21+); p16 positive and p21 negative (p16+ p21-); p16 
negative and p21 positive (p16- p21+); and p16 and p21 negative (p16- p21-). Bars denote mean 
percentage of nuclei per subgroup. Two-way ANOVA and Tukey’s test * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. NS=not significant. Significance colours match nuclei subgroup and are 
ordered left to right in the following order: p16- p21-; p16- p21+; p16+ p21-; p16+ p21+. N=2 
throughout. Error bars=SD of two independent experiments, each performed with three 
replicates. (D) Representative immunofluorescence images of siGLO, p16, p21, and p16+p21 





Figure 3.14 Percentage of cells positive for 8-oxoG in siRNA transfected DS fibroblasts.  DS cells 
were seeded at 15,000 cells/cm2 in 384-well plate format and forward transfected with 30 nM 
siGLO (siGLO), 30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21), or 15 nM p16 together with 15 
nM p21 siRNA (p16+p21) using 0.15 µL Dh2 according to Section 2.6.1. After five days, cells were 
fixed, stained with DAPI, mouse anti-8-oxoG, donkey anti-mouse Alexa Fluor 488, and 8-oxoG 
cellular density was quantitated according to Section 2.7 and Section 2.8. A cellular density 
threshold was established to define 8-oxoG positive or negative cells. (A) Bars denote mean 
percentage of 8-oxoG positive cells. One-way ANOVA and Dunnett’s test * p<0.05. N=2 
throughout. Error bars=SD of two independent experiments, each performed with three 
replicates. (B) Representative frequency distribution of cellular 8-oxoG density in siGLO, p16, 
p21, and p16+p21 siRNA transfected 8-oxoG positive HMFs. (C) Representative 
immunofluorescence images of siGLO, p16, p21, and p16+p21 transfected DS HMFs. DAPI (blue), 
8-oxoG (green). Scale bar denotes 100 µm.  
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3.3.3 Identification of membrane stiffness as a novel potential marker of senescence  
Recent evidence has suggested that dermal fibroblasts (Kim et al., 2015) and epithelial 
cells (Berdyyeva, Woodworth and Sokolov, 2005) exhibit increasing membrane stiffness 
in vitro during serial passaging. In addition, dermal fibroblasts isolated from healthy 
older donors have been shown to exhibit increased membrane stiffness ex vivo (Schulze 
et al., 2012). However, the relationship between cell membrane stiffness and 
senescence remains currently unexplored. To investigate the relationship between cell 
membrane stiffness and senescence, SICM was used to map the topography and 
stiffness of EP, DS, and reversed HMF membranes at high resolution according to Section 
2.9 (Appendix Figure A.10). This work was performed in collaboration with BSc and MSc 
students within Dr Pavel Novak’s lab., and part of this work formed the basis of a 
manuscript recently published in Soft Matter (Clarke et al., 2016). Analysis of Young’s 
modulus, a measure of the stiffness of a solid material, showed that DS fibroblasts had 
significantly stiffer membranes (6,311 ± 2,214 Pa; p=0.05) than EP HMFs (2,916 ± 2,465 
Pa), and that p16 and p21 double knockdown enabled reversal of the membrane to a 
stiffness similar to that of EP HMFs and significantly softer than DS HMFs (3,132 ± 1,737 




Figure 3.15 High resolution mapping of EP, DS, and reversed HMF membranes using scanning 
ion conductance microscopy. (A) Representative images of the topography and Young’s 
modulus of EP, DS, and DS HMFS transfected with 15 nM p16 and 15 nM p21 (p16+p21) siRNA 
HMFs. (B) Distribution of local Young’s modulus E in the EP (left), DS (middle), and DS HMF 
transfected with p16+p21 siRNA (right). (C) The mean of median Young’s moduli of DS cells (N=6) 
is significantly different from both the EP (N=17) and DS cells transfected with p16+p21 siRNA 
(N=22). One-way ANOVA and Tukey’s test * p<0.05. The data displayed within this figure was 
generated in collaboration with Ashna Gopal, Devesh Dillum, Jeswy Thankam Shaji, and Ho Ting 
Au, BSc and MSc students within Dr Pavel Novak’s lab.  
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3.4 Discussion and future work 
3.4.1 Validation and characterisation of the DS HMF phenotype  
Within this Chapter, a model of fibroblast replicative senescence was established by 
serially passaging EP HMFs to deep senescence. Recent literature has suggested that 
senescence is a dynamic, multi-step process through which senescent cells continue to 
evolve during extended periods in culture (Freund et al., 2012; De Cecco et al., 2013; 
Shah et al., 2013; Swanson et al., 2013, Kim et al., 2013) (see Section 1.2). In order to 
ensure that the senescent population had progressed into a permanent senescence 
phenotype from an initial senescence arrest, fibroblasts were passaged to replicative 
senescence then kept in culture for three weeks further to the state defined here as 
‘deep senescence’. Furthermore, DS fibroblasts kept in culture for 150 days beyond 
replicative senescence remained stably arrested, demonstrating the development of a 
permanent senescence phenotype (Figure 3.2). Subsequently, the EP and DS 
phenotypes were characterised using morphological multi-parameter analysis as well as 
immunofluorescence staining for multiple well-established senescence markers. This 
analysis identified a panel of senescence-associated markers which validated and 
defined the DS phenotype, enabling subsequent experiments to identify changes to the 
DS phenotype induced by siRNA knockdown.  
In summary, the DS phenotype includes a stable cell cycle arrest, characterised by both 
a stable cell number (see Section 3.2.2) and a lack of BrdU incorporation (see Section 
3.2.3). In line with the literature, DS fibroblasts possessed an enlarged nucleus with an 
elongated and less round nuclear morphology, as well as an enlarged and less elongated 
cellular morphology (see Section 3.2.2) (Sharpless and Sherr, 2015). In addition, DS 
fibroblasts displayed an increased expression of the tumour suppressors, p16 and p21, 
indicating activation of the p16/pRB and p53/p21 pathways (see Section 3.2.3) (Alcorta 
et al., 1996). Furthermore, DS fibroblasts accumulated the products of oxidative DNA 
damage as characterised by an increase in 8-oxoG (see Section 3.2.3) (Chen et al., 1995). 
Further markers of the senescence phenotype were also investigated (see Section 1.4). 
DS fibroblasts induced paracrine senescence in EP fibroblasts (Figure 3.8) (work 
performed by an MSc student, AR under supervision of ET), indicating the presence of 
the SASP (Acosta et al., 2013). Furthermore, DS fibroblasts have decreased lamin B1 
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expression in comparison to EP cells (Appendix Figure A.2), indicating deepening of the 
senescence phenotype (Freund et al., 2012). In the future, it would be interesting to 
explore the DS phenotype further, including investigating telomere length using 
qRTPCR; the presence of telomere associated foci (TAF) using confocal microscopy 
(Hewitt et al., 2012), and telomerase activity using the telomeric repeat amplification 
protocol (TRAP) assay. In addition, DDR markers such as 53BP1 or γ-H2AX; and the 
presence of SASP components, such as IL-6 and IL-8, could be explored using 
immunofluorescence microscopy. Furthermore, enzyme-linked immunosorbent assay 
(ELISA) or Luminex-based assays could be used to detect secretion of SASP components 
into the surrounding medium. In addition, replicatively senescent fibroblasts possess 
extensive changes to DNA methylation in comparison with proliferating cells 
(Cruickshanks et al., 2013). To investigate DNA methylation dynamics between EP and 
DS fibroblasts and define a senescence-associated methylation signature in these cells, 
an Illumina EPIC array could be performed to assess methylation at >900,000 different 
cytosine residues. 
3.4.2 siRNA transfection targeting p16 and p21 reverses deep senescence in normal 
adult HMFs 
Fibroblast replicative senescence is commonly referred to as an irreversible cell cycle 
arrest in the literature. Previous work has demonstrated that knockdown of p53 in 
senescent human neonatal fibroblasts reinitiates DNA synthesis but with only limited 
proliferation (Gire and Wynford-Thomas, 1998) (see Section 1.7). In addition, 
Beauséjour et al. (2003) demonstrated that the reversibility of fibroblast senescence 
was dependent on their p16 expression levels. For example, senescent BJ fibroblasts 
(neonatal foreskin), which had low levels of p16 expression, were reversible by 
inactivating pRB or p53, but senescent WI38 fibroblasts (foetal lung), with higher p16 
expression levels, were not. In order to further explore the p16 reversal block, 
Beauséjour et al. (2003) inactivated p53 in senescent WI38 cells following p16 
knockdown, and found that DNA synthesis was stimulated but not proliferation, leading 
the authors to suggest that neither p53 nor pRB inactivation is sufficient to allow cell 
proliferation once the p16/pRB pathway is engaged.  
As the previous work on senescence reversal in human cells has been performed on 
fibroblasts derived from foetal or neonatal tissues, it is important to note that recent 
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evidence has suggested that during normal embryonic development, cells undergo 
acute senescence via a different mechanism to cells which undergo age-related chronic 
senescence (Muñoz-Espín et al., 2013; Storer et al., 2013) (see Section 1.5.2). Ultimately, 
the aim of this project is to further our understanding of the drivers of age-related 
chronic senescence, thus, adult DS HMFs were used throughout this project. 
Previous work in our lab. has demonstrated that p16 siRNA knockdown in DS HMECs 
reverses p16-dependent cellular senescence (Lowe et al., 2015). Given this, it was 
hypothesised in this Chapter that reversal of p16- and p21-dependent replicative 
senescence would require knockdown of p16 and p21 together in DS HMFs. In support 
of this hypothesis, p16 siRNA knockdown alone in DS HMFs did not increase cell number 
or alter the senescence markers examined in this Chapter (see Section 3.3.2, Figure 
3.10). Interestingly, p21 siRNA knockdown in DS HMFs consistently increased cell 
number and altered morphological markers which defined the DS phenotype (see 
Section 3.3.2, Figure 3.10). However, in comparison to p21 siRNA transfected DS HMFs, 
knockdown of both p16 and p21 together further increased cell number and altered four 
morphological markers of senescence, including decreased nuclear and cellular area, 
decreased nuclear elongation and increased nuclear roundness (see Section 3.3.2, 
Figure 3.10). Further investigation of the siRNA transfected DS HMFs revealed that BrdU 
incorporation was significantly increased in the p21 siRNA knockdown DS HMFs, and 
further significantly increased in the p16+p21 siRNA knockdown DS HMFs compared to 
the siGLO transfected DS HMFs, indicating the presence of cycling cells in the population 
(see Section 3.3.2, Figure 3.11). Strikingly, BrdU incorporation in the p16+p21 siRNA 
knockdown DS HMFs was higher than in the EP population, potentially as a result of an 
increased number of cells entering the cell cycle at the same time due to synchronisation 
of cell cycle re-entry in the p16+p21 siRNA transfected DS population. Examination of 
p16 and p21 levels revealed that only p16+p21 siRNA knockdown significantly increased 
the proportion of the double negative subgroup in the DS population compared to siGLO 
transfected cells, indicating a potential subpopulation of reversed cells (see Section 
3.3.2, Figure 3.13). Furthermore, investigation of 8-oxoG revealed that the percentage 
of cells positive for 8-oxoG significantly decreased in p21 siRNA and further significantly 
decreased in p16+p21 siRNA knockdown DS HMFs compared to siGLO transfected cells, 
indicating that oxidative damage levels were also reduced following siRNA knockdown 
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(see Section 3.3.2, Figure 3.14A). Further interrogation revealed that the p21 siRNA and 
p16+p21 siRNA knockdown DS HMFs defined as positive for 8-oxoG possessed lower 
levels of 8-oxoG than the 8-oxo+ siGLO transfected DS HMFs, providing further 
confirmation that oxidative damage levels were reduced upon reversal (see Section 
3.3.2, Figure 3.14B). Taken together, these findings indicate that knockdown of both p16 
and p21 in adult DS HMFs is necessary to reverse deep senescence. In addition, a novel 
marker of senescence, membrane stiffness, was identified in this Chapter, which further 
confirmed the p16+p21 siRNA knockdown DS HMF reversed phenotype (see Section 
3.3.3). In future, it would be interesting to determine whether membrane stiffness is a 
universal feature of senescence and determine whether membrane stiffening plays a 
role driving senescence. This is explored in more detail in Chapter 6 Section 6.1.3. 
Interestingly, p16 and p21 levels were identified to increase following knockdown of p21 
or p16 in DS HMFs, respectively, indicating the presence of a potential compensatory 
feedback mechanism. To explore the kinetics of this potential compensatory 
mechanism, a time course experiment could be performed to explore p16 and p21 levels 
using immunofluorescence at one, three, and five days post-transfection. Interestingly, 
previous evidence has suggested that p16 transcription may be regulated by a negative 
feedback loop via pRB (Hara et al., 1996). In order to explore the presence of this pRB-
dependent negative feedback mechanism in DS HMFs, it would be interesting to 
determine whether pRB siRNA knockdown prevents p21 or p16 overexpression 
following p16 or p21 siRNA knockdown, respectively.  
To further validate the reversed phenotype of the p16+p21 siRNA transfected DS HMFs, 
analysis of the p16+p21 knockdown DS HMF phenotype could be expanded to 
encompass other markers, including telomere length, DDR markers 53BP1 or γ-H2AX, 
and SASP components, such as IL-6 and IL-8, as described in Section 3.4.1 and explored 
in more detail in Chapter 6 Section 6.1.1. Furthermore, previous work in our lab. has 
defined senescence-associated differentially methylated positions (senDMPs) in DS 
HMECs relative to EP cells, and demonstrated that reversal of senescence in DS HMECs 
using p16 siRNA knockdown effectively reversed the senDMP signature (Lowe et al., 
2015). In order to further validate the reversed DS fibroblast phenotype, the 
methylation dynamics following p16+p21 siRNA transfection in DS HMFs could be 
examined and compared to the EP and DS HMF methylation signatures. Importantly, the 
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senescence-associated methylation signature has been associated with bypass of 
senescence, a process which is potentially required for tumour progression to 
malignancy (Cruickshanks et al., 2013). Thus, investigation of the p16+p21 siRNA 
transfected DS HMF methylation signature in comparison to EP and DS HMFs would 
further test whether p16+p21 siRNA knockdown induces reversal of senescence, and 
this is discussed in more detail in Chapter 6 Section 6.1.2.  
Given the previous work on senescence reversal performed in foetal and neonatal 
fibroblasts (Gire and Wynford-Thomas, 1998; Beauséjour et al., 2003) (see Section 1.7), 
future analysis could be expanded to encompass reversal of senescence in other primary 
cells, including foetal and neonatal fibroblasts. Narita et al. (2003) previously noted that 
SAHF formation is less pronounced in senescent BJ fibroblasts than senescent WI38 cells, 
leading the authors to suggest that the presence of SAHF indicates an irreversible cell 
cycle arrest. Consistent with this hypothesis, the DS fibroblasts used throughout this 
project did not display SAHF (see Section 3.2.2). However, the authors also noted that 
SAHF-forming senescent WI38 fibroblasts had increased p16 expression in comparison 
to senescent BJ fibroblasts, implying that p16 up-regulation induces SAHF formation, 
thus altering chromatin structure and enforcing permanent arrest. The DS fibroblasts 
used in this project exhibited robust p16 expression (see Section 3.2.3) and remained 
arrested for over 150 days in culture (see Section 3.2.1), indicating a stable and 
permanent cell cycle arrest despite the lack of SAHF formation. In light of this, it would 
be of interest to investigate whether senescence reversal is also achievable in WI38 
fibroblasts. It would also be of interest to explore senescence reversal in HMFs which 
have undergone senescence in response to alternative triggers including OIS and SIPS 
(see Section 1.3.2).  
In summary, the data presented in this Chapter has demonstrated for the first time that 
deep senescence can be effectively reversed in normal adult HMFs using siRNA 
transfection targeting p16 and p21 (see Section 3.3.2). The successful reversal of deep 
senescence in adult HMFs subsequently provided the opportunity to screen novel 
siRNAs that induce reversal in both DS HMECs and DS HMFs, as will be explored in 
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In this Chapter, siRNA screening in DS HMFs will be employed as a route to identifying 
novel genes driving the senescent phenotype. Our lab. has previously shown that 
reversal of cellular senescence in DS HMECs is achievable using p16 siRNA knockdown 
(Lowe et al., 2015) (Figure 4.1A) (see Section 1.7). Using gene expression arrays, previous 
work identified genes with expression changes between EP, DS, and reversed DS HMECs 
(Bishop, unpublished). In order to distinguish between genes driving the senescent 
phenotype and downstream 'passenger' genes, a siRNA screen of the top 200 genes 
identified to have increased expression in DS HMECs compared to the EP and reversed 
cells was previously performed in the DS HMECs (see schematic in Figure 4.1B). From 
this, 28 siRNAs were identified to strongly induce reversal in the DS HMECs, as defined 
by the loss of a panel of senescence markers, including reduced cellular area and nuclear 
area, and the resumption of the cell cycle (as measured by increased cell number). 
Accordingly, these 28 genes were classified as potential 'drivers' of senescence in DS 
HMECs. 
Unlike replicative senescence in fibroblasts, HMECs undergo p16-dependent cellular 
senescence in the absence of telomere erosion and p53/p21 expression. In order to 
determine whether genes driving cellular senescence in HMECs also play a role in driving 
replicative senescence in other cell types, siRNA screening in DS HMFs will be employed 
in this Chapter. Ultimately, by identifying genes that enable senescence reversal in both 





Figure 4.1 Schematic of senescence reversal strategy in both HMECs and HMFs, and mRNA 
expression profiling as a route to identifying new 'drivers' of senescence. (A) Our lab. has 
previously achieved reversal of p16-dependent epithelial cellular senescence (blue line) using 
siRNA targeting p16 in DS HMECs. (B) mRNA microarray data identified genes with expression 
changes between early proliferating (EP, red), deep senescence (DS, blue), and reversed (R, 
purple) HMECs. The top 200 genes with increased expression in the DS versus the EP and 
reversed HMECs were investigated in a siRNA screen, and 28 siRNAs were identified to strongly 
induce reversal in DS HMECs. These 28 hits are classified as potential 'drivers' of senescence 
(purple). 
4.1.1 Chapter aims 
1. To use bioinformatics to construct an interaction network between the 28 
previously identified drivers of senescence in HMECs (including p16) in order 
to expand the pool of genes to be screened in the adult DS HMFs.  
2. To perform a siRNA screen of 60 siRNAs in adult DS HMFs comprising the 27 
siRNAs (i.e. the 28 drivers not including p16) identified to strongly induce 
reversal in adult DS HMECs and 33 siRNAs targeting interactors identified 
through bioinformatics, in order to identify novel drivers of senescence in 
both cell types. 
3. To conduct multi-parameter analysis of top hits selected from the siRNA 
screen in order to explore the reversal phenotypes in more detail and to 
select a candidate for validation and further investigation. 
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4.2 Bioinformatics interaction network of previously identified 
hits  
To investigate the potential relationships between the 28 previously identified drivers 
and to expand the pool of genes to be screened in the DS HMFs, a bioinformatics 
interaction network was constructed. In summary, each of the 28 hits was probed for 
protein interactors using the BioGRID database (http://www.thebiogrid.org) in order to 
generate protein interaction datasets (see Section 2.10). The hit protein interaction 
datasets were then overlaid to reveal a total of 33 protein interactors, which were 
defined as proteins which generated a chain with at least two other drivers. Using this 
method, only one protein interaction network was generated (Figure 4.2). Of the 28 
previously identified drivers, 13 were not found to be present in this stringently 
generated network.  
To further explore the relationships between drivers and interactors, a less stringent 
interaction network was built using GeneMANIA, a bioinformatics database with 
genomic and proteomic data collated from a variety of sources, including co-expression 
data, genetic interactions, co-localisation, predicted interactions, pathways, and shared 
protein domains. Remarkably, using these criteria, the network identified interactions 
between all of the drivers and interactors except for one driver, zona pellucida-like 
domain containing 1 (ZPLD1), an understudied gene for which there are only six citations 





Figure 4.2 Protein interaction network of drivers and interactors.  Twenty-eight potential 
drivers of senescence (purple) were identified in the previous DS HMEC screen. Using 
bioinformatics, 33 interactors (pink) were identified to generate a chain with at least two other 
drivers. Lines represent physical interactions determined by the BioGRID database. Thirteen 




It is important to note that ubiquitin C (UBC), a highly-connected protein in the BioGRID 
database (1,435 interactors), has the potential to create false positive connections in a 
bioinformatics network. In order to ensure that the previous interactors were not falsely 
identified, UBC was removed and the protein interaction network regenerated. Using 
BioGRID physical interactions as the most stringent criteria to identify interactors, one 
interactor, known as CD9 molecule (CD9) was lost from the re-generated interaction 
network (Appendix Figure A.5). However, a re-generated interaction network using 
GeneMANIA demonstrated that CD9 remains present in the network through both co-
expression and co-localisation relationships with multiple drivers and interactors 
(Appendix Figure A.6). In summary, the removal of the highly-connected protein UBC 
from the network does not cause the loss of previously identified interactors, except 
CD9, which remains present in the less stringently generated GeneMANIA network.  
4.2.1 Pathway analysis identifies functional categories of hits and interactors 
Using Panther, KEGG pathways, and Gene Ontology (GO) bioinformatics tools, these 61 
genes (28 previously identified drivers (including p16) and 33 interactors) were grouped 
into six functional categories: immune response; cell adhesion/cytoskeleton; 
metabolism; transcription; growth/proliferation; and protein/vesicle trafficking (Figure 
4.3). Strikingly, the cell adhesion/cytoskeleton subgroup contained the largest number 
of proteins (four drivers and 12 interactors), indicating a potential role for extracellular 
interactions in driving senescence. The metabolism subgroup contained the second 
largest number of proteins (seven drivers and two interactors) and, perhaps 
unsurprisingly, the growth/proliferation subgroup contained the third largest number of 
proteins (one driver, CDKN2A (p16), and six interactors). Interestingly, the six main 
functional categories identified here showed overlap with the spectrum of cell processes 
altered during human ageing (immunity, focal adhesion/cytoskeleton, metabolism, and 




Figure 4.3 Functional subgrouping of protein interaction network.  Using PANTHER, KEGG 
pathways, and GO bioinformatics tools, potential drivers (outlined in purple) and interactors 
(outlined in pink) were subgrouped into functional categories: immune response (purple), 
metabolism (red), transcription factor (green), cell adhesion/cytoskeleton (orange), 
growth/proliferation (teal), protein/vesicle trafficking (blue), other (grey). Lines represent 




4.3 siRNA screening to identify unknown drivers of senescence 
in adult DS HMFs 
4.3.1 Identification of 45 hits for senescence reversal in DS HMFs 
In the DS HMEC screen, p16 siRNA was amongst the 28 ‘driver’ siRNAs identified to 
reverse HMEC p16-dependent cellular senescence (Lowe et al., 2015). However, in DS 
HMFs, p16 siRNA alone was found to not be sufficient to reverse replicative senescence 
(see Section 3.3.2). With this in mind, p16 siRNA was not included as a target siRNA in 
the DS HMF screen, bringing the total number to 60 target siRNAs (27 drivers and 33 
interactors). Furthermore, as DS HMF reversal was found to require siRNA knockdown 
of both p16 and p21 (see Section 3.3.2), it was hypothesised that the hits identified in 
the DS HMEC screen may additionally require knockdown of either the p16/pRB or the 
p53/p21 pathway to induce reversal in the DS HMFs. Accordingly, DS HMFs were 
screened with 60 target siRNAs in three conditions: 30 nM siRNA individually (Group 1); 
15 nM siRNA in combination with 15 nM p16 siRNA (Group 2); or 15 nM siRNA in 
combination with 15 nM p21 siRNA (Group 3) (Figure 4.3).  
To perform the siRNA screen, DS fibroblasts were seeded at a previously optimised 
seeding density of 15,000 cells/cm2 (see Section 2.5.2) and forward transfected with 30 
nM siRNA according to the above listed conditions (Group 1, 2, and 3) using the 
previously optimised dose of 0.15 µL Dh2 (see Section 2.6.2). After five days, cells were 
stained with DAPI and cell number quantified according to Section 2.7 and 2.8.  
There was no significant change in proliferation for DS fibroblasts transfected with siGLO 
compared with the UTC DS HMF control, indicating an acceptable level of siRNA 
transfection cytotoxcity in the experiment (Appendix Figure A.3). As such, the data 
generated by the siGLO transfected control was used as a baseline for Z score generation 
(see Section 2.8.2) in order to determine the effects on proliferation of each of the 60 
siRNAs in each of the three conditions. 
Using this approach, a hit list was generated for each of the three conditions. In order 
to increase the window for hit detection and allow as many hits to be identified as 




Figure 4.4 Gene list and siRNA screening workflow.  (A) In the DS HMF screen, the following 
gene lists were investigated: 27 drivers (purple; 28 minus p16 siRNA) identified to reverse 
senescence in a previous DS HMEC siRNA screen, and 33 interactors (pink) identified using 
bioinformatics. (B) Schematic illustrating the experimental design of the siRNA screen. Using a 
previously optimised seeding density and transfection reagent dose (see Section 2.6.2), DS HMFs 
were forward transfected with the 60 target siRNAs in three conditions: 30 nM siRNA individually 
(Group 1); 15 nM siRNA in combination with 15 nM siRNA (Group 2); and 15 nM siRNA in 
combination with p21 siRNA (Group 3).  
control for each condition (see Section 2.8.2). DS HMFs transfected with Group 1 (siRNAs 
individually) were compared to 30 nM siGLO control; Group 2 (siRNAs in combination 
with p16 siRNA) were compared to 30 nM p16 siRNA control; and Group 3 (siRNAs in 
combination with p21 siRNA) were compared to cells transfected with 30 nM p21 siRNA 
(Figure 4.4).  
Using this hit identification criteria, only one Group 1 member (30 nM siRNA individually) 
was defined as a hit (one Z score), which was early growth response 2 (EGR2), a 
transcription factor involved in several cellular processes, including cell cycle and 
proliferation (Parkinson et al., 2004; Atanasoski et al., 2006; Srinivasan et al., 2012) 
(Figure 4.4). Interestingly, the identification of a siRNA which did not require additional 
knockdown of p16 or p21 potentially indicates a hit which is essential for driving 
senescence upstream of both the p16/pRB and p53/p21 pathways. Two Group 2 siRNAs 
(in combination with p16 siRNA), fraser extracellular matrix complex subunit 1 (FRAS1), 
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an extracellular matrix protein, and ring finger protein 20 (RNF20), an E3 ubiquitin ligase, 
were defined as hits (one Z score) (Figure 4.4). Potentially, this may indicate that these 
hits sit upstream of the p53/p21 pathway and interact with the p16/pRB pathway to 
drive senescence. Importantly, FRAS1 is a driver identified to reverse p16-dependent 
HMEC cellular senescence, suggesting a role for FRAS1 upstream of the p16/pRB 
pathway in HMECs and potentially upstream of p53/p21 in the DS HMFs. This may 
indicate an interplay between the p16/pRB and p21/p53 pathways which is dictated in 
a cell-type dependent manner. Remarkably, 45 of the 60 siRNAs in Group 3 (in 
combination with p21 siRNA) were defined as hits (Figure 4.4). Of these, eight Group 3 
siRNAs increased cell number greater than 10 Z scores, including EGR2, basic helix-loop-
helix family member e41 (BHLHE41), fibronectin (FN1), and actin gamma 1 (ACTG1) 
siRNA, similar to the p16+p21 reversed HMFs (12 Z scores). As the 28 'driver' siRNAs in 
the screen were identified as hits for senescence reversal in p16-dependent HMEC 
cellular senescence, it is perhaps unsurprising that 21 of these were identified as hits 
requiring additional knockdown of the p53/p21 pathway to reverse senescence in DS 
HMFs, thus indicating potential roles for these genes upstream of the p16/pRB pathway. 
However, 24 of the 33 'interactors' investigated in this screen were also identified as 
Group 3 hits (in combination with p21 siRNA), which highlights the utility of the 
bioinformatics approach and provides phenotypic validation of the bioinformatics-
generated network. Interestingly, there were also two siRNAs, histone deacetylase 1 
(HDAC1) and UBC, which were identified to eliminate senescent cells in all three 





Figure 4.5 Representative images of a siRNA screen conducted to identify the top siRNAs 
inducing a reversal phenotype in DS HMFs using analysis of cell number and nuclear 
morphologies.  Two independent siRNA screens, each in triplicate, were performed in DS HMFs 
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according to Section 2.6.2. Cells were fixed, stained with DAPI, imaged and cell number 
quantified according to Section 2.7 and 2.8. (A) Representative nuclei of 30 nM siGLO (siGLO), 
30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21), and 15 nM p16 siRNA together with 15 nM p21 
siRNA (p16+p21) transfected DS HMFs. (B) Representative nuclei of top hits in Group 1, (C) 
Group 2 and (D) Group 3 identified in the siRNA screen. DAPI (blue). Scale bar denotes 100 µM. 





Figure 4.6 Identification of the top siRNAs which induced an increase in cell number in DS 
HMFs using analysis of cell number.  Two independent siRNA screens, each in triplicate, were 
performed in DS HMFs according to Sections 2.6.2. Cells were fixed, stained with DAPI, imaged 
and cell number quantified according to Section 2.7 and 2.8. Z scores were then generated 
according to Section 2.8.2. (A) Key. The colour saturation reflects the number of Z scores from 
the control mean. Scores highlighted in red denote an increase in cell number significantly 
greater than the siGLO control mean indicating a release of cell cycle arrest. White denotes no 
significant change from the siGLO control mean. Blue denotes a significant decrease in cell 
number compared to the siGLO control mean. (B) Heatmap depicting significant changes in cell 
number from the 30 nM siGLO control mean for 30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21), 
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and 15 nM p16 together with 15 nM p21 siRNA (p16+p21) controls. (C) Heatmap depicting 
significant changes in cell number for each of the 60 siRNAs in three different conditions: 30 nM 
siRNA individually (Group 1); 15 nM siRNA in combination with 15 nM siRNA (Group 2); and 15 




In order to explore the nuclear phenotype of DS HMFs transfected with the 60 target 
siRNAs, multi-parameter analysis was performed using the previously defined panel of 
senescence-associated nuclear morphologies, including nuclear area, roundness, and 
elongation. To determine the effects on nuclear morphology of each of the 60 siRNAs in 
each of the three conditions, the data generated by the siGLO transfected control was 
used as a baseline for Z score generation (see Section 2.8.2). This analysis showed that 
in addition to increasing cell number (one Z score) (Figure 4.6), EGR2 siRNA in Group 1, 
also decreased nuclear area (one Z score) compared to the siGLO control (Figure 4.7). In 
Group 2, FRAS1 and RNF20 siRNA were previously defined as hits using cell number 
(Figure 4.6) but did not significantly alter nuclear phenotype for the three nuclear 
morphologies examined. Previously, 45 Group 3 siRNAs were scored as hits using cell 
number (Figure 4.6). Of these, 35 siRNAs also significantly decreased nuclear area and 
elongation, and increased nuclear roundness (Figure 4.7). Together, these findings 
suggest that one siRNA individually, EGR2, and 35 siRNAs in combination with p21 siRNA 







Figure 4.7 Identification of the top siRNAs which induced a reversal phenotype in DS HMFs 
using multi-parameter analysis of nuclear morphology. Two independent siRNA screens, each 
in triplicate, were performed in DS HMFs according to Section 2.6.2. Cells were then fixed, 
stained with DAPI, imaged and nuclear morphologies quantified according to Section 2.7 and 
2.8. Z scores were then generated according to Section 2.8.2. (A) Key. The colour saturation 
reflects the number of Z scores from the control mean. Scores highlighted in red denote a 
significant change in nuclear area, roundness, or elongation towards the reversed phenotype 
compared to the siGLO control mean. White denotes no significant change from the siGLO 
control mean. Blue denotes a significant change in nuclear area, roundness, or elongation away 
from the reversed phenotype compared to the siGLO control mean. (B) Heatmap depicting 
significant changes in nuclear area, roundness and elongation from the siGLO control mean for 
p16 siRNA (p16), p21 siRNA (p21), and p16 together with p21 siRNA (p16+p21) controls. (C) 
Heatmap depicting significant changes in nuclear area, roundness and elongation for each of the 
60 siRNAs in three different conditions: 30 nM siRNA individually (Group 1); 15 nM siRNA in 
combination with 15 nM siRNA (Group 2); and 15 nM siRNA in combination with p21 siRNA 




In summary, 45 potential novel drivers of senescence were identified in the siRNA 
screen, including 21 'drivers' identified in both DS HMECs and HMFs and 24 'interactors' 
identified as hits in DS HMFs. The top siRNA in Group 1 (EGR2) and Group 2 (FRAS1) were 
selected for further investigation and characterisation of senescence-associated 
parameters. In addition, the top 12 siRNAs in Group 3 were classified as 'strong’ hits for 
senescence reversal as they induced an increase in proliferation greater than eight Z 
scores from the siGLO control. Subsequently, these 14 siRNAs were chosen for inclusion 
in a siRNA screen to find the most potent reversal phenotype by investigating dose 
effect, time point extension, and further characterisation of morphological senescence-
associated parameters. 
4.4 Further investigation of the top siRNA hits 
4.4.1 Investigation of dose effect, time point extension, and multi-parameter analysis 
for the top hits 
Following the siRNA screen, the 14 top siRNAs were selected for further investigation. 
In order to identify the most potent reversal protocol and therefore the strongest hits 
for senescence reversal, siRNA dose effect and time point extension were investigated 
for the 14 top siRNAs: EGR2; FRAS1; hypoxia inducible factor 1-alpha (HIF1A); heat shock 
protein 90 alpha family class A member 1 (HSP90AA1); S100 calcium-binding protein A4 
(S100A4); BHLHE41; FN1; ACTG1; PTPRF interacting protein alpha 1 (PPFIA1); junction 
plakoglobin (JUP); CD9; programmed cell death 6 interacting protein (PDCD6IP); myosin 
light chain 12A (MYL12A); death associated protein like 1 (DAPL1). Potentially, weakly 
specific or non-specific siRNAs in the pool may not provide sufficient knockdown to 
induce the most potent reversed phenotype at the 30 nM dose. To investigate this, an 
increased dose of 60 nM was compared to the original 30 nM dose. In addition, to 
determine whether the kinetics to generate the most potent phenotype required a 
longer incubation period, these experiments were harvested at five days or a later seven 
day time point.  
To perform the siRNA screen, DS fibroblasts were seeded at a previously optimised 
seeding density of 15,000 cells/cm2 (see Section 2.5.2). After ensuring that the 
transfection reagent dose (0.15 µL/well) plus 60 nM siGLO produced minimal toxicity in 




Figure 4.8 Gene list of the 14 top hits and siRNA screening workflow for investigation of dose 
effect and time point extension. (A) Following the large scale DS HMF screen, the 14 top hits 
were selected for further investigation: five drivers (purple), and nine interactors (pink). (B) 
Schematic illustrating the experimental design of the smaller siRNA screen investigating dose 
effect and time point extension in the top 14 hits. Using a previously optimised seeding density 
and transfection reagent dose (see Section 2.6.2), DS HMFs were forward transfected with the 
14 siRNAs in four conditions: 30 nM siRNA individually (Group 1); 60 nM siRNA individually 
(Group 1B); 15 nM siRNA in combination with 15 nM siRNA (Group 2); and 15 nM siRNA in 
combination with p21 siRNA (Group 3). After five or seven days, cells were fixed and stained 
with DAPI and Cell Mask, and quantified according to Section 2.7 and 2.8.  
siRNA (Group 1), 60 nM siRNA (Group 1B), and 15 nM siRNA in combination with 15 nM 
p16 (Group 2) or 15 nM p21 siRNA (Group 3) (see Section 2.6.2) (Figure 4.8). After five 
or seven days, cells were fixed and stained with DAPI and Cell Mask, and quantified 
according to Section 2.7 and 2.8. Three independent siRNA screens were performed for 
both the five day and seven day incubation, each in triplicate.  
To explore morphological changes in the DS HMFs following siRNA knockdown, multi-
parameter analysis of the previously defined panel of senescence-associated 
morphological markers was combined with the increased dose and time-course (see 
Section 3.2.2). Thus, each condition was analysed for cell area, nuclear area, nuclear 
elongation, nuclear roundness, and cell elongation, with the data generated by the 30 
nM siGLO used as the baseline for Z score generation (see Section 2.8.2). These 
measures are ranked in order of their effectiveness at discriminating senescence from 
reversal (i.e. the magnitude of difference in Z scores between the p16+p21 siRNA 
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reversed DS HMFs and the 30 nM siGLO transfected control cells) with cell area ranking 
highest. Using this approach, a hit list was generated for each of the four conditions. In 
order to increase the window for hit detection and allow as many hits to be identified 
as possible, significance was defined as at least one Z score greater than the respective 
control for each condition (see Section 2.8.2). DS HMFs transfected with Group 1 (30 nM 
siRNAs individually) were compared to 30 nM siGLO control; Group 1B (60 nM siRNA 
individually) were compared to 60 nM siGLO control; Group 2 (siRNAs in combination 
with p16 siRNA) were compared to 30 nM p16 siRNA control; and Group 3 (siRNAs in 
combination with p21 siRNA) were compared to cells transfected with 30 nM p21 siRNA. 
In line with findings from previous experiments (see Section 3.3.2 and Section 4.3.1), 
p21 siRNA knockdown altered nuclear and cellular morphology, but siRNA knockdown 
of p16 and p21 together induced a greater shift in nuclear and cellular morphology 
(Figure 4.9A, Figure 4.10B).  
Interestingly, at the 30 nM dose, four siRNAs (EGR2, MYL12A, BHLHE41, and DAPL1) 
induced a reduction in cell area relative to the 30 nM siGLO control mean (three Z scores 
for EGR2 and MYL12A siRNA, one Z score for BHLHE41 and DAPL1 siRNA) (Figure 4.9B, 
Figure 4.10C). Furthermore, 30 nM EGR2, BHLHE41, and DAPL1 siRNA induced an 
increase in cell elongation greater than the siGLO control mean. Five siRNAs, HIF1A, 
S100A4, CD9, PDC6IP, and ACTG1 increased cell elongation at the 30 nM dose relative 
to the 30 nM siGLO control mean but did not alter the other five senescence-associated 
morphologies. Strikingly, 13 siRNAs induced nuclear and cellular morphological changes 
towards a reversed phenotype in a dose dependent manner. Of the four siRNAs which 
altered cellular morphology at the 30 nM dose, all four siRNAs, EGR2, MYL12A, BHLHE41, 
and DAPL1, further significantly decreased cell area (five, four, four, and two Z scores, 
respectively) relative to the 60 nM siGLO control mean. In addition, 60 nM EGR2 further 
increased cell elongation (two Z scores) relative to the 60 nM siGLO control mean but 
BHLHE41 and DAPL1 siRNA did not. Furthermore, at the 60 nM dose, EGR2, MYL12A, 
BHLHE41, DAPL1, HIF1A, and PPFIA1 siRNA also decreased nuclear area (one Z score) 
compared to the 60 nM siGLO control. Nuclear elongation and nuclear roundness were 




At the seven day time point, the reversed morphologies of the p21 and p16+p21 controls 
are weaker in comparison to the five day time point, potentially demonstrating the 
transient nature of siRNA knockdown which has allowed the cells to begin reverting to 
a senescent morphology. However, the dose dependent effect was still present (Figure 
4.11, Figure 4.12), but the decrease in cell area induced by EGR2, MYL12A, BHLHE41, 
and DAPL1 siRNA was reduced in comparison to the five day screen. Interestingly, at the 
later time point, seven siRNAs, including EGR2, MYL12A, BHLHE41, and DAPL1, induced 
a dose dependent effect on nuclear area morphology which was not present at the five 
day time point. Furthermore, it is interesting to note that although the Group 3 siRNA 
(in combination with p21) reversal morphology was weaker at seven days when 
compared to the five day time point, there were multiple siRNAs in combination with 
p21 siRNA which induced a greater reversed morphology than the controls at the seven 
day time point. 
In summary, in both the five day and seven day screens, these analyses showed that 
many of the top siRNAs induced significant changes towards a reversal phenotype in 
multiple senescence-associated parameters in a dose dependent manner. This approach 
allowed the top siRNAs to be ranked by the strength of the reversal phenotype induced 
in a dose dependent manner. Accordingly, EGR2 siRNA ranked highest, followed by 







Figure 4.9 Representative images of a siRNA screen conducted to further investigate the top 
siRNAs inducing a reversal phenotype in DS HMFs at day five using analysis of nuclear and 
cellular morphologies.  Three independent siRNA screens, each in triplicate, were performed 
for the five day time point in DS HMFs according to Section 2.6.2. Cells were fixed, stained with 
DAPI and Cell Mask, imaged and nuclear and cellular morphologies quantified according to 
Section 2.7 and 2.8. (A) Representative images of 30 nM siGLO, 60 nM siGLO, 30 nM p16 siRNA 
(p16), 30 nM p21 siRNA (p21), and 15 nM p16 siRNA together with 15 nM p21 siRNA (p16+p21) 
transfected DS HMFs. (B) Representative images of top hits in Group 1 (30 nM individually) and 
(C) Group 1B (60 nM individually) identified in the siRNA screen. DAPI (blue), Cell Mask (red). 




Figure 4.10 Multi-parameter analysis of the top siRNAs identified to reverse senescence in the 
DS HMFs at day five.  Three independent siRNA screens, each in triplicate, were performed for 
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the five day time point in DS HMFs according to Section 2.6.2. Cells were fixed, stained with DAPI 
and Cell Mask, imaged and nuclear and cellular morphologies quantified according to Section 
2.7 and 2.8. Z scores were then generated according to Section 2.8.2. (A) Key. The colour 
saturation reflects the number of Z scores from the siGLO control mean. Scores highlighted in 
red denote a shift towards the reversed phenotype and blue denotes a shift away from the 
reversed phenotype. (B) Heatmap depicting significant changes in each of the panel of five 
morphological senescence-associated markers from the 30 nM siGLO control mean (Group 1 
control) for 60 nM siGLO (Group 1B control), 30 nM p16 siRNA (p16) (Group 2 control), 30 nM 
p21 siRNA (p21) (Group 3 control), and 15 nM p16 together with 15 nM p21 siRNA (p16+p21) 
transfected DS HMFs. (C) Heatmap depicting significant changes in each of the panel of five 
morphological senescence-associated markers for the hit siRNAs selected from the previous 
screen in four different conditions: 30 nM siRNA individually (Group 1); 60 nM siRNA individually 
(Group 1B); 15 nM siRNA in combination with 15 nM siRNA (Group 2); and 15 nM siRNA in 






Figure 4.11 Representative images of a siRNA screen conducted to further investigate the top 
siRNAs inducing a reversal phenotype in DS HMFs at day seven using analysis of nuclear and 
cellular morphologies.  Three independent siRNA screens, each in triplicate, were performed 
for the seven day time point in DS HMFs according to Section 2.6.2. Cells were fixed, stained 
with DAPI and Cell Mask, imaged and quantified according to Section 2.7 and 2.8. (A) 
Representative images of 30 nM siGLO, 60 nM siGLO, 30 nM p16 siRNA (p16), 30 nM p21 siRNA 
(p21), and 15 nM p16 siRNA together with 15 nM p21 siRNA (p16+p21) transfected DS HMFs. 
(B) Representative images of top hits in Group 1 (30 nM individually) and (C) Group 1B (60 nM 
individually) hits identified in the siRNA screen. DAPI (blue), Cell Mask (red). Scale bar denotes 






Figure 4.12 Multi-parameter analysis of the top siRNAs identified to reverse senescence in the 
DS HMFs at day seven. Three independent siRNA screens, each in triplicate, were performed for 
the seven day time point in DS HMFs according to Section 2.6.2. Cells were fixed, stained with 
DAPI and Cell Mask, imaged and quantified according to Section 2.7 and 2.8. Z scores were then 
generated according to Section 2.8.2. (A) Key. The colour saturation reflects the number of Z 
scores from the siGLO control mean. Scores highlighted in red denote a shift towards the 
reversed phenotype and blue denotes a shift away from the reversed phenotype. (B) Heatmap 
depicting significant changes in each of the panel of five morphological senescence-associated 
markers from the 30 nM siGLO control mean (Group 1 control) for 60 nM siGLO (Group 1B 
control), 30 nM p16 siRNA (p16) (Group 2 control), 30 nM p21 siRNA (p21) (Group 3 control), 
and 15 nM p16 together with 15 nM p21 siRNA (p16+p21) transfected DS HMFs. (C) Heatmap 
depicting significant changes in each of the panel of five morphological senescence-associated 
markers for the hit siRNAs selected from the previous screen in four different conditions: 30 nM 
siRNA individually (Group 1); 60 nM siRNA individually (Group 1B); 15 nM siRNA in combination 
with 15 nM siRNA (Group 2); and 15 nM siRNA in combination with p21 siRNA (Group 3), 




4.4.2 Immunofluorescence staining for p16 and p21 expression to further rank the top 
hits 
In order to further characterise and rank the top hits, p16 and p21 nuclear intensities 
were examined for each siRNA condition using mouse anti-p16 (JC8) and rabbit anti-p21 
(12D1) double immunofluorescence staining according to Section 2.7. Using the 
secondary only control, thresholds for positivity were determined for p16 and p21 which 
enabled the cell population for each siRNA condition to be fractioned into four 
subgroups: double negative; double positive; and positive for either p16 or p21. 
In order to further rank the top hits on the strength of their reversal phenotype, the 
double negative subgroup was used as a measure to identify the subpopulation of 
'reversed' cells. In line with the findings from previous experiments (see Section 3.3.2), 
the proportion of cells in the double negative subgroup was not significantly increased 
following p16 (5% ± 1%) or p21 (12% ± 1%) siRNA knockdown; however, the proportion 
of cells in the double negative subgroup was significantly increased following p16+p21 
siRNA knockdown (19% ± 4%; p=0.005) compared to the siGLO control (2% ± 1%) 
(Appendix Figure A.7). 
Given that EGR2 siRNA induced a modest but significant increase in cell number at the 
30 nM dose as well as induced nuclear and cellular morphological changes towards a 
reversed phenotype in a dose dependent manner, it was hypothesised that an increase 
in the double negative subgroup would be observed at the 30 nM and 60 nM EGR2 siRNA 
dose. At the 30 nM (Group 1) and 60 nM (Group 1B) doses, as well as in combination 
with p16 siRNA (Group 2), no siRNA significantly increased the double negative subgroup 
(Figure 4.14A-C). However, it is important to note here that p21 siRNA knockdown 
increased cell number (see Section 4.3.1) and BrdU incorporation (see Section 3.3.2) but 
did not significantly increase the double negative subgroup, indicating that a small pool 
of ‘reversed’ cycling cells captured at the five day time-point can increase cell number 
over the time-course of the experiment.  
In line with previous data which demonstrated a significantly increased cell number 
(Figure 4.6) as well as significantly altered nuclear and cellular morphologies towards a 
reversed phenotype (Figure 4.10) following Group 3 siRNA knockdown, eight Group 3 
siRNAs significantly increased the double negative subgroup relative to the 30 nM siGLO 
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control, namely FN1, JUP, EGR2, HSP90AA1, FRAS1, PDCD6IP, ACTG1, and MYL12A 
(Figure 4.13D), indicating a significant increase in the ‘reversed’ subpopulation. 
However, six Group 3 siRNAs did not significantly increase the double negative subgroup 
relative to the 30 nM siGLO control: HIF1A; S100A4; PPFIA1; CD9; BHLHE41; and DAPL1. 
As previous data have demonstrated that these Group 3 siRNAs significantly increased 
cell number and altered nuclear and cellular morphology towards a reversed phenotype, 
these data potentially implicate these as oncogenic siRNAs which induce senescence 
bypass, not senescence reversal. 
Interestingly, the double positive subgroup was significantly increased and the p21+p16- 
subgroup significantly decreased for two Group 1 siRNAs, BHLHE41 and PPFIA1, relative 
to the 30 nM siGLO control. Together, these data revealed an increase in p16 levels 
following BHLHE41 or PPFIA1 siRNA knockdown. Furthermore, 14 Group 1B siRNAs 
significantly increased the double positive subgroup as well as significantly decreased 
the p21+p16- subgroup (Figure 4.14B), indicating that siRNA knockdown of these genes 
increased p16 levels in a dose dependent manner. Importantly, 60 nM siGLO did not 
significantly alter the subgroup proportions relative to 30 nM siGLO (Figure 4.14B). Thus, 
the increased double positive subgroup and decreased p21+p16- subgroup following 
Group 2 (60 nM) siRNA knockdown was not a consequence of siRNA dose toxicity. 
Previous data has suggested the presence of a p21-dependent compensatory feedback 
loop which regulates p16 levels (see Section 3.3.2). Potentially, siRNA knockdown of 
these genes may induce the p21-dependent compensatory feedback mechanism, 
resulting in an increase in p16 levels.  
It should be noted that an ANOVA and post-hoc Dunnett’s test generate a unique 
adjusted p value for each comparison dependent on the entire family of comparisons, 
resulting in p values which are interpretable only within the context of the entire family 
of comparisons. Thus, the p values generated for each condition (30 nM siRNA, 60 nM 
siRNA, + 15 nM p16 siRNA, + 15 nM p21 siRNA) cannot be directly compared here.   
In conclusion, these analyses allowed the top 14 hit siRNAs to be further ranked, with 
FN1 (34% ± 7%; p=0.001), JUP (31% ± 25%; p=0.005), EGR2 (30% ± 7%; p=0.008) ranked 
as the top three siRNAs inducing the greatest increase in the double negative subgroup. 
Notably, EGR2 siRNA, the strongest scorer in the 60 siRNA screen (Figure 4.6, Figure 4.7), 
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and strongest scorer in the multi-parameter analysis of the subsequent top hit screen 
(Figure 4.10), was ranked highly in this analysis. Taken together, the morphological and 
double negative subgroup data revealed three hits scoring highly in both analyses, EGR2, 





Figure 4.13 Representative images of a siRNA screen conducted to further investigate the top 
siRNAs inducing a reversal phenotype in DS HMFs at day five using analysis of p16 and p21 
nuclear expression.  Three independent siRNA screens, each in triplicate, were performed for 
the five day time point in DS HMFs according to Section 2.6.2. Cells were fixed, stained with 
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DAPI, p16, and p21, imaged and quantified according to Section 2.7 and 2.8. (A) Representative 
images of 30 nM siGLO, 60 nM siGLO, 30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21), and 15 
nM p16 siRNA together with 15 nM p21 siRNA (p16+p21) transfected DS HMFs. (B) 
Representative images of Group 3 top hits (15 nM siRNA in combination with p21 siRNA) 
identified in the siRNA screen. DAPI (blue), p16 (green), p21 (red). Scale bar denotes 100 µM. 






Figure 4.14 Ranking top siRNAs according to p16 and p21 double negative subgroup frequency 
at day five.  Two independent siRNA screens, each in triplicate, were performed for the five day 
time point in DS HMFs according to Section 2.6.2. Cells were then fixed and stained with DAPI, 
mouse anti-p16 (JC8), rabbit anti-p21 (12D1), donkey anti-mouse Alexa Fluor 488, and goat anti-
rabbit Alexa Fluor 546. Cells were imaged and intensities were quantitated according to Section 
2.7 and 2.8. Nuclear intensity thresholds were established for p16 and p21 to define positive or 
negative nuclei. Nuclei were classified into four subgroups: p16 and p21 positive (p16+ p21+); 
p16 negative and p21 positive (p16- p21+); p16 positive and p21 negative (p16+ p21-); and p16 
and p21 negative (p16- p21-). Bars denote nuclei per subgroup. Two-way ANOVA and Dunnett’s 
test * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. N=2 throughout. Error bars=SD of two 
independent experiments, each performed with three replicates. (A) 30 nM hit siRNA (Group 1) 
relative to 30 nM siGLO control. (B) 60 nM hit siRNA (Group 1B) and 60 nM siGLO control relative 
to the 30 nM siGLO control. (C) 15 nM hit siRNA + 15 nM p16 siRNA (Group 2) and 30 nM p16 
siRNA control relative to the 30 nM siGLO control. (D) 15 nM hit siRNA + 15 nM p21 siRNA (Group 




At the seven day time point, there was an increase in the double positive subgroup and 
decrease in the double negative subgroup for the p21 siRNA and p16+p21 siRNA 
transfected DS HMFs compared to the five day time point, indicating that p16 and p21 
expression levels were beginning to increase following the transient siRNA knockdown 
(N=1, Figure 4.15, Figure 4.16). Furthermore, only two siRNAs in combination with p21 
siRNA, MYL12A, and FN1, demonstrated an increased double negative subgroup at 





Figure 4.15 Representative images of a siRNA screen conducted to further investigate the top 
siRNAs inducing a reversal phenotype in DS HMFs at day seven using analysis of p16 and p21 
nuclear expression.  One independent siRNA screen, in triplicate, was performed for the seven 
day time point in DS HMFs according to Section 2.6.2. Cells were fixed, stained with DAPI, mouse 
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anti-p16 (JC8), and rabbit anti-p21 (12D1), donkey anti-mouse Alexa Fluor 488, and goat anti-
rabbit Alexa Fluor 546, imaged and quantified according to Section 2.7 and 2.8. (A) 
Representative images of 30 nM siGLO, 60 nM siGLO, 30 nM p16 siRNA (p16), 30 nM p21 siRNA 
(p21), and 15 nM p16 siRNA together with 15 nM p21 siRNA (p16+p21) transfected DS HMFs. 
(B) Representative images of Group 3 top hits identified in the siRNA screen. DAPI (blue), p16 







Figure 4.16 Ranking top siRNAs according to p16 and p21 double negative subgroup frequency 
at day seven.  A single siRNA screen, in triplicate, performed for the seven day time point in DS 
HMFs according to Section 2.6.2. Cells were then fixed and stained with DAPI, mouse anti-p16 
(JC8), rabbit anti-p21 (12D1), donkey anti-mouse Alexa Fluor 488, and goat anti-rabbit Alexa 
Fluor 546. Cells were imaged and intensities were quantitated according to Section 2.7 and 2.8. 
Nuclear intensity thresholds were established for p16 and p21 to define positive or negative 
nuclei. Nuclei were classified into four subgroups: p16 and p21 positive (p16+ p21+); p16 
negative and p21 positive (p16- p21+); p16 positive and p21 negative (p16+ p21-); and p16 and 
p21 negative (p16- p21-). Bars denote nuclei per subgroup. N=1 throughout. No statistical test 
performed. Error bars=SD of one independent experiment, performed with three replicates. (A) 
30 nM hit siRNA (Group 1) relative to 30 nM siGLO control. (B) 60 nM hit siRNA (Group 1B) and 
60 nM siGLO control relative to the 30 nM siGLO control. (C) 15 nM hit siRNA + 15 nM p16 siRNA 
(Group 2) and 30 nM p16 siRNA control relative to the 30 nM siGLO control. (D) 15 nM hit siRNA 




In order to explore EGR2, the top hit from the morphological and double staining 
analysis, in more detail, the morphologies of the different p16 and p21 subgroups were 
examined (Figure 4.17). This analysis showed a clear shift towards a reversal phenotype 
in nuclear and cellular morphology for all of the subgroups between 30 nM EGR2, 60 nM 
EGR2, EGR2+p21 siRNA and their controls (30 nM siGLO, 60 nM siGLO, 30 nM p21 siRNA, 
respectively), indicating that EGR2 knockdown affects DS HMF morphology towards a 
reversal phenotype even in the presence of p16 or p21, potentially indicating a role for 






Figure 4.17 Interrogation of p16 and p21 subgroup morphologies at day five following 
transfection with EGR2 siRNA in three different conditions, and the respective controls.  Two 
independent siRNA screens, each in triplicate, were performed for the five day time point in DS 
HMFs according to Section 2.6.2. Cells were then fixed and stained with DAPI, mouse anti-p16 
(JC8), rabbit anti-p21 (12D1), donkey anti-mouse Alexa Fluor 488, and goat anti-rabbit Alexa 
Fluor 546. Cells were imaged and intensities were quantitated according to Section 2.7 and 2.8. 
Nuclear intensity thresholds were established for p16 and p21 to define positive or negative 
nuclei. Nuclei were classified into four subgroups: p16 and p21 positive (p16+ p21+); p16 
negative and p21 positive (p16- p21+); p16 positive and p21 negative (p16+ p21-); and p16 and 
p21 negative (p16- p21-). Scatter points denote the average median values per subgroup. 
Dashed lines indicate the 30 nM siGLO mean. N=2 throughout. Error bars=SD of two 
independent experiments, each performed with three replicates. (A) 30 nM siGLO. (B) 30 nM 
EGR2 siRNA. (C) 60 nM siGLO (D) 60 nM EGR2 siRNA. (E) 30 nM p16 siRNA. (F) 15 nM EGR2 + 15 





4.5 Discussion and future work 
4.5.1 siRNA screening identified 45 siRNAs that drive senescence in both HMECs and 
HMFs and two siRNAs which eliminate DS HMFs 
In summary, siRNA screening identified 45 siRNAs that induced a significant increase in 
cell number in comparison to the 30 nM siGLO control; one siRNA individually (EGR2 
siRNA), two siRNAs in combination with p16 siRNA (FRAS1 and RNF20 siRNA), and 42 
siRNAs in combination with p21 siRNA. Subsequently, EGR2 siRNA, FRAS1 siRNA, and the 
top 12 siRNAs in combination with p21 siRNA which induced an increase in proliferation 
greater than eight Z scores from the siGLO control were chosen as the top 14 siRNAs to 
investigate further. 
Interestingly, siRNA screening also identified two genes, knockdown of which eliminated 
senescent cells, HDAC1 and UBC. Senescent cell accumulation is thought to cause 
progressive harm to the surrounding microenvironment. Targeted destruction of 
senescent cells is a promising therapy to treat age-related diseases, but senescent 
fibroblasts show reduced sensitivity to apoptosis making them a difficult target to clear 
(reviewed in Childs et al. 2014) (see Section 1.6). HDAC1 and UBC represent novel 
targets for senescent cell clearance, and act as a proof of principle that it is possible to 
shift human adult fibroblasts from a senescent state to apoptosis. However, a major 
limitation of these genes is that they are likely to be essential for normal cell growth and 
proliferation. HDAC1 is a component of the histone deacetylase complex, which 
interacts with pRB, deacetylates p53, and is a key element in control of cell proliferation 
and apoptosis. UBC is a polyubiquitin precursor associated with numerous cellular 
processes such as protein degradation, DNA repair, and cell cycle regulation. To 
investigate the potential role for HDAC1 and UBC in targeted senescent cell clearance, 
siRNA knockdown of these genes could be performed in normal EP HMFs and HMECs. 
4.5.2 Ranking of top hits using multi-parameter analysis identifies candidates for 
future work 
In order to identify the most potent reversal protocol, dose effect and time point 
extension were investigated in the top 14 siRNAs. Multi-parameter analysis revealed 11 
siRNAs that shifted DS fibroblast cell morphology towards a reversed phenotype in a 
dose dependent manner at the five day time point. This analysis allowed ranking of the 
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top 14 hit siRNAs, with EGR2 siRNA inducing the strongest dose dependent shift in 
cellular phenotype and thus ranking highest, followed by MYL12A, BHLHE41, and DAPL1 
siRNA. By the seven day time point, fewer siRNAs induced a dose dependent shift in cell 
morphology, but 12 siRNAs induced a shift in DS fibroblast nuclear morphology towards 
a reversed phenotype in a dose dependent manner, including EGR2, MYL12A, BHLHE41, 
and DAPL1 siRNA. Furthermore, double immunofluorescence staining using p16 and p21 
antibodies identified eight siRNAs which, in combination with p21 siRNA, significantly 
increased the double negative subgroup of cells when compared to the 30 nM siGLO 
control. Of these, EGR2 siRNA had the third greatest increase in the double negative 
subgroup, after FN1 and JUP siRNA. By the seven day time point, two siRNAs had an 
increased double negative subgroup compared to the 30 nM siGLO control: MYL12A and 
FN1 siRNA, indicating that the kinetics of the siRNA knockdown of these genes impacts 
the cells over a longer time-course than the other siRNAs investigated. Interestingly, this 
increase in the p16 and p21 double negative subgroup was observed upon knockdown 
of these genes in combination with p21 and not p16, suggesting that the reversal of 
senescence via silencing of these genes may be mediated by p16. Given this, it is 
hypothesised that these genes may act upstream of p16. 
In summary, these analyses revealed two siRNAs, EGR2 and MYL12A, which altered 
cellular and nuclear morphology in a dose dependent manner when transfected alone, 
and, increased the double negative subgroup in combination with p21 siRNA. BHLHE41 
and DAPL1 siRNA transfected alone altered cellular and nuclear morphology in a dose 
dependent manner but did not significantly increase the double negative subgroup in 
any condition. FRAS1, JUP, PDCD6IP, HSP90AA1, ACTG1, and FN1 siRNA in combination 
with p21 siRNA significantly increased the double negative subgroup, but when 
transfected individually did not rank highly for altered cellular and nuclear morphology 
at five days or seven days.  
Notably, of the 10 siRNAs ranked highly in either one or both analyses, MYL12A, FRAS1, 
JUP, ACTG1, and FN1 all encode proteins involved with cytoskeleton and cell adhesion; 
EGR2 and BHLHE41 both encode transcription factors; and DAPL1, PDCD6IP, and 
HSP90AA1 encode proteins with disparate functions and are thus grouped as ‘other’ 
(Figure 4.18A). DAPL1, an understudied gene with only six citations in PubMed, has been 
identified as a susceptibility locus for age-related macular degeneration and human 
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longevity (Flachsbart et al., 2010; Grassmann et al., 2015), and it has been proposed to 
play a role in epithelial differentiation (Sun et al., 2006). PDCD6IP encodes an endosome 
sorting complexes required for transport (ESCRT) protein which is a key player in 
membrane budding (Sun et al., 2016) and also thought to participate in apoptosis 
(Strappazzon et al., 2010). HSP90AA1, a stress inducible isoform of the molecular 
chaperone Hsp90, functions to promote proper protein maturation and structural 
maintenance (Zuehlke et al., 2015).  
The most enriched functional group identified in the top 10 hits siRNAs was genes 
involved in the cytoskeleton and cell adhesion. MYL12A encodes a myosin regulatory 
light chain, which regulates the activity of myosins, including non-muscle myosin II (NM 
II) (Park et al., 2011). NM II is an actin-binding protein which can regulate the actin 
cytoskeleton to play an important role in cell structure, adhesion, and migration. 
Notably, ACTG1, a cytoplasmic actin found in non-muscle cells (Baranwal et al., 2012), 
was also identified as one of the 10 siRNAs ranking highly in this Chapter. Two current 
theories exist for how NM II mediates cell adhesion through regulation of the actin 
cytoskeleton (Vicente-Manzanares et al., 2009). Potentially, NM II mediates adhesion 
maturation either through clustering of actin filaments, therefore increasing molecular 
interactions between adhesion proteins and increasing their strength, or through the 
generation of force which activates adhesion components by mechanical stretching. For 
example, fibronectin is known to undergo conformational changes induced by an 
integrin-transmitted mechanical force which allows self-assembly into aggregates and 
fibrils. Furthermore, MYL12A mRNA has been previously identified to increase in 
premature senescent human colon cancer cells (Dabrowska and Skoneczny, 2011). 
FRAS1, a transmembrane protein, appears to function in the regulation of epidermal 
adhesion during embryogenesis and may be an important regulator of ECM remodeling 
(Short, Wiradjaja and Smyth, 2007). FRAS1 contains a motif structurally similar to a 
cadherin fold, which is capable of binding to ECM proteins such as FN1 and collagen, as 
well as furin motifs which bind and activate TGF-β, potentially allowing regulation of 
TGF-β signaling (Short, Wiradjaja and Smyth, 2007).  
JUP is a member of the catenin family and a cytoplasmic protein which provides a 
mechanical link between desmosomal cadherins and the cytoskeleton. Interestingly, JUP 
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has previously been shown to regulate FN1 mRNA stability in murine keratinocytes 
(Todorović et al., 2010). In addition, JUP and β-catenin are known to up-regulate PML, a 
marker of senescence (Ferbeyre et al., 2000) (see Section 1.4), which then forms a 
complex with β-catenin, transactivating a subset of genes including ARF (Shtutman et 
al., 2002). 
FN1 is a major ECM component and plays an important role in cell adhesion, spreading 
and migration. Fibronectin mRNA increases significantly during replicative senescence 
in at least two fibroblast strains as well as vascular endothelial cells (Kumazaki, 1992; 
Kumazaki, Kobayashi and Mitsui, 1993). Integrin-linked kinase (ILK), an integrin-binding 
cytoplasmic protein, mediates interactions between multiple cytoskeletal proteins, and 
is involved in the regulation of adhesion, proliferation, and ECM accumulation. A 
previous study has shown that ILK, fibronectin, and other extracellular matrix 
components, such as smooth muscle alpha actin (α-SMA) and vimentin, accumulate with 
age in rat cardiac fibroblasts (Chen et al., 2006). Interestingly, in the cardiac fibroblasts 
isolated from old rats, ILK siRNA knockdown significantly reduced fibronectin protein 
expression, as well as α-SMA and vimentin, and prevented fibroblasts from entering 
senescence, as indicated by down-regulated p21 and p53 expression and decreased SA-
β-Gal staining (Chen et al., 2006). 
Currently, the relationship between ECM composition, cellular mechanical forces, and 
senescence remains unclear. Potentially, alterations to ECM composition either through 
changes in gene expression or induction of conformational changes by internal or 
external mechanical forces could impact integrin signalling and cytoskeleton dynamics, 
subsequently affecting nuclear and cellular morphology and inducing expression of 
genes driving senescence. In support of this, ECM from young cells is sufficient to restore 
multiple features of the youthful, proliferative phenotype in senescent human 
fibroblasts, including lower SA-β-Gal activity and increased BrdU incorporation (Choi et 




Figure 4.18 Functional analysis of 10 hit siRNAs and theoretical network of siRNAs with cell 
adhesion/cytoskeleton function.  (A) Functional analysis of 10 hit siRNAs revealed five siRNAs 
targeting genes involved in cell adhesion/cytoskeleton processes, two transcription factors and 
three defined as ‘other’. (B) Theoretical network of mechanical force, extracellular matrix, and 
intracellular signalling. Internal or external forces via MYL12A, NMII, and ACTG1 stretch diffuse 
FN1 into fibrils, activating signal propagation to the nucleus and potential activation of 
transcription factors such as EGR2 from outside the cell, potentially via integrin signalling, FRAS1, 
or cadherin signalling and JUP. 
Together, the cytoskeletal and cell adhesion hit siRNAs identified in this Chapter could 
form a theoretical model for the relationship between ECM, mechanical forces and 
senescence (Figure 4.18B). Potentially, external mechanical forces or internal forces 
generated by NMII and MYL12A via ACTG1 could stretch diffuse FN1 in the extracellular 
matrix into fibrils, thus activating signal propagation to the nucleus and activation of 
transcription factors such as EGR2 via integrins and integrin-like kinases, cadherin 
signalling and JUP or other transmembrane proteins such as FRAS1, subsequently 
altering gene expression and driving senescence induction. 
The second largest functional group identified in the top 10 hit siRNAs was transcription 
factors. BHLHE41 is a transcription factor that represses the clock gene, PER1, through 
E-box promoter binding and interaction with the transcription factor Sp1, leading to 
regulation of the circadian rhythm (Li et al., 2004). There is some evidence to suggest a 
link between senescence and the circadian rhythm; for example, NONO, a multi-
functional nuclear protein and partner of PER proteins, binds to p16, thus coupling the 
cell cycle to the circadian clock (Kowalska et al., 2013). In addition, age-dependent 
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changes in circadian rhythm have been observed using in vitro bioluminescence 
recordings of Per1 (circadian clock gene) -luciferase at different ages in primary rat 
dermal fibroblast cultures (Sandu et al., 2015). However, previous work has 
demonstrated that overexpression of BHLHE41 inhibits proliferation of lung cancer cells 
via down-regulation of cyclin D1 expression (Falvella et al., 2008). In line with this, 
BHLHE41 siRNA did not significantly increase the double negative subgroup in 
combination with p21 siRNA despite inducing an increase in cell number, potentially 
indicating a role in senescence via an alternate mechanism to the p16/pRB and p53/p21 
pathways, as well as suggesting BHLHE41 may act as a tumour suppressor inducing 
senescence bypass following siRNA knockdown (Figure 4.14). There is also growing 
support for a connection between disruption of circadian clock function, long 
interspersed element-1 (LINE-1; L1) retrotransposon-associated genomic instability and 
ageing. Melatonin, a neuro-hormone produced during the dark phase of the light/dark 
cycle, suppresses expression of L1 retrotransposons, preventing DNA damage via 
insertions and DNA double-strand breaks, thereby preventing senescence (Belancio et 
al., 2014). Consistent with this theory, transient L1 overexpression in primary normal 
human fibroblasts and stem cells leads to senescence (Belancio et al., 2010).  
In an earlier screen, EGR2 was identified as one of the most potent inducers of 
senescence reversal in DS HMECs. EGR2 is a transcription factor and putative tumour 
suppressor; and expression of EGR2 is often decreased in human tumours and cancer 
cell lines (Unoki and Nakamura, 2001) (see Section 1.8.5). Defects in this gene are 
associated with diseases such as Charcot-Marie-Tooth syndrome, a demyelinating 
neuropathy of the PNS (Šafka Brožková et al., 2012) (see Section 1.8.3). In PNS glial cells 
(Schwann cells), EGR2 is required to initiate myelin formation and to control exit from 
the cell cycle in a manner potentially involving p16 and p21 (Atanasoski et al., 2006; 
Srinivasan et al., 2012). One study determined that EGR2 over-expression blocks 
proliferation in both rat Schwann cells and mouse fibroblasts (Parkinson et al., 2004). In 
a ChIP-Seq study of EGR2 in myelinating rat sciatic nerve, peaks of EGR2 binding were 
identified in the p21 gene (Srinivasan et al., 2012). In addition, analysis of EGR2-deficient 
mice has identified decreased expression of p21 (Le et al., 2005). The wider role of EGR2 
was explored in more detail in Chapter 1 Section 1.8, and further discussion of EGR2 will 
be presented in Chapter 5 Section 5.7, and Chapter 6 Sections 6.3 and 6.4. 
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Once validated, these hits represent potential drivers of senescence and future novel 
therapeutic targets. In summary, this data reveals EGR2 siRNA as the strongest scorer 
for senescence reversal in the DS fibroblasts, followed by MYL12A, FRAS1, BHLHE41, 
DAPL1, JUP, PDCD6IP, HSP90AA1, ACTG1, and FN1 siRNA. Subsequently, EGR2 was 
selected for further validation and investigation as a potential driver senescence, and as 












Chapter 5  Validation of EGR2 as a 





In Chapter 4, siRNA screening revealed EGR2 siRNA as the top hit for senescence reversal 
in both DS HMECs and HMFs, potentially identifying a novel driver of senescence. Within 
this Chapter, the mechanism by which EGR2 drives senescence will be explored and 
EGR2 will be validated as a hit for senescence reversal. In order to achieve this, 
bioinformatics analysis will be performed identifying genes containing predicted EGR2 
binding sites which are associated with HMEC senescence, thus revealing potential 
EGR2-regulated genes driving senescence. Furthermore, genes which are known to be 
directly regulated by EGR2 in the literature will be compared to genes up-regulated in 
HMEC senescence in order to further identify potential EGR2-regulated genes in 
senescence. EGR2 protein levels will be investigated to determine whether an increase 
is observed during senescence in HMECs and HMFs, and EGR2 siRNA knockdown will be 
validated using phenotypic analysis and immunofluorescence staining of the 
deconvoluted siRNA pool. The interplay between the p16/pRB and p53/p21 pathways 
and EGR2 levels will also be explored using immunofluorescence staining following 
siRNA knockdown of p16 or p21 in DS HMFs.  
5.1.1 Chapter aims 
1. To investigate the potential mechanism of EGR2 driving senescence using 
bioinformatics. 
2. To determine whether EGR2 expression increases in HMF and HMEC senescence. 
3. To validate EGR2 as a driver of senescence in DS HMFs using three individual 
siRNAs targeting EGR2. 
4. To investigate the interplay between siRNA knockdown of p16 and p21, and 
EGR2 protein levels. 
5.2 Bioinformatics to decipher the mechanism of EGR2 driving 
senescence 
5.2.1 Re-mining the HMEC gene expression array for EGR2 binding sites 
To explore the potential mechanisms through which EGR2 may be driving senescence 
and identify a panel of genes that might be regulated by EGR2 during senescence, 
bioinformatics was used to re-mine the senescence-associated genes identified in the 
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HMEC gene expression array (Bishop, unpublished) (see Section 4.1) for EGR2 
transcription factor binding sites in collaboration with Dr Rob Lowe. 
MethylCap-seq, a method based on affinity purification of methylated DNA using the 
methyl-CpG-binding domain (MBD) of the methyl-CpG-binding protein 2 (MeCP2) and 
subsequent next-generation sequencing, has revealed differentially methylated regions 
(DMRs) during long-term culture of adult human dermal fibroblasts (Hänzelmann et al., 
2015). To correlate senescence-associated DMR changes with gene expression changes, 
the transcriptome of early and late passage fibroblasts was sequenced (Hänzelmann et 
al., 2015). Following this, analysis of transcription factor binding sites in genes found to 
be differentially expressed in senescence revealed that the EGR2 transcription factor 
binding site is significantly enriched in the promoter regions of both up- and down-
regulated genes. Interestingly, GO analysis of the differentially expressed genes 
revealed a highly significant enrichment for cell division and DNA repair in down-
regulated genes, and for cell adhesion and extracellular matrix organisation in up-
regulated genes. Further investigation of the differentially expressed genes identified 
two hits for senescence reversal in the DS HMF siRNA screen, sortilin 1 (SORT1), 
proliferating cell nuclear antigen (PCNA), as well as actin, gamma 2 (ACTG2), a 
cytoplasmic actin similar to the highly-ranking reversal hit, ACTG1 (see Section 4.3.1).  
Given this, it was hypothesised that EGR2 could selectively bind to promoters driving 
expression of genes important for the initiation and/or maintenance of senescence in 
DS HMECs. In order to investigate this, the senescence-associated differentially 
expressed genes identified in the HMEC gene expression array (Bishop, unpublished) 
were analysed for the previously published EGR2 consensus binding sequences 
(ACGCCCACGCA) (Jolma et al., 2013; Mathelier et al., 2016) (Figure 5.1A) and compared 
to randomly sampled background gene sets, according to Section 2.11. In line with the 
literature, there was a small but significant enrichment for EGR2 binding sites at the 
promoters of genes dynamic in HMEC senescence relative to random sampling (1.03 fold 
enrichment; p=0.04) (Figure 5.1B). Strikingly, 13 of the genes differentially expressed 
during HMEC senescence identified to contain an EGR2 binding site were also identified 
as drivers of senescence in the DS HMEC screen (Figure 5.1C). Furthermore, nine of these 
genes were identified as hits for senescence reversal in the DS HMF siRNA screen 
(S100A4, MUM1 like 1 (MUM1L1), cystatin E/M (CST6), FXYD domain containing ion 
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transport regulator 3 (FXYD3), phospholipase C gamma 2 (PLCG2), ZPLD1, 
fucosyltransferase 2 (FUT2), SORT1, and flavin containing monooxygenase 4 (FMO4)) 
(see Section 4.3.1). This suggests that EGR2 may drive senescence by altering the 
expression of these genes. S100A4, for example, was classified as a top hit in the DS HMF 
screen (see Section 4.4), and in combination with p21 siRNA knockdown induced a 
reversed phenotype in the DS HMFs similar to EGR2 siRNA knockdown (see Section 
4.4.1). Interestingly, no interactors were identified to contain predicted EGR2 
transcription factor binding sites in the dataset of genes dynamically expressed during 
HMEC senescence (Figure 5.1C). However, closer examination of the dataset revealed 
that no interactor met the stringent threshold used to define dynamic expression during 
HMEC senescence (q value<0.01), and thus all were excluded from the analysis. 
Consequently, these interactors may potentially contain predicted EGR2 binding sites 
that were not identified here.  
Interestingly, both p16 and p15 were also identified to contain EGR2 transcription 
binding sites in this analysis. p21 expression increased in HMEC senescence but did not 
meet the stringent threshold (q value<0.01) used in this analysis, therefore it was 
excluded from this analysis. However, post-hoc examination of the p21 promoter 
identified the presence of EGR2 binding sites, in line with the literature (Zhu et al. 2008; 
Srinivasan et al. 2012). These data suggest a direct role for EGR2 up-regulation of p16 
and p21 expression during senescence, supporting the previous observation that p16 
and p21 protein levels decreased in DS HMFs following EGR2 siRNA knockdown (see 
Section 4.4.1). It is also important to note that the EGR2 promoter did not contain EGR2 
transcription factor binding sites, indicating that EGR2 does not auto-regulate its 





Figure 5.1 Identifying EGR2 binding sites in drivers of senescence using bioinformatics. (A) 
EGR2 DNA binding motif (Jolma et al., 2013; Mathelier et al., 2016). (B) The EGR2 DNA binding 
motif was investigated in the promoters of genes up-regulated in HMEC senescence (red) 
relative to random sampling (grey). Analysis performed by Dr Rob Lowe. (C) The gene promoters 





5.2.2 Cross comparison of genes up-regulated in HMEC senescence with genes 
regulated by EGR2 in the literature  
To further identify potential EGR2-regulated genes driving senescence, the genes found 
to increase during senescence in the HMEC gene expression array were cross-referenced 
with genes known to be directly regulated by EGR2 in the literature. 
As the current literature focuses on the role of EGR2 in myelinating Schwann cells and T 
cell anergy (see Section 1.8), previous work identifying targets directly regulated by 
EGR2 has been performed in rat myelinating nerve and mouse T cell anergy models 
(Srinivasan et al., 2012; Zheng et al., 2013). Genome-wide ChIP-Seq has been performed 
using pooled rat myelinating sciatic nerve to reveal 153 genes with EGR2 binding peaks 
within 100 kb which were previously identified to be down-regulated by EGR2 deficiency 
in microarray analyses (Srinivasan et al., 2012). This identified peaks of EGR2 binding 
within genes involved in neurogenesis, myelination, and cell cycle exit, including p21 and 
p27 (Srinivasan et al., 2012). Using a T cell anergy model, microarray analysis of 
anergised CD4+ T helper 1 (Th1) cells harvested from an EGR2flox/flox mouse model 
compared with or without prior EGR2 Cre-mediated deletion revealed 90 probes up-
regulated upon anergy induction in an EGR2-dependent manner (Zheng et al., 2013). 
Subsequent ChIP-Seq for EGR2 binding sites comparing anergised Th1 cells to untreated 
Th1 cells identified 47 genes which were directly up-regulated by EGR2 in T cell anergy 
(Zheng et al., 2013). Given that the aim of this Chapter is to investigate the mechanism 
of EGR2 in adult human fibroblast and epithelial senescence, these data sets are used 
for cross-comparison with the senescence-associated HMEC gene expression array with 
the caveat that many of the EGR2 gene targets identified in these data may be species- 
or cell-type specific. 
As EGR2 is thought to act as a transcriptional activator (Fang et al., 2011; Srinivasan et 
al., 2012; Zheng et al., 2013), the genes identified to be up-regulated during HMEC 
senescence (q value<0.05) were cross-compared with the 153 gene targets identified in 
pooled rat sciatic nerve and the 47 gene targets identified in murine T cell anergy (Figure 
5.2A). This analysis revealed 30 genes up-regulated in HMEC senescence which are 
known to be directly regulated by EGR2 in the literature, including 17 genes identified 
as EGR2 targets in pooled rat sciatic nerve (Figure 5.2B) and 13 in murine T cell anergy 
(Figure 5.2C). Of these 30 genes, further interrogation revealed five genes which were 
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predicted to possess EGR2 transcription factor binding sites in the HMEC array analysis 
performed in Section 5.2.1: regulator of cell cycle (C13ORF15); MTSS1, I-BAR domain 
containing (MTSS1); Kruppel like factor 9 (KLF9); protocadherin 7 (PCDH7); and ferritin 
heavy chain 1 (FTH1). Fascinatingly, GO analysis of these five genes identified a 
significant enrichment for ‘negative regulation of epithelial cell proliferation’ (>100 fold 
enrichment; p=0.0015), indicating that the genes potentially directly regulated by EGR2 
in HMEC senescence (RGCC, KLF9, MTSS1, and FTH1) function to inhibit proliferation. 
Furthermore, as the q value for the increase in p21 (CDKN1A) expression in HMEC 
senescence was below the threshold used in this analysis (q value<0.05), it was included 
in this comparison and thus identified as a direct target of EGR2 which was up-regulated 
in both HMEC senescence and rat nerve myelination. Interestingly, EGR2 was identified 
as an auto-regulatory target in murine T cell anergy, although EGR2 was not identified 
to possess EGR2 transcription factor binding sites in the analysis performed in Section 
2.11, indicating potential species and/or cell type-specific auto-regulation. 
In addition, genome-wide transcriptional profiling of EGR2 overexpressing human 
foreskin fibroblasts has revealed 348 genes which showed a greater than twofold 
expression increase in response to EGR2 overexpression (Fang et al., 2011). Cross-
comparison of these 348 genes with those found to be up-regulated during HMEC 
senescence identified 46 genes which were present in both datasets. Interestingly, five 
of these genes were also identified in the DS HMF siRNA screen as potential drivers of 
senescence: actin beta (ACTB); ACTG1; CTNNB1; HIF1A; and FYN proto-oncogene, Src 
family tyrosine kinase (FYN) (see Section 4.3.1). Further interrogation of the 46 genes 
up-regulated in HMEC senescence and in EGR2-overexpressing fibroblasts revealed nine 
genes which were predicted to contain EGR2 transcription factor binding sites in the 
HMEC array analysis (TSC22 domain family member 2 (TSC22D2), SPARC/osteonectin, 
cwcv and kazal like domains proteoglycan 1 (SPOCK1), unc-51 like autophagy activating 
kinase 1 (ULK1), membrane metalloendopeptidase (MME), lysyl oxidase like 4 (LOXL4), 
monooxygenase DBH like 1 (MOXD1), ankyrin repeat and FYVE domain containing 1 
(ANKFY1), reversion inducing cysteine rich protein with kazal motifs (RECK), and 
fibroblast growth factor 2 (FGF2)) (Figure 5.2D). However, these were not found to be 
significantly enriched for a biological process using GO analysis. Interestingly, the pro-
inflammatory protein, protein S (alpha) (PROS1), was identified as a transcriptional 
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target of EGR2 in both rat myelinating nerve and murine T cell anergy. In addition, 
caveolin 2 (CAV2) was identified as a direct target of EGR2 in both rat myelinating nerve 
and human foreskin fibroblasts (Figure 5.2E). Fascinatingly, caveolins function to form 
specialised invaginations of the plasma membrane called caveolae, which are thought 
to play vital roles in diverse cellular processes, including cell signalling, cell adhesion and 
mechanosensing (reviewed in Pat-Horenczyk & Brom 2007). Together with the drivers 
identified to be putative EGR2 transcriptional targets in the HMEC gene expression array 
(see Section 5.2.1), these genes could form the basis for future work investigating 
downstream EGR2-regulated genes and potential pathways driving senescence, which 







Figure 5.2 Cross comparison of genes up-regulated in HMEC senescence with the literature.  
(A) Schematic depicting methodology for comparison of the HMEC senescence-associated up-
regulated genes (Bishop, unpublished) with three published datasets of EGR2-regulated genes. 
(B-D) Genes with increased expression in HMEC senescence (q value<0.05) were cross compared 
with genes identified to be directly up-regulated by EGR2 in (B) pooled rat sciatic nerve 
(Srinivasan et al., 2012) (C) mouse T cell anergy (Zheng et al., 2013) or (D) up-regulated in EGR2 
overexpressing human foreskin fibroblasts by a greater than twofold change (Fang et al., 
2011).(E) Overlap between the genes identified in the cross-comparison as directly up-regulated 





5.3 Investigating EGR2 protein levels in senescence  
As reversal of senescence can be achieved in both HMECs and HMFs following EGR2 
siRNA knockdown, EGR2 has been implicated as a driver of senescence in both cell types 
(see Section 4.5.1). In support of this, previous work in the lab. has shown that EGR2 
gene expression increases in HMEC senescence (Bishop, unpublished). Given this, it was 
hypothesised that both HMECs and HMFs would possess elevated EGR2 protein levels 
during senescence. As EGR2 is a member of the EGR family (see Section 1.8.1), it is 
important to note that although both EGR2 and EGR3 had significantly increased gene 
expression in DS HMECs, EGR2 was the only member of the EGR2 family whose gene 
expression significantly decreased in reversed HMECs (Bishop, unpublished), indicating 
that EGR2 may act to drive senescence, whilst EGR3 may simply be a passenger in the 
process.  
5.3.1 Identification of a suitable anti-EGR2 antibody for quantification of EGR2 protein 
levels  
In order to investigate EGR2 protein levels in HMECs and HMFs, the literature was mined 
to identify a suitable anti-EGR2 antibody, revealing rabbit anti-human EGR2 (PRB-236P) 
(BioLegend, UK (formerly Covance)) as the gold standard anti-EGR2 antibody for western 
blotting (Grunewald et al., 2015; Nafez et al., 2015; Salotti et al., 2015), 
immunofluorescence staining (Gomez-Sanchez et al., 2013; Wu et al., 2016), and ChIP 
experiments (Srinivasan et al., 2012; Zheng et al., 2013). Interestingly, EGR2 has a 
predicted molecular weight 53 KDa; however, rabbit anti-human EGR2 (PRB-236P) has 
been shown to identify multiple bands between 75 and 50 KDa using western blotting 
(Grunewald et al., 2015; Nafez et al., 2015; Salotti et al., 2015) . These multiple EGR2 
bands may be generated as a result of multiple isoforms and/or post-translational 
modifications altering the molecular weight or proper migration of the protein. 
Investigation of the EGR2 gene and protein sequence identified multiple EGR2 
transcripts encoding two isoforms: isoform A (predicted molecular weight, 50.31 KDa), 
and a slightly shorter isoform B (predicted molecular weight, 44.97 KDa), with both 
isoforms containing three phosphorylation sites, which could result in proteins of 
varying molecular weights due to de-phosphorylation events during lysate collection 
(Figure 5.3). Furthermore, both isoforms contain 14 cysteines capable of forming 




Figure 5.3 Schematic representation of the two human EGR2 isoforms, EGR2 family conserved 
regions, post-translational modification sites, EGR2 siRNA target sequences and anti-EGR2 
antibody binding sites.  There are several conserved regions between the EGR family members: 
the DNA binding zinc finger domains (blue), regions flanking the zinc finger domains and NAB 
interaction domain (green), and transcriptional activation domains (grey). Three 
phosphorylation sites have been identified in both EGR2 isoforms 
(http://www.phosphosite.org) as well as a potential glycosylation site present in isoform A. The 
siRNA mRNA target sequence translated into its location on the protein is also indicated for the 
three individual EGR2 siRNAs used in this project. Anti-EGR2 antibody binding sites are indicated: 
rabbit anti-human EGR2 (PRB-236P) which binds to the N-terminus between amino acids 8 and 
95; rabbit anti-human EGR2 (H220) which binds to the N-terminus between amino acids 1 and 
220; and mouse anti-human EGR2 (OTI1B12) which binds to the C-terminus between amino 
acids 156 and 476. There is no information provided on the binding site of rat anti-mouse EGR2 
(erongr2). 
conformation, preventing complete denaturation and monomeric migration of the 
protein. In addition, O-N-Acetylglucosamine (O-GlcNAc) glycosylation, the covalent 
attachment of β-N-acetylglucosamine to serine or threonine residues, has been shown 
to occur at the N-terminal A1 activation domain of family member EGR1, a domain which 
is shared with EGR2 isoform A (Khidekel et al., 2007) (see Section 1.8.1; Figure 5.3). 
Unfortunately, the rabbit anti-human EGR2 antibody (PRB-236P) was discontinued in 
October 2015 due to batch variability. Subsequently, multiple commercially available 
EGR2 antibodies were tested in multiple conditions in an attempt to identify a suitable 
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EGR2 antibody for investigation of EGR2 protein levels (see Appendix Table A.3). It 
should be noted that validation was focused at the protein level as this is the functional 
unit of the EGR2 transcription factor. As mouse EGR2 and human EGR2 proteins are 
highly homologous (89% identical and 95% similar sequences), anti-EGR2 antibodies 
were tested using WT and conditional EGR2 knockout murine T cell (EGR-/-) lysates 
harvested from hCD2-Cre x EGR2flox/flox mice, kindly donated by Prof. Wang and Dr Miao 
(see Appendix Figure A.8). Antibodies tested included mouse anti-human EGR2 
(OTI1B12), rat anti-mouse EGR2 (erongr2), and rabbit anti-human EGR2 (H220) 
antibodies (binding sites indicated in Figure 5.3). However, mouse anti-human EGR2 
(OTI1B12) recognised numerous non-specific bands (approximate molecular weights: 
25; 30; 50; 70; and 80 KDa) (see Appendix Figure A.8), and rat anti-mouse EGR2 (erongr2) 
generated a poor signal, thus requiring a high antibody concentration and long 
incubation period which resulted in irreproducible results via western blotting (see 
Appendix Figure A.8 and Appendix Table A.3). Only one antibody, rabbit anti-human 
EGR2 (H220), consistently produced a smeary band between 50 and 75 KDa, in line with 
the molecular weight of the multiple bands present in the literature (Grunewald et al., 
2015; Nafez et al., 2015; Salotti et al., 2015). Importantly, this smeary band was of 
stronger intensity than the non-specific bands (Appendix Figure A.9). Accordingly, rabbit 
anti-human EGR2 (H220) was selected for future optimisation. 
In order to enable investigation of EGR2 protein levels using western blotting, multiple 
attempts were undertaken to improve the resolution of the rabbit anti-human EGR2 
(H220) band. As previous inspection of the EGR2 gene and protein sequence had 
identified three phosphorylation sites, phosphatase inhibitors were added to the lysis 
buffer according to Section 2.4.1 in order to maintain the phosphorylated protein state 
and prevent potential de-phosphorylation events which may generate EGR2 proteins of 
varying molecular weights. In addition, as both EGR2 isoforms possess 14 cysteines 
capable of forming covalent di-sulphide bonds, the concentrations of β-
mercaptoethanol and SDS in the Laemmli sample buffer were increased to 10% and 4%, 
respectively, in order to ensure complete denaturation of the protein and proper 
migration of the protein through the gel. Furthermore, lysate fractionation was 
performed to isolate the nuclear extract, potentially enriching the lysate for nuclear 
EGR2 transcription factor and maximising antibody binding specificity. Despite these 
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attempts to improve the resolution (see Appendix Table A.3), the EGR2 band between 
50 and 75 KDa remained a smear, preventing accurate quantitation of EGR2 protein 
levels. In future, as EGR2 may possess O-GlcNAc glycosylation at the N-terminus (Figure 
5.3), and protein glycosylation is known to impact protein folding, stability, and 
molecular weight, de-glycosylation of EGR2 could be investigated in order to attempt to 
improve resolution of the EGR2 band and allow future investigation of EGR2 protein 
levels using western blotting, as explored in more detail in Chapter 6 Section 6.3.1.  
Although the smeary band generated by rabbit anti-human EGR2 (H220) antibody was 
not quantifiable via western blotting, the band was at the appropriate molecular weight 
(between 50 and 75 KDa) in EP and DS HMFs in line with the literature (Grunewald et 
al., 2015; Nafez et al., 2015; Salotti et al., 2015), and was identified to be significantly 
stronger than the few non-specific bands present (see Appendix Figure A.9). As such, 
EGR2 protein levels were not interrogated via western blotting in this Chapter and the 
rabbit anti-human EGR2 (H220) antibody was subsequently optimised for 
immunofluorescence staining which was then used as the primary method for EGR2 
protein level investigation.  
5.3.2 Immunofluorescence staining for EGR2 protein levels in EP and DS HMFs and 
HMECs  
Following optimisation of rabbit anti-human EGR2 (H220) antibody for 
immunofluorescence, EGR2 protein expression was quantified in the EP and DS 
fibroblasts using immunofluorescence staining. EP and DS HMFs were seeded at the 
previously optimised density of 15,000 cells/cm2 (see Section 2.6.3). After five days, cells 
were stained with DAPI, rabbit anti-EGR2, and Cell Mask according to Section 2.7 and 
Section 2.8.  
As a transcription factor, EGR2 possesses a nuclear localisation signal and functions to 
regulate gene transcription within the nucleus (see Section 1.8.1), thus it is hypothesised 
that functional EGR2 would be localised within the nucleus during senescence. In 
support of this, immunofluorescence staining of EGR2 in EP and DS HMFs showed a 
trend towards increased nuclear density in the DS population (Figure 5.4, Figure 5.5A), 
and a significant increase in the number of nuclear EGR2 foci in DS HMFs (Figure 5.5B). 
Importantly, transcription occurs at discrete sites in the nucleus known as ‘transcription 
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factories’ (Jackson et al., 1993). Thus, a significant increase in EGR2 nuclear foci may 
demonstrate an increase in the functional transcriptional foci of EGR2 during 
senescence, indicating a role for EGR2 in senescence. Interestingly, the number of 
cytoplasmic EGR2 foci was not significantly increased in DS compared to EP HMFs (Figure 






Figure 5.4 Representative images of EGR2 expression in EP and DS HMFs using 
immunofluorescence.  EP and DS HMFs were seeded at 15,000 cells/cm2 in 384-well plate 
format, fixed at day five, stained with DAPI, rabbit anti-human EGR2 (H220), goat anti-rabbit 
Alexa Fluor 488, and Cell Mask. EGR2 cellular and nuclear density and foci were quantitated 
according to Section 2.7 and Section 2.8. (A) Representative immunofluorescence images of EP 
and DS fibroblasts. DAPI (blue), EGR2 (green), Cell Mask (red). Scale bar denotes 50 µm. (B) 
Enlarged representative immunofluorescence images stained with DAPI, EGR2, and Cell Mask 




Figure 5.5 EGR2 expression in EP and DS HMFs using immunofluorescence.  EP and DS HMFs 
were seeded at 15,000 cells/cm2 in 384-well plate format, fixed at day five, stained with DAPI, 
rabbit anti-human EGR2 (H220), goat anti-rabbit Alexa Fluor 488, and Cell Mask. EGR2 cellular 
and nuclear density and foci were quantitated according to Section 2.7 and Section 2.8. 
Frequency distribution plots for (A) nuclear EGR2 density levels and (B) number of nuclear EGR2 
foci, and (C) cellular EGR2 protein density levels and (D) number of cytoplasmic EGR2 foci for EP 
and DS HMFs. Un-paired two-tailed t-test of the medians * p<0.05. Two independent 




Given that EGR2 was first identified as a driver of senescence in HMECs (see Section 
4.5.2), it was hypothesised that EGR2 nuclear levels should also increase during HMEC 
senescence. EP (P6) and DS (P11+3) HMECs were seeded at the previously optimised 
density of 7,500 or 10,000 cells/cm2, respectively. HMEC cell culture and seeding was 
performed by Dr Cleo Bishop. After five days, cells were stained with DAPI, rabbit anti-
EGR2, and Cell Mask according to Section 2.7 and Section 2.8. 
Similar to the trend in DS HMFs towards increased nuclear EGR2 density, DS HMECs had 
significantly increased EGR2 nuclear density levels (Figure 5.6, Figure 5.7A). 
Furthermore, a trend towards increased nuclear foci was also observed, but this did not 
appear to be statistically significant in HMECs (Figure 5.6, Figure 5.7B). However, HMEC 
populations are known to undergo p16-dependent senescence heterogeneously, 
leading to the presence of approximately 20% p16-positive senescent HMECs within the 
EP population (see Section 1.3.1) (Bishop et al., 2010). Accordingly, senescent HMECs 
were observed in the EP population which displayed nuclear EGR2 foci (Figure 5.6), 
indicating up-regulation of EGR2 nuclear foci during HMEC senescence in the EP 
population. Subsequent removal of senescent HMECs from the EP dataset by 
thresholding for increased cell area, a marker of senescence and a measure previously 
validated to correlate p16-positive status (Bishop et al., 2010), revealed a significant 
increase in nuclear foci in DS HMECs compared to the solely EP population (Figure 5.6, 
Figure 5.7C). In addition, EGR2 cellular density was significantly increased in the DS 
HMECs (Figure 5.6, Figure 5.7D), and, in line with the DS HMFs, a trend towards 
increased cytoplasmic foci was observed in DS HMECs (Figure 5.6, Figure 5.7E). However, 
unlike EGR2 nuclear foci, subsequent removal of senescent HMECs from the EP dataset 
did not reveal a significant increase in cytoplasmic foci in DS HMECs compared to the 
solely EP population (Figure 5.6, Figure 5.7F), suggesting that the significantly increased 
nuclear foci represent the important functional unit of EGR2 in HMEC senescence. In 
conclusion, both HMFs and HMECs have significantly increased EGR2 nuclear foci in 
senescence, potentially indicating the presence of EGR2 'transcription factories' driving 




Figure 5.6 Representative images of EGR2 expression in EP and DS HMECs using 
immunofluorescence. EP and DS HMECs were seeded at 7,500 or 10,000 cells/cm2, respectively 
in 384-well plate format, fixed at day five, stained with DAPI, rabbit anti-human EGR2 (H220), 
goat anti-rabbit Alexa Fluor 488, and Cell Mask. EGR2 cellular and nuclear density and foci were 
quantitated according to Section 2.7 and Section 2.8. HMEC cell culture and seeding was 
performed by Dr Cleo Bishop. (A) Representative immunofluorescence images of EP and DS 
HMECs. DAPI (blue), EGR2 (green), Cell Mask (red). Scale bar denotes 50 µm. (B) Enlarged 
representative immunofluorescence images stained with DAPI, EGR2 and Cell Mask with the 




Figure 5.7 EGR2 expression in EP and DS HMECs using immunofluorescence. EP and DS HMECs 
were seeded at 7,500 and 10,000 cells/cm2, respectively, in 384-well plate format, fixed at day 
five, stained with DAPI, rabbit anti-human EGR2 (H220), goat anti-rabbit Alexa Fluor 488, and 
Cell Mask. EGR2 cellular and nuclear density and foci were quantitated according to Section 2.7 
and Section 2.8. HMEC cell culture and seeding was performed by Dr Cleo Bishop. Frequency 
distribution plots for: (A) nuclear EGR2 density levels for EP and DS HMECs; (B) the number of 
nuclear EGR2 foci for EP and DS HMECs; (C) the number of nuclear EGR2 foci for EP HMECs with 
a cellular area smaller than 1,990 µm2, a proxy measure to remove senescent HMECs from the 
EP population, and DS HMECs; (D) cellular EGR2 protein density levels for EP and DS HMECs; (E) 
the number of cytoplasmic EGR2 foci for EP and DS HMECs; and (F) the number of cytoplasmic 
EGR2 foci for EP HMECs with a cellular area smaller than 1,990 µm2, a proxy measure to remove 
senescent HMECs from the EP population, and DS HMECs. Un-paired two-tailed t-test of the 
medians * p<0.05, *** p<0.001. Two independent experiments, each containing three technical 
repeats were performed. 
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5.4 Phenotypic validation of three individual siRNAs targeting 
EGR2 
As described in Chapter 4, EGR2 was selected as the top hit for validation and further 
investigation. An important post-screening validation step is to establish whether or not 
knockdown of the specific protein is occurring post-siRNA transfection. De-convolution 
of the siRNA pool helps to control for OTEs, as it is highly unlikely that an OTE generated 
by two unique siRNA sequences would induce a similar phenotype characterised by four 
different phenotypic parameters. Thus, in order to determine whether EGR2 siRNA 
knockdown was specific, the siRNA pool used in the DS HMF screen was deconvoluted 
(see Section 2.6.3) and the three individual siRNAs targeting EGR2 were first validated 
phenotypically in the DS HMFs. Given that EGR2 is known to encode two isoforms, it is 
important to note that all three individual siRNAs are designed to target both EGR2 
isoforms (Figure 5.3).  
DS HMFs were seeded at an optimised density of 15,000 cells/cm2 and forward 
transfected with an optimised dose of 0.3 µL Dh2 and the three individual siRNAs 
targeting EGR2 in two conditions: 30 nM siRNA, and 15 nM siRNA in combination with 
15 nM p21 siRNA. The appropriate controls were also performed: 30 nM siGLO; 30 nM 
p16 siRNA; 30 nM p21 siRNA; and 15 nM p16 siRNA together with 15 nM p21 siRNA. 
After five days, cells were stained with DAPI and Cell Mask, and cellular and nuclear 
phenotypes quantified according to Section 2.7 and 2.8. Two independent experiments 
were performed, each in triplicate. 
In line with previous experiments (see Section 3.3.2 and 4.3.1), p16+p21 siRNA reversed 
the DS HMFs, as demonstrated by an increased cell number, decreased cell and nuclear 
area, and increased cell elongation (Figure 5.8). Importantly, all three individual EGR2 
siRNAs also altered nuclear and cellular morphologies towards a reversed phenotype in 
comparison to the siGLO control mean: EGR2-1 siRNA increased cell elongation (three Z 
scores); EGR2-2 siRNA increased cell elongation (six Z scores) and decreased nuclear 
area (one Z score); and EGR2-3 siRNA increased cell elongation (five Z scores), as well as 
decreased nuclear and cell area (three and one Z scores, respectively). Furthermore, 
EGR2-3 significantly increased cell number (one Z score) in comparison to the siGLO 
control mean (Figure 5.8), echoing the increase in cell number observed in the original 
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screen (Section 4.3.1, Figure 4.6). In addition, both EGR2-2 siRNA and EGR2-3 siRNA 
significantly increased cell number (seven Z scores each) in combination with p21 siRNA, 
relative to the p21 siRNA control (five Z scores); however, EGR2-1 siRNA did not. These 
data indicate that EGR2-2 and EGR2-3 are both functional siRNAs, with EGR2-3 siRNA 
being the most potent siRNA, and EGR2-1 siRNA potentially acts as a weak or minimally 
functional siRNA in the pool. Importantly, the presence of two siRNAs in the pool which 
generated the same reversal phenotype indicates that the results observed following 





Figure 5.8 Phenotypic validation of three individual siRNAs targeting EGR2 in adult DS HMFs.  
DS HMFs were seeded at 15,000 cells/cm2 in 384-well plate format, fixed at day five, stained 
with DAPI and Cell Mask, imaged, and nuclear and cellular morphologies quantified according 
to Section 2.7 and 2.8. (A) Representative images of 30 nM siGLO (siGLO), 30 nM p16 (p16), 30 
nM p21 (p21), 15 nM p16 siRNA together with p21 siRNA (p16+p21), 30 nM EGR2-1 siRNA (EGR2-
1), 30 nM EGR2-2 siRNA (EGR2-2), 30 nM EGR2-3 siRNA (EGR2-3), 15 nM EGR2-1 + 15 nM p21 
siRNA (EGR2-1+p21), 15 nM EGR2-2 + 15 nM p21 siRNA (EGR2-2+p21), 15 nM EGR2-3 + 15 nM 
p21 siRNA (EGR2-3+p21) transfected DS HMFs. DAPI (blue), Cell Mask (red). Scale bar denotes 
50 µm. (B) Key. Z scores were generated according to Section 2.8.2. The colour saturation 
reflects the number of Z scores from the control mean. Scores highlighted in red denote an 
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increase in cell number significantly greater than the siGLO control mean indicating a shift 
towards the reversed phenotype. White denotes no significant changes from the siGLO control 
mean. Blue denotes a significant decrease in cell number compared to the siGLO control mean. 
(C) Heatmap depicting significant changes in cell number, cell area, nuclear area, and nuclear 
elongation from the siGLO control mean for p16, p21, and p16+p21 controls, as well as the 
individual EGR2 siRNAs (EGR2-1, EGR2-2, EGR2-3), and individual EGR2 siRNAs in combination 
with p21 siRNA (EGR2-1+p21, EGR2-2+p21, and EGR2-3+p21). Two independent experiments 




5.5 Immunofluorescence validation of three individual siRNAs 
targeting EGR2 
In addition to phenotypic validation of the individual siRNAs targeting EGR2, protein 
knockdown following siRNA knockdown of EGR2 was also assessed using 
immunofluorescence, as described in Section 5.4. After five days, the cells were fixed 
and stained with DAPI, rabbit anti-human EGR2 (H220), and Cell Mask according to 
Section 2.7 and quantified according to Section 2.8. Two independent experiments were 
performed, each in triplicate. 
In line with the phenotypic data presented previously (Figure 5.5), EGR2-2 and EGR2-3 
siRNA transfection induced a greater reduction in nuclear and cellular EGR2 density 
levels and the number of nuclear or cytoplasmic foci than EGR2-1 siRNA, further 
indicating that EGR2-1 is a weak or minimally functional siRNA (Figure 5.9, Figure 5.10A-
D). Importantly, as EGR2 nuclear foci were identified to significantly increase during both 
HMF and HMEC senescence in Section 5.3.2, EGR2-2 and EGR2-3 siRNA significantly 
reduced nuclear EGR2 foci (0.70 ± 0.01 fold change; p=0.0004; 0.74 ± 0.01 fold change; 
p=0.0007, respectively) relative to the siGLO control (Figure 5.9, Figure 5.10B). 
Furthermore, EGR2-3 siRNA reduced nuclear density (0.88 ± 0.07 fold change; p=0.06) 
and EGR2-2 siRNA significantly reduced nuclear density (0.85 ± 0.08 fold change; 
p=0.004) relative to the siGLO control (Figure 5.9, Figure 5.10A). In addition, both EGR2-
2 and EGR2-3 siRNA significantly reduced EGR2 cellular density (0.74 ± 0.006 fold 
change; p=0.005; 0.73 ± 0.02 fold change; p=0.004, respectively) and cytoplasmic foci 
(0.64 ± 0.03 fold change; p=0.003; 0.73 ± 0.08 fold change; p=0.0098, respectively) 
relative to the siGLO control (Figure 5.9, Figure 5.10C-D). Attempts to validate individual 
EGR2 siRNA knockdown using western blotting generated inconsistent results; however, 
multiple blots suggested that EGR2-1 did not decrease EGR2 levels, and that EGR2-3 
siRNA resulted in the greatest EGR2 knockdown, followed by EGR2-2 siRNA, thus 
mirroring the immunofluorescence analysis (Appendix Figure A.10). In summary, 
together with the phenotypic validation data, the immunofluorescence analysis 
indicates that the siRNA pool targeting EGR2 contains two functional siRNAs which are 





Figure 5.9 Representative images of three individual siRNAs targeting EGR2 using 
immunofluorescence in adult DS HMFs.  DS HMFs were seeded at 15,000 cells/cm2 in 384-well 
plate format, fixed at day five, stained with DAPI, rabbit anti-human EGR2 (H220), goat anti-
rabbit Alexa Fluor 488, and Cell Mask according to Section 2.7. (A) Representative images of 30 
nM siGLO (siGLO), 30 nM EGR2-1 siRNA (EGR2-1), 30 nM EGR2-2 siRNA (EGR2-2), and 30 nM 
EGR2-3 (EGR2-3) siRNA transfected DS HMFs. DAPI (blue), EGR2 (green), Cell Mask (red). Scale 




Figure 5.10 Protein knockdown validation of three individual siRNAs targeting EGR2 using 
immunofluorescence in adult DS HMFs.  DS HMFs were seeded at 15,000 cells/cm2 in 384-well 
plate format, fixed at day five, stained with DAPI, rabbit anti-human EGR2 (H220), goat anti-
rabbit Alexa Fluor 488, and Cell Mask. EGR2 cellular and nuclear density and foci were 
quantitated according to Section 2.7 and Section 2.8. (A-D) Bars denote mean fold change of the 
(A) median nuclear EGR2 density, (B) median number of nuclear EGR2 foci, (C) median cellular 
EGR2 density, and (D) median number of cytoplasmic EGR2 foci relative to the siGLO median 
control for 30 nM siGLO (siGLO), 30 nM EGR2-1 siRNA (EGR2-1), 30 nM EGR2-2 siRNA (EGR2-2), 
and 30 nM EGR2-3 (EGR2-3) siRNA transfected DS HMFs. One-way ANOVA and Dunnett’s test 
Non-significant (NS), * p<0.05, ** p<0.01, *** p<0.001. N=2 throughout. Error bars=SD of two 




5.6 Immunofluorescence investigation of the relationship 
between p16, p21, and EGR2 
Previous analysis showed that EGR2 siRNA knockdown significantly increased the 
proportion of cells negative for both p16 and p21 in the transfected DS HMF population 
(see Section 4.4.1), indicating that the presence of EGR2 during senescence may be 
important for driving expression of p16 and p21.  
As the presence of EGR2 potentially drives senescence and p16+p21 knockdown 
reverses senescence, it was hypothesised that p16 or p21 may modulate EGR2 protein 
levels through a feedback loop. In order to explore this, DS HMFs were seeded at an 
optimised density of 15,000 cells/cm2 and forward transfected with 30 nM siGLO, 30 nM 
p16 siRNA, 30 nM p21 siRNA, and 15 nM p16 together with 15 nM p21 siRNA at an 
optimised dose of 30 nM with 0.3 µL Dh2. After five days, the cells were fixed and stained 
with DAPI, rabbit anti-human EGR2 (H220), and Cell Mask according to Section 2.7, and 
quantified according to Section 2.8.  
Interestingly, p16 siRNA alone, which did not reverse senescence (data not shown), did 
not significantly alter nuclear or cellular EGR2 density or the number of nuclear or 
cytoplasmic EGR2 foci (Figure 5.11, Figure 5.12A-D). However, p21 siRNA significantly 
decreased the number of nuclear EGR2 foci (0.49 ± 0.07 fold change; p=0.03) and cellular 
EGR2 density (0.60 ± 0.007 fold change; p=0.02) relative to the siGLO control (Figure 
5.11, Figure 5.12B-C). Furthermore, p16+p21 siRNA reversed some phenotypes of 
senescence (data not shown) and significantly decreased the number of nuclear EGR2 
foci (0.42±0.20 fold change; p=0.01) as well as cellular EGR2 density (0.41 ± 0.02 fold 
change; p=0.004) and the number of cytoplasmic EGR2 foci (0.48 ± 0.06 fold change; 
p=0.04) relative to the siGLO control (Figure 5.11, Figure 5.12B-D). 
The reduction in nuclear EGR2 foci and EGR2 cellular density levels in the p21 siRNA 
transfected DS HMFs suggests that there is a feedback or feed-forward mechanism 
between p21 expression and EGR2 protein levels, with the presence of p21 driving up-
regulation and/or maintenance of EGR2 levels. Although there is a trend towards a 
further decrease in EGR2 nuclear foci and cellular density following double knockdown 
of p16 and p21 siRNA, this was not statistically significant, suggesting that the 
mechanism driving up-regulation of EGR2 is dependent on p21, not p16. In future, it 
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would be interesting to investigate p16 and p21 levels in the individual EGR2 siRNA 
transfected DS HMFs. Further exploration of the relationship between p16, p21, and 





Figure 5.11 Representative images of EGR2 expression in p16 and/or p21 knockdown in adult 
DS HMFs using immunofluorescence.  DS HMFs were seeded at 15,000 cells/cm2 in 384-well 
plate format, fixed at day five, stained with DAPI, rabbit anti-human EGR2 (H220), goat anti-
rabbit Alexa Fluor 488, and Cell Mask. EGR2 cellular and nuclear density and foci were 
quantitated according to Section 2.7 and Section 2.8. (A) Representative images of 30 nM siGLO 
(siGLO), 30 nM p16 siRNA (p16), 30 nM p21 siRNA (p21), and 15 nM p16 siRNA together with 15 
nM p21 siRNA (p16+p21) transfected DS HMFs. DAPI (blue), EGR2 (green), Cell Mask (red). Scale 




Figure 5.12 Relationship between p16 and/or p21 knockdown and EGR2 protein levels in DS 
HMFs using immunofluorescence staining.  DS HMFs were seeded at 15,000 cells/cm2 in 384-
well plate format, fixed at day five, stained with DAPI, rabbit anti-human EGR2 (H220), goat anti-
rabbit Alexa Fluor 488, and Cell Mask. EGR2 cellular and nuclear density and foci were 
quantitated according to Section 2.7 and Section 2.8. (A-D) Bars denote mean fold change of the 
(A) median nuclear EGR2 density, (B) median number of nuclear EGR2 foci, (C) median cellular 
EGR2 density, and (D) median number of cytoplasmic EGR2 foci relative to the siGLO median 
control for 30 nM siGLO (siGLO), 30 nM p16 (p16), 30 nM p21 (p21), and 15 nM p16 siRNA 
together with p21 siRNA (p16+p21) transfected DS HMFs. One-way ANOVA and Tukey’s test 
Non-significant (NS), * p<0.05, ** p<0.01. N=2 throughout. Error bars=SD of two independent 




5.7 Discussion and future work 
Within this Chapter the protein levels of EGR2 during senescence have been investigated 
using immunofluorescence revealing an increase in EGR2 nuclear foci during HMF 
replicative senescence and HMEC cellular senescence. Following this, phenotypic and 
immunofluorescence validation of individual EGR2 siRNAs identified two functional 
siRNAs targeting EGR2, providing evidence that EGR2 acts as a potential driver of 
senescence.  
Within this Chapter and Chapter 4, it has been shown that EGR2 siRNA knockdown 
reverses various phenotypes of senescence, as demonstrated by an increase in cell 
number (Chapter 4 Figure 4.6, Chapter 5 Figure 5.8), altered nuclear and cellular 
morphology towards a p16+p21 siRNA knockdown phenotype (Chapter 4 Figure 4.7, 
Figure 4.10, and Chapter 5 Figure 5.8) and decreased p16 and p21 expression (Chapter 
4 Figure 4.14). Further validation of EGR2 as a driver of senescence and exploration of 
the EGR2-knockdown reversed phenotype is discussed in Chapter 6 Section 6.3.  
5.7.1 Investigating the relationship between EGR2, p16, and p21 driving senescence  
Multiple studies have identified a role for EGR2 in the up-regulation of p21 expression 
(Le et al., 2005; Zhu et al., 2008; Pospisil et al., 2011; Srinivasan et al., 2012). 
Furthermore, ChIP performed in EGR2 overexpressing murine T cells demonstrated that 
EGR2 directly binds to the p21 promoter (Zhu et al., 2008). In line with this literature, 
p21 protein levels decreased in DS HMFs following EGR2 knockdown (see Chapter 4 
Figure 4.14), and EGR2 binding sites were identified in the p21 promoter (see Section 
5.2.1), suggesting that EGR2 directly up-regulates p21 expression in HMF replicative 
senescence. Interestingly, p16 protein levels were also observed to decrease in DS HMFs 
following EGR2 knockdown (see Chapter 4 Figure 4.14), and the p16 promoter was 
identified to contain EGR2 binding sites (see Section 5.6.1), indicating a potential role 
for EGR2 regulating p16 expression. In support of this, EGR2 was the only siRNA 
identified to reverse senescence, although modestly, in the HMFs without additional 
knockdown of p16 or p21, potentially indicating that EGR2 is essential for driving 
senescence upstream of both the p16/pRB and p53/p21 pathways (see Chapter 4 Figure 
4.6, Chapter 5 Figure 5.8, schematic Figure 5.13). To date, there is no evidence linking 
EGR2 to p16 in the literature. In order to investigate the direct relationship between 
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EGR2 and p16, ChIP for EGR2 could be used to determine whether EGR2 binds to the 
p16 promoter, and if this is enriched within the DS HMFs and HMECs. Furthermore, p21, 
p53, TERT, other hits identified in Chapter 4, including MYL12A, FRAS1, JUP, ACTG1, FN1, 
and other genes of interest identified in this Chapter, including p15, S100A4, MUM1L1, 
CST6, FXYD3, PLCG2, ZPLD1, FUT2, SORT1, and FMO4, could be investigated as potential 
direct EGR2 targets using ChIP analysis. In order to achieve this, a ChIP-grade antibody 
would need to be developed, as discussed in more detail in Chapter 6 Section 6.3.1. 
Fascinatingly, p21 siRNA knockdown in DS HMFs stimulated a decrease in EGR2 protein 
levels (see Section 5.5), suggesting the presence of a feedback loop to regulate the levels 
of EGR2 during senescence (Figure 5.13). Previous evidence for EGR2 feedback loops 
exist in the literature, as NAB2, a protein known to bind to EGR2 and inhibit its 
transcriptional activity, has also been identified as a direct EGR2 transcriptional target 
which is activated following EGR2 binding to the promoter, thus forming a feedback loop 
to regulate EGR2 levels (Kumbrink, Gerlinger and Johnson, 2005; Srinivasan et al., 2007). 
As p21 primarily regulates gene transcription in senescence via pRB-mediated inhibition 
of E2F-regulated genes, it would be interesting to determine whether p21 regulates 
EGR2 protein levels indirectly through the E2F family (see schematic Figure 5.13). In 
order to further explore this relationship, the EGR2 locus could be investigated for the 
presence of inhibitory E2F family member binding sites. Subsequently, ChIP could be 
performed using an antibody raised against the inhibitory E2F family member identified 
to possess a binding site within the EGR2 promoter to determine whether E2F binding 
to the EGR2 promoter is enriched in DS HMFs. Furthermore a plasmid overexpressing 
the inhibitory E2F family member could be transduced into DS HMFs and a luciferase 




Figure 5.13 Schematic summarising the proposed relationship between EGR2, p16, p21, p15, 
and the miR-17-92a cluster in senescence.  Theoretical relationship between EGR2 (orange), 
and the senescence effectors: p16 (light blue); p15 (green); p21 (blue), and the miR-17-92a 
cluster (light green): EGR2 directly up-regulates p15, p16, and p21 expression, and inhibits 
transcription of the miR-17-92a. In a theoretical feedback loop, p21 inhibition of E2F 
transcription factor in senescence prevents binding of inhibitory E2F family members to EGR2 
and subsequent transcriptional inhibition. Furthermore, in another theoretical feedback 
mechanism, the miR-17-92a cluster could function to inhibit EGR2 transcription.   
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Additionally, EGR2 has been found to directly repress the miR-17-92 cluster which 
encodes seven related microRNAs known to play important roles in cell proliferation by 
down-regulating expression of p21 amongst other mechanisms (Pospisil et al., 2011). 
Crucially, large-scale microarray analysis has demonstrated that the miR-17-92 cluster is 
down-regulated during replicative senescence in multiple cell types in vitro, including 
adult human dermal fibroblasts (Hackl et al., 2010), as well as in organismal ageing 
represented by three different ex vivo tissue types, including T cells isolated from the 
peripheral blood of healthy individuals (Hackl et al., 2010). These findings are confirmed 
by a study looking at foetal lung IMR-90 fibroblast replicative senescence (Dhahbi et al., 
2011). Furthermore, previous work in the lab. has shown that miR-106a, and -18a from 
the miR-17-92 cluster are down-regulated in senescent HMECs (Overhoff et al., 2014). 
Given this, future work could investigate whether the miR-17-92 cluster is down-
regulated in DS compared to EP HMFs using qRTPCR. In addition, expression of the miR-
17-92 cluster could be investigated following EGR2 siRNA knockdown in DS HMFs using 
qRTPCR. Furthermore, EGR2 has been identified as a target gene of miR-106b, part of 
the miR-17-92 cluster, with significant EGR2 up-regulation observed following 
transfection with a miR-106b inhibitor (Tang et al., 2015), indicating the presence of an 
auto-regulatory feedback loop with the miRNA cluster (Figure 5.13). As the miR-17-92 
cluster is known to be oncogenic and up-regulated in cancer (reviewed in Fuziwara & 
Kimura 2015), over-expression of these miRNAs in DS HMFs could induce senescence 
bypass not reversal, however given that EGR2 has been identified as a target gene of the 
miR-17-92 cluster, it would be interesting to investigate levels of EGR2, p16, and p21 
using immunofluorescence following miRNA overexpression in DS HMFs. The data 
generated here would inform the role of the miR-17-92 cluster in EGR2-driven HMF 
senescence and determine the relationship between EGR2, p16, p21, and the miR-17-
92 cluster (Figure 5.13). 
Fascinatingly, p15 was also identified as a putative EGR2 transcriptional target in the 
previous analysis (see Section 5.2.1). In the SASP pathway, TGF-β up-regulates p16, p21, 
and p15 through the SMAD complex (see Section 1.1.3). Similarly, EGR2 is a known 
target of TGF-β through the canonical SMAD pathway in foreskin fibroblasts (Fang et al., 
2011). Importantly, SMAD3 was identified as a reversal hit in combination with p21 
siRNA in the DS HMF siRNA screen (see Section 4.3.1). To explore this further and 
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determine whether EGR2-driven senescence occurs downstream of the canonical 
SMAD/TGF-β pathway, a small-scale siRNA screen targeting the TGF-β pathway could be 
performed in the adult DS HMFs with immunofluorescence staining for DAPI, EGR2, and 
Cell Mask to investigate the effect on cell number, morphology, and EGR2 protein levels.  
To understand further the downstream pathways and mechanisms through which EGR2 
may drive senescence, future work could explore the panel of genes up-regulated in 
HMEC senescence which contain an EGR2 binding site identified in Section 5.2.1, as well 
as the genes identified in Section 5.2.2 to also be directly regulated by EGR2 in other 
cellular contexts. To identify genes with increased expression during HMF senescence 
which have decreased expression following EGR2 siRNA knockdown, a microarray or 
qRTPCR array could be performed comparing EP HMFs, DS HMFs, and EGR2 siRNA 
transfected DS HMFs. Following validation, the genes identified here could represent 
novel EGR2 targets and drivers of senescence and provide mechanistic insight into the 
route of EGR2-driven senescence. Further elucidation of the mechanism through which 

















6.1 Senescence reversal in HMFs 
As outlined in Section 1.7, this project explores the reversal of DS HMFs to a state similar 
to that of proliferating cells. As discussed in Section 1.7, previous work exploring mTOR 
inhibition in ‘near-senescent’ human neonatal fibroblasts has shown that senescence 
onset is delayed (Walters et al., 2016) and permanent loss of proliferative potential is 
prevented in human and rodent cell lines induced to senesce via exogenous p16 or p21 
expression (Demidenko et al., 2009). However, senescent cells were not stimulated to 
proliferate. As discussed in Section 1.7 and Section 3.4.2, the most recent work 
investigating p16/pRB and p53/p21 pathway knockdown as a route for senescence 
reversal concluded that high levels of p16 expression provide a barrier to senescence 
reversal in human fibroblasts (Beausejour et al., 2003). As such, the data presented in 
this project has demonstrated for the first time that deep senescence can be effectively 
reversed in normal adult HMFs with high levels of both p16 and p21 expression using 
siRNA transfection targeting p16 and p21, as characterised by the loss of a number of 
classic senescence markers, including cell cycle arrest, senescence-associated nuclear 
and cellular morphology, oxidative damage, and expression of CDKIs, p16 and p21, as 
demonstrated in Chapter 3. 
6.1.1 Future work to further profile the DS and reversed phenotype  
Replicative senescence is induced in response to a DDR triggered by critically short 
telomeres (see Section 1.2). In order to further validate DS HMFs and explore the 
reversed HMF phenotype, additional senescence markers could be explored in EP, DS, 
and p16+p21 siRNA transfected DS HMFs. For example, it would be interesting to 
investigate telomere length using qRTPCR, the presence of TAF using confocal 
microscopy (Hewitt et al., 2012), and telomerase activity using the TRAP assay. Previous 
examination of 8-oxoG levels revealed that p16+p21 siRNA transfected DS HMFs have 
decreased cellular oxidative damage compared to DS HMFs (see Section 3.3.2). Given 
that senescence induction is triggered by a DDR in response to DNA damage, further 
investigation of 53BP1, a well-known DDR factor, and γ-H2AX, a histone marker present 
at double-strand DNA breaks, (see Section 1.2) could be performed using 
immunofluorescence. Together, these data could be used to assess whether p16+p21 
siRNA transfected DS HMFs reverse telomere shortening, DNA damage, and DDR 
activation, thus dampening senescence triggers and potentially delaying senescence re-
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induction. Interestingly, conditioned medium experiments demonstrated that DS HMFs 
are able to induce paracrine senescence in EP HMFs (see Section 3.2.4), thus 
demonstrating the presence of the SASP. Given this, SASP components, including IL-6, 
IL-8, or chemokine CXCL-2, could be further explored using immunofluorescence, ELISA, 
or Luminex-based assays. Previous studies of senescence reversal have demonstrated 
that treatments which induce senescent fibroblasts to alter their cellular morphology 
without stimulating proliferation have decreased SA-β-Gal activity (Gire and Wynford-
Thomas, 1998; Dirac and Bernards, 2003; Correia-Melo et al., 2016; Walters, Deneka-
Hannemann and Cox, 2016), suggesting that SA-β-Gal may not be a useful marker for 
senescence reversal. However, Lowe et al. (2015) showed that a substantial fraction of 
reversed DS HMECs stained negative for SA-β-Gal activity. Given this, it would be 
interesting to explore SA-β-Gal activity in non-proliferating p16 siRNA transfected DS 
HMFs; compared to proliferating p21, and p16+p21 siRNA transfected DS HMFs, as well 
as EP and DS fibroblasts. Together, these studies will further characterise the reversed 
phenotype following p16+p21 siRNA knockdown in DS HMFs and provide insight into 
the mechanism of this reversal.  
Interestingly, reversal of fibroblast replicative senescence has previously only been 
achievable in the absence of high levels of p16 expression (see Section 1.7). By contrast, 
the data presented in this thesis has demonstrated that p16+p21 siRNA knockdown 
reverses a DS HMF population which expresses both p16 and p21 (see Section 3.3.2). 
Given this, it would be interesting to perform p16+p21 siRNA knockdown in cell types 
previously investigated for senescence reversal in the literature (for example, WI38 and 
BJ fibroblasts), as well as HMFs induced to senesce via other mechanisms including OIS 
(see Section 1.3.2). This is explored in more detail in Chapter 3 Discussion Section 3.4.2. 
These studies will determine whether p16+p21 siRNA knockdown reverses senescence 
in fibroblasts with differing p16 and p21 levels, thus determining whether p16+p21 
siRNA knockdown is a universal tool for senescence reversal in fibroblasts and enabling 
further elucidation of the roles of p16/pRB and p53/p21 pathways in different cellular 
contexts. Furthermore, understanding the cellular and molecular signatures of OIS-
induced senescent fibroblasts could have important implications for therapies which 
aim to reverse or delay onset of senescence in vivo, as explored in further detail in 
Section 6.4.1. Previous work has shown that senescence is reversible in another cell type 
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from breast tissue, namely DS HMECs, using p16 siRNA knockdown (Lowe et al., 2015). 
In order to determine whether reversal is achievable in cells from other tissue types, 
further experiments could explore whether p16 siRNA or p16+p21 siRNA knockdown 
induces reversal in cells isolated from different tissues including dermal fibroblasts and 
keratinocytes. 
6.1.2 Characterisation of senescence reversal versus bypass 
Senescence is known to be prevalent in the pre-malignant stages of tumourigenesis but 
absent in malignant tumours. It has therefore been hypothesised that progression to 
malignancy requires bypass of senescence (reviewed in Collado and Serrano, 2010). This 
process is characterised by mutations or epigenetic alterations which lead to 
inactivation of the p16/pRB and p53/p21 pathways, telomerase activation, and 
subsequent infinite cell proliferation (reviewed in Shay and Wright, 2005). Given that 
cancer cells may have arisen via bypass of senescence, they may retain phenotypic 
characteristics shared with senescent cells that are distinct from normal proliferating 
cells, which can potentially be used as markers of senescence bypass. For example, cells 
which have bypassed senescence should exhibit infinite proliferation. Importantly, data 
presented in Chapter 4 Section 4.4.1 showed that p16+p21 siRNA knockdown DS HMFs 
began reverting to a senescent morphology at seven days post-transfection, suggesting 
that p16+p21 siRNA knockdown induces transient reversal, not bypass, of senescence. 
Similar observations were made following senescence reversal in DS HMECs (Lowe et 
al., 2015). In order to confirm that knockdown induces reversal not bypass, long-term 
inducible p16+p21 short hairpin RNA (shRNA) knockdown could be performed in DS 
HMFs and subsequently turned off, thus enabling investigation of the kinetics of 
senescence re-entry using the senescence markers examined in this thesis and outlined 
in Section 6.1.1. Furthermore, the duration of inducible p16+p21 shRNA knockdown in 
DS HMFs could be explored to determine whether prolonged shRNA knockdown induces 
further loss of senescence markers, subsequently delaying re-entry into senescence.  
Of relevance, it is well-established that altered DNA methylation is a hallmark of cancer 
(reviewed in Sproul & Meehan 2013). Recent work has demonstrated the presence of a 
senescence-associated methylome within fibroblasts and HMECs which resembles the 
methylation landscape in cancer (Cruickshanks et al., 2013; Lowe et al., 2015). 
Furthermore, this altered methylation landscape is retained in cells which bypass 
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senescence (Cruickshanks et al., 2013). Previous work in our lab. has defined senDMPs 
in DS HMECs relative to EP cells using an Illumina 450K array, and demonstrated that 
senescence reversal in DS HMECs following p16 siRNA knockdown effectively reversed 
the senDMP signature (Lowe et al., 2015). Profiling of methylation dynamics in EP, DS, 
and p16+p21 siRNA knockdown DS HMFs using an Illumina EPIC array for >900,000 
cytosine residues would enable identification of senDMPs in HMFs, and determine 
whether p16+p21 siRNA knockdown in DS HMFs enables reversal of the senDMP 
signature. In addition, the senDMPs identified in p16+p21 siRNA knockdown DS HMFs 
could be cross-compared with the DMRs identified in senescent IMR-90 fibroblasts and 
SV40 T-antigen expressing IMR-90 cells which bypassed senescence (Cruickshanks et al. 
2013), to determine whether there is significant overlap between the methylation 
profile in p16+p21 siRNA knockdown HMFs and IMR-90 fibroblasts which have bypassed 
senescence. Cruickshanks et al. (2013) also compared senescence-associated DMRs and 
senescence bypass-associated DMRs with cancer-associated DMRs reported previously 
for colon and breast cancer and found highly significant overlap. Given this, p16+p21 
siRNA knockdown DS HMFs senDMP signature should be compared with the cancer-
associated Illumina 450K methylation profiles available, including colon and breast 
cancer, within The Cancer Genome Atlas (TCGA) database. Together, these studies will 
establish if the methylome of DS HMFs resembles cancer methylomes and determine 
whether p16+p21 knockdown induces reversal or bypass of senescence.  
6.1.3 Membrane stiffness may act as a novel marker of replicative senescence in 
HMFs 
As human skin undergoes the ageing process, it is evident that there are significant 
changes in its mechanical properties (Daly and Odland, 1979). However, the relationship 
between ageing and the mechanical properties of cells and the cellular 
microenvironment remains poorly understood. Data presented in Chapter 3 Section 
3.3.3 demonstrated that DS HMFs exhibited significantly stiffer membranes than EP 
fibroblasts, which significantly softened following p16+p21 siRNA knockdown, 
suggesting that this may be a novel senescence marker in vitro. In line with these 
findings, Kim et al. (2015) found that late-passage dermal foreskin fibroblasts showed 
an increased stiffness approximately three times greater than early-passage cells. In 
addition, Berdyyeva, Woodworth and Sokolov, 2005 found that epithelial cells exhibit 
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increased stiffness in vitro at later passages due to increased F-actin density in the 
cytoskeleton. Interestingly, cytochalasin B, a chemical that inhibits polymerisation of F-
actin, reduced late-passage epithelial cell membrane stiffness to levels observed in 
cultures of early-passage cells (Sokolov, Iyer and Woodworth, 2006). In order to 
determine whether membrane stiffening is a universal feature of senescence, future 
work could investigate membrane stiffness in senescent epithelial cells as well as HMFs 
induced to senesce via other triggers. Given that both fibroblast and epithelial cells have 
been identified to exhibit increased stiffness at later passages nearing senescence 
(Berdyyeva, Woodworth and Sokolov, 2005; Kim et al., 2015), it is hypothesised that 
HMF membrane stiffening occurs prior to senescence induction, potentially acting as a 
driver of senescence. In order to explore the kinetics of stiffening, membrane stiffness 
could be measured at multiple intervals between EP and DS HMFs. To explore whether 
membrane stiffening is a potential driver of senescence, future work could investigate 
whether treatment of DS HMFs with cytochalasin B reduces senescence-associated 
membrane stiffness and the senescence markers examined in this thesis and outlined in 
Section 6.1.1 could also be assessed to determine whether senescence reversal is 
induced following membrane softening. Conversely, further experiments could be 
performed using jasplakinolide, a drug which polymerises and stabilises actin filaments 
(Bubb et al., 1994), to investigate whether increased actin polymerisation in EP HMFs 
induces senescence, as assessed by the senescence markers examined in this thesis. 
Interestingly, a study by Schulze et al. 2012 showed that dermal fibroblasts isolated from 
older healthy female donors (>60 years old) were stiffer than those isolated from 
younger donors (<42 years old), suggesting that dermal fibroblasts exhibit a significant 
increase in stiffness during ageing in vivo. To explore this further, future work could 
investigate membrane stiffness alongside senescence markers, such as p16 and p21 
expression, in fibroblasts isolated from donors of differing ages. Together, these studies 
may identify membrane stiffness as a novel, universal senescence marker in vitro and in 
vivo as well as a potential driver of senescence. 
The biomechanical properties of the cellular microenvironment are known to regulate 
fundamental cell processes, such as proliferation, via ECM-cell and cell-cell interactions 
(reviewed in Provenzano and Keely, 2011). To explore the effect of external mechanical 
forces on senescence markers, proliferating HMFs were seeded onto substrates of 
211 
 
varying stiffnesses coated with collagen in collaboration with Ana Laly, a PhD student in 
Dr Connelly’s group. The preliminary data generated from these experiments indicated 
that culture of HMFs on a softer substrate increased proliferation as well as decreased 
p21 levels in comparison with HMFs seeded onto collagen-treated plastic (data not 
shown). The data suggests that the stiffness of the extracellular microenvironment may 
play a role in senescence induction. Interestingly, it has been shown that fibroblasts can 
adjust their membrane stiffness to match substrate stiffness (Solon et al., 2007), 
indicating the presence of a signalling pathway between sensing the stiffness of the 
microenvironment and regulation of internal cellular stiffness. In order to assess 
whether a relationship exists between substrate stiffness, membrane stiffness, and 
senescence induction, the membrane stiffness of near-senescent HMFs seeded on 
substrates of differing stiffnesses could be investigated alongside the senescence 
markers outlined in this thesis. 
6.2 siRNA screening hits are enriched for cytoskeletal and cell 
adhesion processes 
The successful reversal of deep senescence in adult HMFs using p16 and p21 siRNA 
subsequently provided the opportunity to screen for novel siRNAs that induced reversal 
in both DS HMECs and HMFs, using the 28 driver siRNAs identified in a screen of 200 
genes in DS HMECs. This strategy revealed 45 siRNAs in DS HMFs which significantly 
increased cell number in comparison to the control, including 22 driver siRNAs 
functional within both HMFs and HMECs and 23 interactors identified in the HMFs. It is 
important to note that an initial genome-wide siRNA screen in DS HMFs may have 
identified additional hits specific to the fibroblast context. However, further 
investigation of the top 14 siRNAs identified using this strategy revealed 10 siRNAs which 
ranked highly as reversal hits in analyses of morphology and p16 and p21 levels. Of 
these, three encoded genes with disparate functions grouped as ‘other’; five encoded 
genes involved with cytoskeleton and cell adhesion; and two encoded transcription 
factors, including EGR2, which will be discussed in more detail in Section 6.3 and Section 
6.4. 
Given the discussion explored in Section 6.1.3, it is noteworthy that the top 10 hits were 
enriched for genes with cytoskeletal and cell adhesion function. Based on these hits, a 
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theoretical mechanism by which mechanical force regulates intracellular signalling via 
the extracellular matrix is proposed in Chapter 4 Section 4.5.2. In summary, external 
mechanical forces or internal forces generated by NMII and MYL12A via ACTG1 may 
stretch diffuse FN1 in the ECM into fibrils, thus activating signal propagation to the 
nucleus potentially via integrins and integrin-like kinases, cadherin signalling and JUP or 
other transmembrane proteins, such as FRAS1, subsequently altering gene expression 
and driving senescence induction. In order to explore this theoretical mechanism and 
potentially identify other drivers of senescence, a siRNA screen for reversal could be 
performed in DS HMFs which investigates interactors within this network, including 
NMII (Park et al., 2011), fibronectin-binding partner integrin α5β1 (Huveneers et al., 
2008), ILK, an integrin-binding cytoplasmic protein, and other extracellular matrix 
components such as smooth muscle alpha actin (α-SMA), F-actin or vimentin (Chen et 
al., 2006). In order to validate these four hits as drivers of senescence, the siRNA pools 
could be deconvoluted and validated using high content analysis, immunofluorescence, 
qRTPCR, and western blotting. In addition, membrane stiffness could be investigated as 
a senescence marker following siRNA knockdown of these hits in DS HMFs. To 
complement these experiments, inducible overexpression of the hits in EP HMFs could 
be performed to determine whether premature senescence is induced. Together, these 
studies may elucidate the mechanism through which mechanical force drives 
senescence induction. 
6.3 EGR2 may represent a novel driver of senescence 
6.3.1 Further validation of EGR2 as a driver of senescence  
As described in Chapter 4, further investigation of the top 14 siRNAs revealed EGR2 as 
the top hit for reversal in multiple analyses, including increasing cell proliferation when 
transfected alone as well reversing senescent cellular and nuclear morphology in a dose-
dependent manner. Accordingly, EGR2 was selected for validation and further 
investigation. As effective knockdown at the protein level must be achieved in order to 
inhibit gene function, an important post-screening validation step was establishing that 
EGR2 knockdown was achieved following siRNA transfection, as explored in detail in 
Chapter 5. To support these endeavours, transcript knockdown following siRNA 
transfection could be assessed using qRTPCR. Of note, EGR2 possesses multiple 
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transcript variants which encode two isoforms: A, and the slightly shorter isoform B (see 
Section1.8.1). Before assessing transcript knockdown, it will be important to examine 
the relative abundance of isoform expression in EP and DS HMFs and HMECs using 
isoform specific primers and qRTPCR. As the individual EGR2 siRNAs used in this project 
knockdown both isoforms (see Section 5.4), the relative isoform abundance could be 
examined post-EGR2 siRNA knockdown using qRTPCR analysis. Further work could 
investigate isoform-A-specific EGR2 siRNA knockdown compared to knockdown of both 
isoforms in order to determine the relative contributions of EGR2 isoforms driving 
senescence. Identification of the functional EGR2 isoform(s) in senescence will be 
important for design of further experiments, including monoclonal antibody generation, 
inducible shRNA or inducible overexpression, as discussed in more detail below.  
To extend EGR2 protein knockdown validation, future work could explore the potential 
EGR2 post translational modifications. Attempts could be made to remove these 
modifications in order to improve EGR2 band resolution and enable EGR2 protein levels 
to be investigated using western blotting. As explored in Chapter 5, a potential post-
translational modification could be N-terminal O-GlcNAc glycosylation, and this can be 
removed from proteins using commercially available hexosaminidases (Zachara, 
Vosseller and Hart, 2011). In order to ensure that deglycosylation has been performed, 
a positive control should be included, such as ovalbumin which bears terminal GlcNAc 
residues and migrates several KDa lower on a 10-12% gel following deglycosylation. If 
deglycosylation does not improve the anti-EGR2 (H220) band resolution, a monoclonal 
antibody specific for the known functional isoform EGR2 could be developed. Following 
this, the monoclonal anti-EGR2 antibody would be validated for detection of an 
appropriate band or bands using western blotting for DS HMFs and HMECs, and 
subsequently optimised for immunofluorescence staining in DS HMFs and HMECs. 
Production of a validated monoclonal antibody which probes the known functional EGR2 
isoform(s) in DS HMFs and HMECs would enable further EGR2 investigation in EP, DS and 
reversed HMFs and HMECs at the protein level as well as further validation of EGR2 
siRNA protein knockdown using western blotting and further experiments outlined 
below.  
To further validate EGR2 as a driver of senescence, an inducible EGR2-overexpressing 
plasmid could be transduced into EP HMFs to investigate whether EGR2 overexpression 
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induces premature senescence using the senescence markers examined in this thesis 
and outlined in Section 6.1.1. In addition, long-term inducible EGR2 shRNA knockdown 
in EP HMFs could be performed to determine whether EGR2 knockdown extends 
replicative lifespan. Further to this, EGR2 knockdown could be turned off prior to 
senescence in order to investigate whether long-term EGR2 suppression delays entry 
into senescence. To determine whether EGR2 shRNA knockdown can induce senescence 
reversal, HMFs transduced with the inducible EGR2 shRNA construct could be passaged 
to senescence and EGR2 knockdown turned on post-senescence induction. Following 
this, inducible EGR2 shRNA knockdown could then be turned off, thus enabling 
investigation of senescence re-entry in reversed DS HMFs.  
6.3.2 Exploring the mechanism of EGR2 driving fibroblast replicative senescence  
In order to further explore the reversed DS HMF phenotype following EGR2 siRNA 
knockdown, the senescence markers outlined in Section 6.1.1 and Section 6.1.3 could 
be investigated and compared to p16+p21 siRNA knockdown DS HMFs, including DNA 
damage markers, the SASP and membrane stiffness. Together, these studies may 
identify whether EGR2 regulates particular processes during senescence induction and 
help to elucidate the mechanism by which EGR2 drives senescence.  
As discussed in Section 6.1.2 for p16+p21 siRNA knockdown, characterisation of the 
methylation profile following EGR2 siRNA knockdown in DS HMFs could be performed 
using an Illumina EPIC array. The data generated here could be cross-compared with EP 
and DS methylation profiles to determine whether the EGR2 siRNA knockdown 
methylation profile resembles either the proliferating methylation profile or the 
senescence-associated methylation profile present during senescence bypass or indeed, 
if the DS HMF profile remains unaltered. In addition, the data could be cross-compared 
with the ‘bypass’ signature generated by Cruickshanks et al. (2013) and cancer-
associated methylation profiles present in the TCGA. It would also be interesting to 
cross-compare the EGR2 siRNA knockdown methylation profile with the p16+p21 siRNA 
knockdown profile to identify differentially methylated positions that may elucidate 
commonalities and differences in the senescence induction mechanism.  
Using the ChIP-grade antibody which could be generated as part of the future work 
presented in Section 6.3.1, the presence of EGR2 binding sites in the promoters of the 
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INK4/ARF locus, p21, p53, TERT and other genes of interest could be investigated in EP 
versus DS HMFs using ChIP, as outlined in Chapter 5 Discussion. Given the correlation  
demonstrated between p16, p21 and EGR2 in Chapter 5, it would also be interesting to 
investigate whether p16 and members of the E2F family bind to the EGR2 promoter in 
DS HMFs compared to EP HMFs using ChIP. To identify global EGR2 binding targets 
during senescence, ChIP-Seq could then be performed comparing EGR2 binding sites in 
EP and DS HMFs. Further, a microarray or targeted qRTPCR experiment for the reversal 
hits identified to possess EGR2 binding sites (see Section 5.2) could be performed in 
inducible EGR2-overexpressing HMFs compared to normal DS HMFs to explore the 
EGR2-regulated transcriptome. Together, these studies will facilitate cross comparison 
of the EGR2-regulated transcriptome, EGR2 binding sites and EGR2-regulated 
methylation dynamics during senescence thus elucidating the mechanism by which 
EGR2 drives senescence. 
Furthermore, a number of senescence-associated signalling pathways have been 
implicated upstream of EGR2 signalling, including PI3K/AKT/mTOR, MEK/ERK, p38, TGF-
β, and the miR-17-92 cluster (see Section 1.8 and Section 5.7). In order to explore the 
pathways upstream of EGR2 driving senescence, a siRNA screen of genes in these 
pathways could be performed to identify other hits for senescence reversal. As part of 
this strategy, EGR2 levels could be investigated in this screen using immunofluorescence 
staining. 
6.3.3 Is EGR2 a universal driver of senescence?  
Data presented within this thesis indicates that EGR2 plays a role driving both mammary 
epithelial cellular senescence and fibroblast replicative senescence. In order to further 
explore EGR2 as a universal senescence driver, analysis of EGR2 siRNA knockdown could 
be expanded to encompass HMFs which have undergone senescence induced by other 
triggers and other senescent cell types including dermal fibroblasts, keratinocytes, and 
T cells. Mazzatti et al. (2007) identified an increase in EGR2 expression during T cell 
senescence, a process defined by the loss of co-stimulatory molecules (see Section 
1.3.3). Interestingly, multiple studies have demonstrated that increased EGR2 
expression is a master regulator of T cell anergy, a proliferation-arrested state 
stimulated by TCR activation in the absence of co-stimulatory molecules (see Section 
1.8.4) (Harris et al., 2004; Safford et al., 2005; Anderson et al., 2006; Zhu et al., 2008; 
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Zheng et al., 2012). Given this, it is hypothesised that down-regulation of co-stimulatory 
molecules in T cells nearing senescence may potentially stimulate increased EGR2 
expression which subsequently inhibits proliferation and induces T cell senescence. In 
order to investigate this, analysis of proliferation using high content microscopy could 
be performed following EGR2 siRNA knockdown in senescent T cells. However, T cells 
are notoriously difficult to transfect and there are significant challenges involved with 
siRNA delivery techniques. Currently, high voltages are required to be applied to T cells 
in order to induce transient membrane permeabilisation, frequently resulting in loss of 
cell viability or cell death (reviewed in Freeley and Long, 2013). Furthermore, siRNA gene 
silencing using this technique is known to be less efficient in non-activated T cells, i.e. 
senescent T cells. In future, further elucidation of the mechanism by which EGR2 drives 
senescence may allow identification of a potential druggable target which could be 
investigated for treatment in T cell senescence. Importantly, immunosenescence during 
ageing is in part characterised by a loss of T cells due to T cell senescence (see Section 
1.5.1), thus these studies may help to expand our understanding of the mechanism of T 
cell senescence and identify a potential target to treat immunosenescence in the future. 
As EGR2 expression has been identified to increase during T cell senescence in vitro 
(Mazzatti et al., 2007) and a recent whole-blood gene expression meta-analysis looking 
at over 7,000 human samples showed that EGR2 increases with age (Peters et al., 2015), 
it would be interesting to explore whether EGR2 expression and protein increases in T 
cells in vivo during human ageing. In order to investigate this, T cells isolated from the 
peripheral blood of healthy older donors and younger donors using flow cytometry 
could be interrogated for EGR2 expression using qRTPCR and fluorescence-activated cell 
sorting (FACS). Further sub-fractionation of older and younger T cells into CD28+ 
proliferating and CD28- senescent T cells using flow cytometry would enable 
investigation of EGR2 expression and protein in both proliferating and senescent 
populations with age (reviewed in Koch et al. 2008). The data generated here could 
determine whether EGR2 expression is increased in the CD28- senescent T cell 
population in comparison to the proliferating T cell sub-fraction in both older and 
younger donors, potentially confirming a role for EGR2 expression during T cell 
senescence in vivo.  
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As the data generated in this thesis indicates that EGR2 drives senescence in fibroblasts 
and epithelial cells, it is hypothesised that EGR2 expression would increase with age in 
these cell types in vivo. To investigate this, fibroblasts and epithelial cells isolated from 
older healthy donors could be investigated for increased EGR2 expression in comparison 
to younger donors using qRTPCR. In addition, future work could investigate whether 
EGR2 expression is increased in situ in sun-protected cutaneous tissue obtained from 
older healthy donors compared to younger donors using immunohistochemical staining 
and cell-type specific markers. Together, these studies could help determine whether 
EGR2 is a universal driver of senescence and, potentially, ageing in humans. 
6.4 EGR2 may represent a novel therapeutic target for 
rejuvenation  
6.4.1 Can we target senescence for reversal in vivo?  
Targeted transient reversal of replicatively senescent populations could potentially 
rejuvenate aged tissues and exert a beneficial effect on healthspan in humans (see 
Section 1.6). However, senescence reversal therapies face a number of significant 
challenges in vivo. First, siRNA reversal therapy as a delivery mechanism would need to 
overcome significant technical challenges, including a high siRNA uptake by the kidney, 
liver and spleen which function to clear siRNAs, as well as the enzymatic siRNA 
degradation by nucleases in the blood (Whitehead, Langer and Anderson, 2009). 
Alternatively, future work elucidating the mechanism driving senescence as outlined in 
Sections 6.3.1, 6.3.2 and 6.3.3 may lead to the identification of a druggable target for 
senescence reversal which could subsequently enable investigation of a drug reversal 
therapy.  
However, regardless of the therapeutic delivery strategy, it is important to note that 
senescence is known to occur as a tumour suppressor mechanism in vivo. As outlined in 
Section 6.1.1, future work could investigate whether reversal is achievable in OIS 
fibroblasts using EGR2 siRNA knockdown. If OIS fibroblasts are found to be reversible in 
a similar manner to DS fibroblasts, the current lack of methodology to distinguish 
different senescence types in vivo presents a significant challenge to both siRNA and 
drug-dependent senescence reversal therapeutics. In order to enable specific targeting 
of non-OIS cells and preclude reversal of senescence in pre-cancerous cells, markers 
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must be identified to distinguish between replicative senescence and OIS in vivo. In 
order to address this, a potential solution could be the development of a delivery system 
designed to specifically release cargo in replicatively senescent cells. For example, 
Agostini et al. (2012) have developed silica nanoparticles capped with galacto-
oligosaccharides which are hydrolysed by SA-β-Gal to release the cargo following 
internalisation by senescent cells. Identification of an enzyme overexpressed during 
replicative senescence but not OIS, cancer, or normal cells could enable development of 
a nanoparticle cap designed to be digested for release specifically in cells which have 
undergone replicative senescence. To explore this, the differences in gene expression 
between replicative senescence and OIS could be interrogated to identify an enzyme 
overexpressed during replicative senescence but not OIS (Nelson et al., 2014). However, 
following development of this delivery system, there would need to be extensive 
validation in vitro using numerous OIS cell types in order to ensure target specificity as 
well as preliminary investigation of target specificity in an experimental human context 
reflecting in vivo conditions, as explored in more detail in the following section.  
6.4.2 Future work to explore EGR2 as a novel therapeutic target  
At present, senescent cell reversal in vivo remains unexplored. As there are numerous 
senescence triggers, cell-type-dependent senescence mechanisms, and roles of 
senescence in vivo (see Introduction Sections 1.3 and 1.5, respectively), further 
understanding of the mechanisms driving senescence is required in order to evaluate 
the potential consequences of reversal therapeutics in vivo. The data which could be 
generated in the future work outlined in Section 6.3 may help elucidate these 
mechanisms. Further, as explored in Section 6.4.1, delivery systems capable of targeting 
specific senescence types in vivo will potentially need to be developed in order to 
prevent ‘off-target’ reversal and unintended consequences.  
A second promising therapeutic strategy involves deceleration of senescence in vivo. 
Recent studies have demonstrated that delayed senescent cell accumulation in vivo 
exerts a beneficial effect on murine healthspan (see Introduction Section 1.6) (Wang et 
al., 2010; Schafer et al., 2016). Thus, it would be interesting to ask whether suppression 
of EGR2, or a target potentially identified within the mechanism of EGR2-driven 
senescence in Section 6.3, could act as a means of restraining senescence, ageing 
mechanisms, and potentially extending healthspan. As outlined in Section 6.3.1, 
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investigation of long-term inducible EGR2 shRNA knockdown in proliferating HMFs could 
determine whether EGR2 suppression extends replicative lifespan in vitro. Furthermore, 
as outlined in the future work discussed in Section 6.3.3, investigation of EGR2 siRNA 
knockdown in senescent dermal fibroblasts and keratinocytes could identify EGR2 as a 
universal driver of senescence. Following this, long-term inducible EGR2 shRNA 
knockdown in proliferating dermal fibroblasts and keratinocytes could be performed to 
investigate whether replicative lifespan is extended in multiple cell types.  
As the mechanism of human senescence is known to be distinct from murine cell 
senescence (see Section 1.7), it is important to explore the implications of in vivo anti-
senescence strategies in a human context. The living skin equivalent (LSE), a three-
dimensional organotypic model comprised of dermal fibroblasts and stratified 
epidermal keratinocytes, has been widely used to study many aspects of cutaneous 
biology (reviewed in Mertsching et al. 2008). Thus, development of an LSE comprised of 
near-senescent or DS dermal fibroblasts and keratinocytes which re-capitulates the 
characteristics of skin ageing in vivo would enable investigation of anti-senescence 
therapeutic strategies for senescence suppression or reversal. For example, loss of 
senescence markers and skin ageing characteristics could be explored following 
p16+p21 or EGR2 siRNA knockdown treatment in a DS LSE model to determine whether 
siRNA reversal can be achieved in an in vivo context and whether reversal has an effect 
on skin ageing phenotypes. In addition, investigation of senescence markers and skin 
ageing features in a near-senescent LSE model could be compared with an LSE 
comprised of identical passage dermal fibroblasts and keratinocytes which have 
undergone long-term inducible EGR2 shRNA knockdown to determine whether EGR2 
suppression has an effect on skin ageing phenotypes. Furthermore, development of an 
LSE comprised of both OIS and DS dermal fibroblasts and keratinocytes could enable 
investigation of the target specificity of the delivery system described in Section 6.4.1 in 
an experimental setting reflecting in vivo aged skin. Together, these studies will help to 
further our understanding of the mechanisms driving senescence and ageing, as well as 
explore whether EGR2 can be used as a novel therapeutic target in humans in vivo for 
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Senescence marker Description References 
Arrested 
proliferation 
 Stable G1 cell cycle arrest 
characterised by reduced 
BrdU incorporation. 
Reviewed in (Sikora et al., 
2011) 
Altered nuclear and 
cellular morphology 
 Enlarged, flattened 
cellular morphology. 
 Enlarged, irregular nuclear 
morphology. 
 Down-regulated lamin B1 
expression. 









 Increased expression of 
p15, p16, ARF, p53, 
and/or p21. 
(Alcorta et al., 1996; Gil 
and Peters, 2006) 
DNA damage 
response 
 Telomere dysfunction. 
 DNA damage foci 
characterised by γ-H2AX 
and 53BP1. 
 Increased oxidative DNA 
damage foci characterised 
by 8-oxoG. 
(Bodnar et al., 1998) 
 
(di Fagagna et al., 2003) 
 
 
(Chen et al., 1995) 
Epigenetic 
alterations 
 Genomic DNA 
hypomethylation. 
 Hypermethylation at 
specific sites composes a 
senescence-associated 
methylation signature. 
 SAHF (not universal), 
characterised by HP1.  
 
 
(Bork et al., 2010; 
Cruickshanks et al., 2013; 
Hänzelmann et al., 2015; 
Lowe et al., 2015) 
 
(Narita et al., 2003; Kosar 
et al., 2011) 
Increased 
lysosomal activity 
 Increased SA-β-Gal 
activity. 





 Increased secretion of 
cocktail of factors 
including inflammatory 
cytokines (IL-6, IL-8), 




(Freund et al., 2010; 
Acosta et al., 2013) 
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Figure A.1 Uncropped western blots of p21 and p16 in WT Loxo26 UV+ p21+, Loxo26 p21-/-, 
and MDA-MB-468 cells loaded by total protein concentration. Cell lysates were probed for (A) 
rabbit anti-p21 (ab7960), (B) rabbit anti-p21 (C-19 sc397), and (C) rabbit anti-p21 (12D1) 
according to Section 2.4. (D). MDA-MB-468 p16-positive cells were probed for mouse anti-p16 




Figure A.2 Western blot analysis of p21, p16 and lamin B1 levels in EP and DS HMFs loaded by 
cell number. (A) Western blot depicting p21, p16, and lamin B1 levels in EP and DS HMFs. Lysates 
were probed for rabbit anti-p21 (12D1), mouse anti-p16 (JC8), and the rabbit anti-lamin B1 
antibody according to Section 2.4. Antibody dilutions and conditions may be found in Section 
2.4.3. (B) Densitometry analysis of p21 levels in EP and DS HMFs. (C) Densitometry analysis of 
p16 levels in EP and DS HMFs. (D) Densitometry analysis of lamin B1 levels. Analysis was 







Figure A.3 Analysis of untransfected, Dh2 only, and siGLO transfected controls. DS cells were 
seeded at 15,000 cells/cm2 in 384-well plate format and were either untransfected (UTC) or 
forward transfected with either Dh2 alone, or with 30 nM siGLO. Cells were then fixed, stained 
with DAPI, mouse anti-BrdU Alexa Fluor 488, or mouse anti-p16 (JC8) and rabbit anti-p21 (12D1), 
or mouse anti-8-oxoG, and donkey anti-mouse Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 
546, and Cell Mask. Nuclear and cellular morphologies, BrdU nuclear intensity, p16 and p21 
nuclear intensities, and 8-oxoG cellular density was quantitated according to Section 2.7 and 
Section 2.8. Using the secondary only control, a nuclear intensity threshold was established to 
define BrdU positive or negative nuclei. Nuclear intensity thresholds were established for p16 
and p21 to define positive or negative nuclei. Nuclei were classified into four subgroups: p16 
and p21 positive (p16+ p21+); p16 positive and p21 negative (p16+ p21-); p16 negative and p21 
positive (p16- p21+); and p16 and p21 negative (p16- p21-). A cellular density threshold was 
established to define 8-oxoG positive or negative cells. (A) Mean cell number/well. (B) Mean 
nuclear area (µm2). (C) Mean nuclear elongation (µm2). (D) Mean nuclear roundness (AU). (E) 
Mean cell area (µm2). (F) Mean cell elongation (AU). N=4. Error bars=SD of four independent 
experiments, each performed with three replicates. (G) Bars denote mean percentage of BrdU 
positive nuclei. N=1. Error bars=SD of a single experiment containing three replicates. (H) Bars 
denote mean percentage of nuclei per subgroup. N=2. Error bars=SD of two independent 
experiments, each performed with three replicates. (I) Bars denote mean percentage of 8-oxoG 






Figure A.4 GeneMANIA interaction network of drivers and interactors. 28 potential drivers of 
senescence were identified in the previous DS HMEC screen. Using the BioGRID bioinformatics 
database, 33 interactors were identified which physically interacted with at least two other 
drivers. To further explore the relationships between drivers and interactors, GeneMANIA was 
used to generate an interaction network using data from a variety of sources, including physical 
interactions (red), co-expression (purple), genetic interactions (green), co-localisation (dark 





Figure A.5 BioGRID interaction network of drivers and interactors, not including UBC. 28 
potential drivers of senescence were identified in the previous DS HMEC screen. Using the 
BioGRID bioinformatics database, 33 interactors were identified which physically interacted with 
at least two other drivers. In order to ensure that the previous interactors were not falsely 





Figure A.6 GeneMANIA interaction network of drivers and interactors, not including UBC. 28 
potential drivers of senescence were identified in the previous DS HMEC screen. Using the 
BioGRID bioinformatics database, 33 interactors were identified which physically interacted with 
at least two other drivers. In order to ensure that the previous interactors were not falsely 





Figure A.7 Comparison of control siRNAs according to p16 and p21 double negative subgroup 
frequency at day five. Two independent siRNA screens, each in triplicate, were performed for 
the five day time point in DS HMFs according to Section 2.6.2. Cells were then fixed and stained 
with DAPI, mouse anti-p16 (JC8), rabbit anti-p21 (12D1), donkey anti-mouse Alexa Fluor 488, 
and goat anti-rabbit Alexa Fluor 546. Cells were imaged and intensities were quantitated 
according to Section 2.7 and 2.8. Nuclear intensity thresholds were established for p16 and p21 
to define positive or negative nuclei. Nuclei were classified into four subgroups: p16 and p21 
positive (p16+ p21+); p16 negative and p21 positive (p16- p21+); p16 positive and p21 negative 
(p16+ p21-); and p16 and p21 negative (p16- p21-). Bars denote nuclei per subgroup. Two-way 
ANOVA and Dunnett’s test ** p<0.01, **** p<0.0001 relative to the 30 nM siGLO control. N=2 
throughout. Error bars=SD of two independent experiments, each performed with three 
replicates. Bars denote the 30 nM siGLO control, 60 nM siGLO control, 30 nM p16 siRNA control, 





Figure A.8 Uncropped western blots of EGR2 antibodies in wild-type (WT) and Egr-2 knockout 
mouse lysates loaded by total protein concentration. Lysates of CD4+ T cells isolated from WT 
and Egr-2 conditional knockout (EGR2-/-) mice kindly donated by Prof. Ping Wang and Dr Tizong 
Miao were probed for (A) mouse anti-human EGR2 (OTI1B12) antibody, (B) rabbit anti-human 
EGR2 (H220) antibody, (C) rat anti-mouse EGR2 (erongr2) antibody, according to Section 2.4. 




Appendix Figure A.9 Uncropped western blot of rabbit anti-human EGR2 (H220) antibody in 
EP and DS HMF lysates loaded by cell number. (A) Representative western blot of EP and DS 
HMFs cell lysates probed for rabbit anti-human EGR2 (H220). (B) Densitometry analysis of bands 
in rabbit anti-human EGR2 (H220) stained siGLO transfected DS HMFs. Analysis was performed 
using ImageJ software. Bars denote density levels normalised to the EGR2 band. Lysates were 





Antibody Protocol Condition tried 
Rb anti-Hu EGR2 (H220) Lysate collection Included phosphatase inhibitors 
 Lysate fractionation Probing nuclear extract 
 Laemmli sample buffer 
10% β-mercaptoethanol 
concentration 
  4% SDS concentration 
 Primary block .05% PBST versus .1% PBST 
  
5% milk versus 5% BSA versus no 
block 
Rt anti-Mo EGR2 
(erongr2) 
Primary concentration Range between 1:1,000 - 1:100 




1:10,000 versus 1:5,000 
Appendix Table A.3 Optimisation of conditions for anti-EGR2 antibodies using western 
blotting. The gold standard EGR2 antibody in the literature, rabbit anti-human EGR2 (PRB-236P), 
was discontinued in October 2015 due to batch variability. Consequently, a number of EGR2 





Appendix Figure A.10 Uncropped western blot of rabbit anti-human EGR2 (H220) antibody in 
DS HMFs transfected with individual EGR2 siRNAs loaded with total protein concentration. 
(A) Representative western blot of DS HMFs transfected with 30 nM siGLO (siGLO), or 30 nM 
individual EGR2 siRNA (EGR2-1, EGR2-2, EGR2-3) cell lysates were probed for rabbit anti-
human EGR2 (H220). (B) Densitometry analysis of EGR2 bands in rabbit anti-human EGR2 
(H220) probed siGLO transfected DS HMFs. Analysis was performed using ImageJ software. 
Bars denote density levels normalised to the EGR2 band in siGLO control. Lysates were probed 
according to Section 2.4. Antibody dilutions and conditions may be found in Section 2.4.3. 
